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Abstract 
The immune system relies on the correct spatial and temporal positioning of cells in order 
to function; cells need to be able to move throughout the circulatory system to survey for 
pathogens, to migrate from their resident sites in tissues when they sense infection or 
injury to alert other cells, or to migrate to the site of damage or infection to help mobilise a 
response. These functions often involve chemokines, small cytokines that signal through 
chemokine receptors, which are G-protein coupled receptors expressed on the cell 
membrane. Different chemokines are regulated differentially and can be associated with 
certain tissues or developmental processes, meaning the suite of receptors expressed by 
each cell type determines which tissues it is capable of entering, and the precise location it 
takes up once inside the tissue. 
Atypical chemokine receptors are a class of chemokine receptors that do not initiate the 
downstream signalling pathways typical of a G-protein coupled receptor, as they do not 
recruit intracellular G-proteins, and generally don’t induce cell migration. Instead, these 
receptors are thought to function mainly as chemokine scavenging receptors, internalising 
and destroying their ligands before rapidly recycling to the cell surface. In this way, the 
levels of chemokines in the body are prevented from becoming oversaturated thus 
dampening the ability of cells to respond to signals.  
ACKR3 and ACKR4 are two atypical chemokine receptors that are expressed on 
endothelial cells and keratinocytes in the skin. Here, I have studied their expression on 
cultured human lymphatic endothelial cells and keratinocytes, and modulation in response 
to immune stimuli on these cells using a combination of qPCR and immunofluorescent 
staining. These strategies revealed that ACKR3 and ACKR4 are expressed on cultured 
LECs and keratinocytes and may be differentially regulated by both cell types in response 
to inflammatory stimuli including bacterial (LPS) and viral (Unmethylated CpG DNA) 
signatures. Although chemokine scavenging activity could not be detected on these cells, 
these findings suggested a role for ACKRs 3 and 4 in the inflammatory response. 
Further experiments in vivo explored the expression and modulation of ACKR3/CXCR4 
and ACKR4 on epithelial cells including lymphatic endothelial cells, keratinocytes and 
vascular endothelial cells in the spleen. Flow cytometry was used to examine tissues both 
at rest and after inflammation (Aldara-mediated psoriasis model, or TPA-mediated contact 
hypersensitivity model) and investigate the regulation of ACKR3/CXCR4 or ACKR4 in 
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response to these stimuli. Key findings included the strong overlap and differential 
regulation of ACKR3 and CXCR4 in response to TPA in the infundibulum subset of 
keratinocytes.  
Additionally, lymph nodes of Ackr4-/- mice were significantly enlarged after repeated 
treatments with Aldara. This appeared to be due to CCL19 dysregulation, but adoptive 
transfer suggested that there was no defect in leukocyte homing in these mice. This 
suggested an as yet undetermined response to enhanced CCL19 bioavailability that did not 
prevent the correct migration of leukocytes to secondary lymphoid organs. 
Overall, these experiments suggested that ACKR3 and ACKR4 are modulated in response 
to several inflammatory stimuli both in vivo and in vitro, and that the modulation of 
homeostatic chemokines can play a role in the response to inflammatory events. This was 
particularly important in the context of skin inflammation, where inflammatory 
chemokines, CXCR4 and ACKR2 have all been implicated in severity and duration of 
inflammatory events, but few studies have yet described the potential contributions of 
ACKR3 or ACKR4.  
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1 Introduction 
1.1 General Introduction 
The vertebrate immune system is composed of a complex interplay of highly specialised 
molecules, cells and organs. These interactions have been finely tuned over millions of 
years of evolution to form an essential part of the body’s defence against external threats, 
such as pathogens and parasites. Cells of the immune system also maintain the body’s 
integrity, destroying unfit or aberrant cells, helping to repair damaged tissues and 
preventing the formation of cancers. A fine balance is required for an effective immune 
system, as it must mount a robust response to any threat, without overreacting and 
attempting to destroy beneficial antigen. This extends to the body’s own tissues (central 
tolerance), and to foreign antigen such as commensal bacteria or ingested food (peripheral 
tolerance). When tolerance breaks down, it can lead to severe autoimmune disorders; This 
highlights the incredibly sensitive nature of the immune system, where every aspect must 
be held in check.  
The immune system of vertebrates is classified into two branches: the innate and the 
adaptive. The innate immune system is generally the first line of defence and is applicable 
to a broad range of threats. It relies on the recognition of specific molecules associated 
with foreign microorganisms and damaged tissues. These are known as pathogen-
associated molecular patterns (PAMPs) and damage-associated molecular patterns, 
respectively, and are recognised by specific receptors known as pattern-recognition 
receptors (PRRs). These can be either membrane bound or cytoplasmic; membrane-bound 
PRRs include Toll-like Receptors (TLRs) and C-type Lectin Receptors. Upon ligand 
binding, PRRs initiate cellular defence mechanisms, which can include directly destroying 
damaged or infected cells via phagocytosis or induced apoptosis, or by secreting signals 
that attract other cells to the site to aid the immune response. The innate immune system 
can respond to threats extremely quickly; however, it is not always sufficient to clear 
infections and the adaptive immune system is required at this point. 
The adaptive immune system is considerably slower to respond when a new threat is 
encountered, and generally has a lag phase of at least 2-3 days. Once immunity against an 
antigen is gained it is long-lasting, leading to a swift and specific response against any 
future infections by the same pathogen. Innate and adaptive immune systems can be linked 
by specialised cells, usually called innate-like cells, or by direct interactions between cells 
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of the innate and adaptive immune systems. Professional antigen-presenting cells (APCs) 
are a key class of cells that act as a link between innate and adaptive immune systems. 
APCs can be tissue-resident or migratory and possess PRRs on their surfaces, allowing 
them to recognise PAMPS and in turn activate molecular pathways that cause them to 
become ‘mature’ APCs capable of heightening the immune response. APCs continually 
sample antigen from their environment; these are processed into epitopes, short peptides 
that are displayed on the cell surface by Major Histocompatibility Locus Class II (MHC-II) 
molecules. Once this occurs, the APC is activated by upregulating specific proteins and 
receptors that allow it to migrate to a secondary lymphoid organ (SLO) and to interact 
directly with T cells to activate the adaptive immune response. This generates short-lived 
effector cells that can fight infection both directly and indirectly; for example, by releasing 
cytotoxins to destroy infected cells, or by secreting cytokines to activate other immune 
cells to clear a threat. Some effector cells give rise to memory cells that persist in the body 
for the remaining lifespan of the individual. These cells are capable of rapidly dividing to 
produce more effector and memory cells when they contact cognate antigen, meaning 
pathogens that have been encountered previously can be destroyed quickly.  
Cell migration is a central requirement for immunity. Although the local 
microenvironment at the site of infection or tissue damage can often contribute to the 
resolution of trauma, or create preventative barriers against external threats, this is not 
sufficient to protect the organism from invasion by pathogens. Immunity requires a suite of 
specialised cells that can be rapidly deployed to a specific anatomical location when they 
are required. In addition, cell migration is essential for immunity even when the body is 
not undergoing a specific immune challenge: the development of the immune system 
requires precise spatial and temporal positioning of cells, and the selection processes that B 
and T leukocytes undergo during their maturation are also dependent on cell migration. 
Furthermore, cell migration is key to the processes of immune surveillance and tolerance. 
Cell migration can be induced by the secretion of small cytokines called chemokines, 
which induce effects that can also include cell proliferation, survival and adhesion. 
Chemokines induce migration in responding cells via their chemokine receptors. 
Chemokine availability can be modulated by a class of proteins called Atypical Chemokine 
Receptors (ACKRs). The four confirmed members of this family are known as 
‘scavenging’ receptors due to their ability to clear specific chemokines from the local 
environment or transport them across endothelial barriers. This provides a further layer of 
regulation to the immune system, where cell migration can be fine-tuned by cells at the site 
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of inflammation. Chemokines, chemokine receptors and atypical chemokine receptors will 
be discussed in depth later (See sections 1.5, 1.6, and 1.7). 
1.1.1 Innate Immunity 
The first wave of the inflammatory response is initiated by the innate immune system. This 
can be in response to a detected pathogen or to tissue damage and contributes to the typical 
redness and swelling seen at sites of infection or wounding. Tissue-resident macrophages 
and stromal cells of the affected tissue can both secrete cytokines including chemokines, 
and other inflammatory stimuli, to promote leukocyte recruitment to the site of infection or 
wounding. The first cells to arrive are typically neutrophils. These are highly mobile cells 
that are mainly found in the bloodstream. They are phagocytes, so are capable of directly 
engulfing infected or damaged cells and bacteria, and can also secrete granules and 
chromatin which coalesce to form neutrophil extracellular traps, structures that can engulf 
and destroy bacteria 1.  as well as secreting a host of cytokines including chemokines to 
attract further cells to the site 2. Monocytes from bone marrow are also early recruits to the 
site of infection or inflammation and can differentiate into macrophages and classical 
dendritic cells (cDCs) once in the tissue. Macrophages, as their name suggests, are large 
phagocytic cells, but can also aid the immune response by secreting inflammatory stimuli. 
Although they are professional phagocytes, macrophages are also capable of presenting 
antigen to T cells via MHC-II molecules 3, providing a bridge between innate and adaptive 
immunity. 
This gap is also crossed by innate-like cells, which possess features of both innate and 
adaptive arms of the immune system. These include γδT cells, natural killer (NK) T cells, 
marginal zone (MZ) B cells, and B1 B cells 4. Although these cells possess B or T cell 
receptors (BCR and TCR, respectively), they do not undergo the same processes of 
recombination that lead to the diverse suite of antigen B and T cells are typically capable 
of recognising. Instead, they recognise specific antigen defined by the B or T cell receptor 
variant(s) they express 4. Upon antigen recognition, these cells can often carry out similar 
functions to B or T cells, including secreting antibodies and cytokines, but do not require 
activation by other cells, so can mount a response much more quickly 4.  
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1.1.2 Adaptive Immunity 
There are two types of lymphocyte central to the adaptive arm of the immune system, both 
of which are derived from haematopoietic stem cells in the bone marrow: B cells, which 
remain in the bone marrow to complete their maturation, and T cells, which migrate to the 
thymus to finish their development. On maturation, both B and T cells migrate to populate 
SLOs. At this stage, they are known as naïve cells, as they have not yet contacted their 
cognate antigen. Once this occurs, they are activated and will upregulate specific proteins 
and receptors as well as proliferating to increase the population of cells that can recognise 
the specific antigen and differentiating into effector cells that carry out specific functions; 
this varies depending on the type of cell and the subset it belongs to. B and T cells can 
generally be found circulating through secondary lymphoid organs (SLOs) seeking their 
cognate antigen, and the main routes to their activation in the SLOs will be discussed 
below (See section 1.2.2).  
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1.2 Lymph Nodes 
1.2.1 Structure and Function 
The lymph nodes are key SLOs that play a vital role in immune surveillance and response. 
Lymph nodes are small nodular organs that form as outgrowths of the lymphatic network 
and are located at multiple sites throughout the body. The main benefit of the lymph nodes 
is in providing a site where rare lymphocyte populations can meet, and where resident cells 
can sample blood and lymph circulation for antigen. The structure of the lymph node 
reflects this purpose, as it funnels the flow of lymph through the node via a complex 
labyrinth of channels interspersed with lymphocyte-rich regions, maximising contact 
between tissue-resident cells and the lymph. 
Structurally, the lymph node consists mainly of an outer capsule, a vascular medullary 
region and an inner cortex, which consists of a densely packed collection of lymphocytes 
(Figure 1-1). Interspersed with the cortex is a network of sinuses lined with lymphatic 
endothelium, which allows lymph to flow through the node past the cortex, converging at 
the medulla before leaving the lymph node via efferent lymphatics 5.  
The sinus immediately beneath the capsule is called the subcapsular sinus (SCS), and this 
is the first space cells and antigen will reach on entering the lymph node via the afferent 
lymph. Proximal to the capsule, the cortex contains B cell follicles with germinal centres 
where clonal proliferation can occur. The SCS is lined with lymphatic endothelial cells 
(LECs) and SCS macrophages. The latter are characterised by CD169 expression and play 
an important role as a biological barrier against pathogens arriving at the lymph node via 
the afferent lymph 6. 
The SCS drains into the intermediary sinuses allowing lymph to flow past the B cell 
follicles through the lymphatic labyrinths, loosely-packed networks of lymphatic 
endothelium and reticulum supporting a network of fibroblastic reticular cells (FRCs) and 
lymphocytes, largely T cells and macrophages 5. The FRCs form a system called the 
lymphatic conduits, which lymph and small molecules (<4 nm) can flow through 7. The 
conduits originate at the SCS and are interspersed throughout the cortex. They are formed 
largely from bundles of collagen fibres secreted by FRCs; the FRCs wrap around these to 
form a matrix of interconnected tubules. Lymph node resident DCs can sample lymph 
through small gaps between neighbouring FRCs 8. 
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Figure 1-1: Structure of the lymph node. 
A) Diagram representing the main anatomical features of the lymph node B) Detailed view 
of the highlighted region in A. CD169+ SCS macrophages within the afferent lymph 
capture antigen complexes, which are transported to FDCs by B cells. Upon antigen 
recognition, B cells upregulate CCR7 to approach the CCL21+ CCL19+ cortex. 
Meanwhile, the activated TFH cell has upregulated CXCR5 to approach the CXCL13+ 
follicle. Also shown is a conduit, formed from FRCs wrapped around extracellular matrix 
fibres to form spaces where lymph carrying small molecules can flow. A tissue resident 
DC samples the lymph in a space between two FRCs 
Finally, the lymphatic flow will reach the medulla, a region rich in blood vessels and 
containing mainly lymphocytes in the process of leaving the lymph node. There are also 
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cortical regions interspersed between the medullary sinuses known as the medullary cords. 
These contain mainly macrophages, plasma cells and small populations of DCs. The 
medullary sinuses are lined with a single layer of lymphatic endothelium, allowing cells to 
migrate between the sinuses and the cortex 5. Also found within the medullary region are 
SIGNR1+ medullary macrophages, which continually sample the lymph and phagocytose 
pathogens that have been able to pass through the lymph node. They also clear dead or 
apoptotic lymphocytes from the medullary region, particularly following an immune 
response 9 or to maintain tolerance 10. 
1.2.2 Overview of the Immune Response 
1.2.2.1 T Cell Activation 
All T cells express a TCR on their surface. The TCR is part of the immunoglobulin 
superfamily, and each is able to recognise a MHC class I or II molecule bearing a specific 
peptide. TCRs exist as heterodimers; most T cells bear TCRs composed of α and β chains, 
but a small subset of T cells have γ and δ chains and are known as γδT cells. They are 
functionally unique among T cells and will be discussed separately (See section 1.4.3). In 
addition to TCRs, mature T cells express either CD4 or CD8 molecules on their surface. 
These are both transmembrane glycoproteins that act as co-receptors for the TCR, 
recognising domains of the MHC-II and MHC-I molecules, respectively.  
Mature naïve T cells mainly circulate through the lymphatic system, residing in each 
lymph node for 12-24 hours, then continuing their migration if they do not contact cognate 
antigen. Once in the cortex, T cells are constantly in motion seeking a DC bearing their 
cognate antigen. Although this migration can appear to be random, intravital imaging 
experiments have shown that T cells are in direct contact with FRCs over 90% of the time 
11. FRCs are known to secrete the chemokines CCL19 and CCL21 12 which control the 
migration of naïve T cells and activated DCs, attracting them to the cortex 13; these cells 
also secrete IL-7 to promote the survival of T cells and activated DCs 12. This suggests that 
the FRC conduit system plays a key role not only in transporting molecules to the cortex, 
but in supporting the function and survival of naïve T cells and activated DCs. 
T cells can only recognise antigen when it is bound to an MHC molecule. In the case of a 
CD4+ naïve T cell, this will be a MHC-II molecule on the surface of a professional APC 
such as a DC. Because the TCR has a low affinity for its target, activated DCs express the 
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co-stimulatory molecules CD80 and CD86 which interact with CD28 on the T cell’s 
surface to promote activation and survival. DCs also express the adhesion molecule 
ICAM-1 which binds to the integrin LFA-1 on the T cell’s surface to allow for close cell-
cell contact, enhancing T cell activation and survival 14,15. 
Once activated by this method, the naïve CD4+ T cell becomes a mature follicular helper T 
(TFH) cell, which will upregulate CXCR5 16 and downregulate CCR7 17 in order to migrate 
towards the B cell follicle. Chemokine receptor expression alone is not sufficient to induce 
T cell migration into follicles, suggesting a role for further factors such as adhesion 
molecules 18. 
DCs can also present exogenous antigen to naïve CD8+ T cells on MHC-I molecules. This 
is known as cross-priming, and has been shown to be restricted to a CD8+ subset of DCs 
19. Cross-priming allows the adaptive immune system to detect antigen that cannot be 
displayed on MHC-II molecules, for example pathogens that hide within infected cells. It 
also means that infected DCs could still present the antigen to a naïve CD8+ T cell. 
DC-T cell interactions do not always lead to an active immune response; they are also 
involved in generating and maintaining peripheral tolerance to self and harmless antigen. 
As DCs are constantly sampling antigen from their environment via endocytosis, this will 
regularly include harmless or self-antigen. In the absence of inflammatory signals such as 
pro-inflammatory cytokines and TLR ligands that indicate infection or tissue damage, a 
DC will process and present epitopes without becoming activated 20. When an immature 
DC presents antigen to a T cell, depending on its lineage the T cell may be targeted for 
apoptosis or anergy, or develop into a mature regulatory T cell (Treg) 21. Although Tregs 
are largely generated in the thymus during the development of central tolerance 22, their 
induction by immature DCs ensures that there is a mechanism for the removal of self-
reactive cells that escaped from the thymus, and for preventing overreaction to benign 
antigen that is encountered later in life.  
1.2.2.2 B Cell Activation 
Naïve B cells are most commonly found in lymph node follicles, although similarly to T 
cells they continually circulate between SLOs via blood and lymph. Upon maturation, B 
cells upregulate CXCR5, the receptor for the chemokine CXCL13. Also known as B-
Lymphocyte Chemoattractant, CXCL13 is strongly expressed by FDCs in the lymphoid 
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follicles which leads to naïve B cells homing from the bone marrow to the lymph nodes 18. 
FDCs also secrete B cell activating factor (BAFF) to promote B cell survival 9, and are 
required for B cell survival and retention in follicles and germinal centre formation 23. In 
turn, B cells express lymphotoxin α1β2, which promotes the survival and CXCL13 
expression of FDCs 24. 
Opsonised antigen (that bound to factors which enhance phagocytosis, e.g. antibodies or 
C3b complement) is normally presented to follicular B cells by FDCs which capture 
opsonised antigen complexes on extracellular receptors. There is evidence that SCS 
macrophages play a role in transporting these antigen complexes from the afferent lymph 
to follicles by capturing antigen and extending processes into the follicle to present it to B 
cells, which in turn transport the antigen to FDCs 25,26. In the case of non-opsonised 
antigen, SCS macrophages can also present directly to the cognate B cell 9. 
B cell migration within the follicle is dependent on each cell’s ability to respond to 
chemokines and other migratory signals in the lymph node microenvironment. While naïve 
B cells are highly CXCR5+, responding to CXCL13 signals to remain in the follicle as 
described above, they also express Epstein-Barr Virus induced molecule-2 (EBI2), a G-
protein coupled receptor (GPCR) that binds to 7α, 25-dihydroxycholesterol (7α, 25-OHC). 
EBI2 signalling is thought to attract B cells to the extrafollicular regions 27. Naïve B cells 
also express low levels of CCR7, allowing them to respond weakly to CCL19 and CCL21 
and migrate towards the T cell zone. It is thought that balancing these migratory signals 
allows B cells to circulate throughout the follicle, seeking cognate antigen on FDCs or SCS 
macrophages 28.  
Upon encountering its cognate antigen, a B cell requires an interaction with an activated 
TFH cell to become activated itself. This means B cell responses rely on the ability of the 
antigen-bearing B cell and activated TFH cell to find one another within the vast cellular 
milieu of the lymph node. Cell migration plays a key role in this interaction. After binding 
its cognate antigen, the B cell processes it to generate a peptide, which it presents on its 
surface via MHC-II. The cell also alters its chemokine receptor expression profile, 
upregulating CCR7 to respond more strongly to CCL19 and CCL21 in the cortex 17,29. 
Concurrently, the corresponding activated TFH cell will alter its own expression profile as 
described above, upregulating CXCR5 and downregulating CCR7 16 to allow both cell 
types to migrate to the boundary between the follicle and cortex where they can interact 30.   
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On formation of the MHC-II-antigen-TCR complex between the cells, the TFH cell can 
perform a wide range of functions to support B cell activation, survival and development 
of effector cells 31. One example is the protein CD40L, expressed on the surface of the TFH 
cell, which binds to CD40 on the surface of the B cell and acts as a co-stimulatory 
molecule promoting B cell proliferation 31. TFH cells can also secrete cytokines or 
chemokines to aid the activated B cell 31. 
Upon activation, B cells upregulate CXCR4 and then can undergo one of two main fates: 
they can upregulate EBI2, allowing them to migrate to the edge of the follicle where they 
differentiate into short-lived plasmablasts, which then leave the follicle by migrating 
towards S1P in the circulation (See section 1.2.2.3) and CXCL12 (the ligand for CXCR4) 
in the bone marrow or splenic red pulp; or they can downregulate EBI2 32 and migrate to 
the centre of the follicle, which is CXCL12+, to form the germinal centre dark zone 33 and 
give rise to long-lasting immunity via plasma cells and memory B cells 27. 
During germinal centre formation, the antigen-binding site of the BCR undergoes somatic 
hypermutation to rapidly diverge; this will lead to some B cell clones with higher affinity 
for the target antigen which are promoted in a process of affinity maturation. Activated B 
cells are short-lived but differentiate to both expand their own population and to produce 
plasma cells and memory B cells. Plasma cells have extensive labyrinths of endoplasmic 
reticulum, allowing them to secrete antibodies on a vast scale. While most plasma cells are 
the short-lived plasmablasts, memory B cells can often survive for the lifespan of the 
organism, conferring long-lasting immunity by rapidly proliferating and differentiating to 
produce more plasmablasts if reinfection occurs. 
1.2.2.3 Ingress and Egress of Lymphocytes 
High endothelial venules (HEVs) are specialised blood vessels that allow the ingress of 
lymphocytes to the cortex of the LN (Figure 1-2). In skin-draining LN, lymphocytes 
expressing L-selectin on their surfaces bind to these endothelial cells, which express 
Peripheral Lymph Node Addressin (PNAd). This leads to a weak adhesion of the 
lymphocyte to the vessel wall, initiating a phase known as rolling where the cell continues 
to move with the blood flow, but is slowed and closely associated with the vascular 
endothelial cells. At this stage, chemokines bound to glycosaminoglycan (GAG) molecules 
on the surface of the endothelial cells bind to chemokine receptors on the lymphocyte 
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Figure 1-2: Extravasation of a naïve T cell from a high endothelial venule to the 
lymph node cortex. 
The T cell becomes tethered to the endothelium via L-selectin and PNAd binding, begins 
the rolling process and is able to recognise CCL21 immobilised on a GAG side-chain of a 
peptidoglycan molecule expressed on the surface of the endothelial cells. CCL21 
signalling via CCR7 on the T cell activates the integrin LFA1 on the surface of the T cell, 
allowing it to bind with ICAM-1 on the endothelial cell, leading to adhesion followed by 
transmigration into the lymph node cortex. 
surface leading to the activation of integrins expressed on the lymphocyte’s surface 
including leukocyte function-associated antigen 1 (LFA1). This binds to intercellular 
adhesion molecule-1 (ICAM-1) on the surface of the endothelium, leading to the firm 
adhesion of the lymphocyte to the endothelial wall. The cell can now extravasate by either 
migrating between or across the cells of the endothelium 34. Although this is the 
mechanism by which cells migrate to the skin draining lymph nodes, the specific cell 
adhesion molecules, selectins, integrins and addressins vary in lymph nodes of the mucosa; 
additionally, different chemokines are required to attract different lymphocyte populations. 
Sphingosine-1-Phosphate (S1P) is a sphingolipid signalling molecule that plays a crucial 
role in lymphocyte egress from the lymph nodes. Lymphocytes express receptors for S1P, 
most commonly S1P1, which is essential for lymphocyte egress from lymph nodes mature 
T cell egress from the thymus 35. High levels of S1P are present in the blood, while lymph 
nodes and other SLOs are low in S1P due to the activity of the enzyme S1P lyase, which 
degrades S1P 36. The accepted model for S1P1/S1P activity holds that lymphocytes migrate 
towards S1P chemotactically, but exposure to high levels of S1P in the blood or lymph 
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leads to receptor desensitisation, meaning the cells are temporarily unresponsive to S1P 
allowing them to enter areas of low S1P abundance such as the lymph nodes. Once 
receptor turnover is complete, cells become responsive to S1P again and egress from the 
lymph node 37, as signals from S1P override other chemotactic signals from chemokines 
within the lymph node 38. Under inflammatory conditions, particularly IFN signalling, 
S1P1 expression is negatively regulated by the CD69 receptor on lymphocytes, meaning 
they are retained in the lymph nodes 39. 
1.2.3 Lymph Node Development 
Lymph node development occurs during embryogenesis and involves signalling between 
stromal organiser cells at the site of the future lymph node, which eventually give rise to 
the stromal cell populations of the tissue, and cells derived from haematopoietic precursors 
called lymphoid tissue inducer (LTi) cells. The initial LTi progenitors are recruited from 
the foetal liver to the site of future lymph nodes by the chemokines CXCL13 and CCL21 
expressed by the stromal organiser cells 40. Upon arrival at the future lymph nodes, LTi 
cells promote lymph node development by signalling to the stromal organiser cells via 
lymphotoxin-α1β2 (LTα1β2), a member of the tumour necrosis factor (TNF) superfamily. 
Stromal organiser cells express the receptor for LTα1β2, Lymphotoxin-β Receptor (LβR), 
and ligand binding leads to differentiation, enhanced expression of cellular adhesion 
molecules and the chemokines CCL19, CCL21 and CXCL13 by the stromal cells 41. These 
chemokines are crucial for correct lymph node development, as mice which lack all three 
chemokines had severe disruptions in lymph node formation, although MLN appeared to 
be unaffected 42. 
Stromal cells are also induced to express Receptor activator of nuclear factor kappa-B 
ligand (RANKL) and interleukin-7 (IL-7), both of which induce further LTα1β2 expression 
by LTi cells 43. The receptors for these factors on LTi cells, Receptor activator of nuclear 
factor kappa-B (RANK) and interleukin-7 receptor (IL-7R), respectively, are essential for 
LN development 44,45. 
Retinoic acid signalling has also been shown to play a role in lymph node formation; LTi 
cells express the retinoic acid receptor, RORγt, and require it for their identity as LTi cells 
46. RA is also essential for stromal organiser cells to express CXCL13 to attract LTi cells; 
nerve fibres near the stromal organiser cells are positive for RALDH2, the enzyme 
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required to synthesise RA, suggesting the nerve fibres are the source of RA signalling that 
initiates LTi cell recruitment 40.   
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1.3 Spleen 
1.3.1 Structure and Function 
The spleen is the largest of the SLOs, and is the key site of immune surveillance of the 
blood for pathogens, particularly by macrophages, which are continually replenished by a 
large reservoir of monocytes constituting more than half of the monocytes in the body 47. 
The spleen is also host to significant populations of T cells, B cells and dendritic cells. 
Unlike other SLOs, the spleen is not part of the lymphatic network, and cells must migrate 
to and from the spleen from the blood circulation via splenic arterioles and venules. 
Histologically, the spleen is composed from two main tissue types: the red pulp and the 
white pulp. Red pulp regions are rich in microvasculature; white pulp regions, which form 
around the termini of the larger splenic arterioles, are where the majority of lymphocytes 
are located. 
1.3.1.1 White Pulp 
The architecture of the splenic white pulp is broadly comparable with that of the lymph 
node (Figure 1-3). Adjacent to the arteriole is the periarteriolar lymphoid sheath (PALS), 
composed mainly of T cells, similar to the lymph node cortex. Towards the periphery of 
the white pulp are the B cell follicles, which contain the majority of FO B cells in the 
spleen. The whole white pulp region is bordered by the marginal zone, which has some 
similarities to the subcapsular sinus in the lymph node as it is lined with CD169+ 
macrophages, known as marginal metallophilic macrophages (MMM). There is also an 
outer ring of SIGNR1+ marginal zone macrophages (MZM) in the marginal zone. In 
between lies the marginal sinus. In rodents, this area is connected to the circulation, 
allowing blood-borne cells and antigen to directly enter the white pulp. The ring of MMMs 
also contains gaps, known as bridging channels, that allow leukocytes to enter and exit the 
PALS via the marginal sinus 48. 
There is much similarity between the structure of the T cell zones and B cell follicles of the 
white pulp compared to those of the lymph node. T cell zones are home to mainly naïve T 
cells and DCs, interspersed with a network of conduits formed by FRCs that transport 
small molecules from the marginal zone to the PALS. B cell follicles are interspersed with  
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Figure 1-3: Structure of the spleen. 
A) Overview of the main anatomical features of the spleen. B) detailed view of the 
highlighted region in A, showing the arrangement of the splenic white pulp and marginal 
zone. C) detailed view of the highlighted region in B, showing the B cell follicles with 
FDCs, T cell areas with associated DCs, and DCs entering the marginal sinus via a 
terminal venule. The marginal sinus is bordered by MMMs towards the white pulp, and 
MZMs towards the red pulp. In the marginal zone reside the MZ B cells. 
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FDCs that present antigen to B cells and secrete CXCL13 that maintains their localisation 
in the follicle. CCL19 and CCL21 expressed by endothelial cells lining the splenic venules 
are required for T cell and DC localisation in the PALS 17,49. 
1.3.1.2 Marginal Zone 
The marginal zone can be considered an intermediate tissue type in between red and white 
pulp. It is a specialised network of macrophages, B cells, FRCs and endothelial cells that 
are involved in the surveillance of blood arriving via terminal venules 48. The key 
populations of cells unique to the marginal zone are MMMs, MZMs and MZB cells. 
MMMs are located closest to the white pulp. Similar to CD169+ macrophages in the SCS 
of the lymph node, they interact closely with B cells in the follicles. CD169 (SIGLEC-1) 
binds to sialic acid, potentially using this as a mechanism for capturing pathogens 
expressing these residues on their surfaces 48. They produce high levels of IFN-α and β in 
response to viral challenge 50. 
MZMs are highly phagocytic and are characterised by their expression of scavenging 
receptors including MARCO and SIGNR1. One key role for these cells is in detecting and 
phagocytosing apoptotic cells that enter the spleen from the blood. They also play a role in 
clearing viruses and polysaccharide antigen, as well as clearing important bacterial 
pathogens including Mycobacterium tuberculosis and Streptococcus pneumoniae 48. 
MZMs also express high levels of IFN-α and β, though not as large a quantity as MMMs 
50. 
MZ B cells are the final key population of the marginal zone. They are innate-like B cells, 
meaning they express an invariant BCR rather than the extreme BCR heterogeneity shown 
by follicular (FO) B cells. MZ B cells also distinguish themselves from FO B cells by 
responding directly to cognate antigen detected in the blood without the requirement for 
activation by a helper T cell. MZ B cells play a key role in inducing T-cell independent 
immune responses 51. Interestingly, MZ B cells are also capable of priming CD4+ T cells 
in the white pulp 52. MZ B cell localisation appears to rely on a combination of CXCL13 
and S1P signalling, as FTY720 leads to MZ B cell migration into the white pulp, while this 
response is not present in CXCL13-null mice 53. Moreover, during challenge with LPS, 
MZ B cells downregulate S1P and move into the follicles 53, suggesting these chemotactic 
signals are balanced during steady-state and inflammatory conditions. When mice are 
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treated with pertussis toxin, which ablates Gαi signalling, MZ B cells are absent from the 
marginal zone, while the B and T cell architecture of the white pulp is unaffected, 
suggesting that additional chemokine receptors are involved in MZ B cell positioning 54. 
MZ B cells are derived from immature B cells in the spleen that exit the bone marrow 
before completing maturation, but only a subset will become MZ B cells, while the rest 
develop into FO B cells as normal 55. Notch-2 signalling is essential for the development of 
MZ B cells while all other B cell subsets develop normally 56. Recombining binding 
protein suppressor of hairless (RBP-J), a DNA-binding protein that can be activated by 
binding to the intracellular domain of the Notch receptor, has also been shown to be vital 
for MZ B cell development 57, while the protein Msx2-interacting nuclear target protein 
(MINT), which competes with Notch  for RBP-J binding, is highly prevalent in FO B cells 
of the spleen 58, suggesting that cell fate decisions are influenced by intracellular levels of 
MINT in FO B cells. There is also evidence to suggest that the strength of BCR signalling 
is partially responsible for the FO vs MZ B cell fate decision, with cells that have weak 
BCR signalling becoming MZ B cells 55.  
1.3.1.3 Red Pulp 
The red pulp region has a critical role in blood surveillance and filtration. Specialised 
vessels are lined with sinusoidal endothelial cells, which have holes in between the cell-
cell junctions. When red blood cells attempt to pass through these fenestrae to enter the red 
pulp, they are forced to compress themselves putting strain on their cell membranes. Old or 
damaged red blood cells will break apart under this pressure, and resident macrophages 
scavenge the haemoglobin, as well as free haemoglobin in the blood 48. The red pulp is 
also home to plasma cells, which secrete antibodies into the bloodstream 59. 
1.3.2 Splenic Dendritic Cells 
The spleen is home to several subsets of tissue-resident DCs that are specialised to 
surveying the blood for antigen to present to naïve T cells. The main subsets of resident 
cDCs in SLOs including the spleen are characterised by their expression of various surface 
markers: CD11c+ MHC-IIlow CD8α+ CD205+ CD11b- DCIR2- (referred to here as CD8+ 
DCs) or CD11c+ MHC-IIlow CD8α- CD205- CD11b+ DCIR2+ (referred to here as 
CD11b+ DCs). The receptors CD205 on CD8+ DCs, and DCIR2 on CD11b+ DCs have 
been shown to function in antigen uptake and processing 60,61. CD11b+ DCs can be further 
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subdivided into CD4+ or CD4- 62. CD8+ DCs appear to be lymphoid in origin, while both 
subsets of CD11b+ DCs are derived from the myeloid lineage 63.  
In the spleen, CD8+ DCs appear to be mainly localised in the T cell areas 60,64, while 
CD11b+ DCs are more concentrated in the marginal zone and the red pulp 60. Although the 
distinctions between different DC subsets appear plastic to some extent 65, some distinct 
functions have been identified for these subsets. CD8+ DCs appear to be specialised for 
cross-presentation to CD8+ T cells 66, deletion of self-reactive CD8+ T cells 67 and 
endocytosis of dead cells 68. Conversely, CD11b+ DCs appear to be specialised towards 
priming CD4+ T cells 69-71. This appears to be related to differential antigen processing by 
these cells: CD8+ DCs are capable of presenting antigen on both MHC class I and II 
molecules, while CD11b+ DCs are restricted to presentation via MHC-II, but process and 
display antigen in this way more efficiently than do CD8+ DCs 60.  
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1.4 Skin 
1.4.1 Anatomy and Function of the Skin 
As a functional barrier between the organism and the outside world, the skin is the largest 
organ involved in immune surveillance. The skin is considered by some to be an SLO in its 
own right due to its importance in this regard 72. The skin consists of two main tissues: the 
epidermis and the dermis (Figure 1-4). The epidermis consists mainly of keratinocytes 
which form a tightly-connected sheet, interspersed with secreted keratins. The dermis 
consists mainly of a network of fibroblasts associated with an extracellular matrix (ECM) 
of collagen and elastin. Fibroblasts secrete these proteins to maintain ECM integrity. The 
dermis is rich in capillaries and in lymphatic vessels allowing cells to travel to and from 
the skin from distal sites. There are several anatomical differences between human and 
murine skin, and this section will focus on the latter. 
Keratinocytes in the interfollicular epidermis form layers, with the epidermal stem cells in 
the stratum basale, closest to the basement membrane separating epidermis and dermis, 
followed by three layers of stratum granulosum which contain progressively more 
differentiated cells 73. As they differentiate, cells are pushed upwards and eventually reach 
the stratum corneum, which is a thick outer layer of senescent and dead cells and keratin. 
The stratum corneum forms a physical barrier against the environment. This protective 
layer is continually shed and replenished as more keratinocytes from the epidermis 
eventually senesce. Keratinocyte differentiation is controlled by extracellular Ca2+ 
concentrations, and cells have been shown to regulate their proliferation and their 
expression of differentiation-related proteins, including involucrin, loricrin and keratins in 
response to Ca2+ 74,75. Ca2+ levels broadly increase from the most basal to distal regions of 
the skin, then decrease again in the stratum corneum; this gradient appears to form 
passively, maintained by the permeability barrier of the skin 75.  
The skin is interspersed with hair follicles, which are lined with keratinocytes, and 
therefore could be seen as representing ingrowths of the epidermis. Keratinocytes in the 
epidermis are heterogeneous, falling into five main subsets: interfollicular epidermis 
(epidermis not associated with the hair follicles), infundibulum (the upper region of the 
hair follicle, reaching to the entrance of the sebaceous glands), isthmus (the region  
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Figure 1-4: Structure of the skin. 
A) Overview of the main anatomical features of the skin. Shown are two hair follicles, one 
in anagen and one in telogen. On the anagen follicle, the main anatomical features and 
keratinocyte subsets are outlined: infundibulum, isthmus, bulge, and bulb/suprabulb, and 
the connection of sebaceous glands and arrector pili muscle. Within the dermis are 
lymphatic vessels and capillaries allowing trafficking of leukocytes to and from the SLOs. 
B) magnified view of the area highlighted in A. This shows the layers of keratinocytes in 
the epidermis: SB = stratum basale, SG = stratum granulosum, SC = stratum corneum. In 
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the epidermis, Langerhans cells and DETCs extend processes between keratinocytes to 
contact antigen. C) magnified view of the region highlighted in A. This shows the major 
resident leukocyte populations of the dermis, including mast cells near the basement 
membrane, dermal DCs distributed throughout the tissue and memory T cells divided 
between the epidermis/dermis junction and capillaries. 
extending from the  sebaceous gland to the attachment of the arrector pili muscle), bulge 
(the region where the muscle attaches) and bulb (the cells that produce the growing hair 
bulb) 76. 
Hair follicles cycle through distinct growth phases, the most prominent being anagen (hair 
growth) and telogen (senescence and shedding). When hair follicles are in telogen, the 
follicle undergoes significant remodelling, particularly in the bulge and bulb regions, as 
hair production ceases and the bulb cells undergo apoptosis 76. The stem cells of the hair 
follicle are located in the bulge region 77,78, and all the cells of the hair follicle are derived 
from these cells. Bulge cells are capable of repopulating the epidermis upon injury 78. 
Keratinocytes of the hair follicle have also been shown to play roles in immunity, by 
secreting chemokines during inflammatory conditions to attract immune cells, particularly 
Langerhans cells (LCs) 79, which will be discussed further below. 
While large numbers of leukocytes will be recruited to the skin during inflammation, there 
are several resident populations of leukocytes in non-inflamed skin. T cells are abundant in 
resting skin; the majority are CD4+ memory T cells 80,81, but there are also populations of 
regulatory T cells 80 and CD8+ memory T cells 81. Memory T cells are descended from T 
cells that migrated to the skin in response to a previous infection and formed a stable, long-
lasting population to protect against future infections by the same pathogen.  
Mast cells are mainly located in the upper dermis. They are known as the main cells 
involved in allergy; they irreversibly bind IgE antibodies produced by plasma cells to their 
cell-surface FcεRI receptors. When they encounter the antigen specific to the IgE 
molecules on their surface they respond by releasing histamine and cytokines to provoke 
an inflammatory response. Further roles for mast cells in immunity have been discovered, 
however, including secretion of cytokines, activating keratinocytes and remodelling ECM 
proteins to allow ingress of leukocytes 82. 
There are also several resident populations of dendritic cells in the skin. In the dermis, 
there are three major subsets of DCs characterised by CD103 and Langerin expression: 
Langerin+ CD103+, Langerin+ CD103-, Langerin- CD103+ and Langerin- CD103-, 
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although the Langerin- cells can also be subdivided into CD11b+ and CD11b- subsets 83. 
These cells are important for immune surveillance of the skin, and continually circulate 
between skin and skin-draining lymph nodes. 
1.4.2 Langerhans Cells 
Langerhans cells (LCs) are a unique class of myeloid-derived APCs. They are the only 
resident MHC-II+ cells in the epidermis. They express Langerin, a protein originally 
thought to be specific to LCs, but later discovered to be expressed by other DC subsets. In 
LCs, Langerin is found mainly in cytoplasmic organelles called Birbeck granules, which 
have an unknown function but are thought to be part of the endosomal recycling system 
and may be similar in role to clathrin-coated pits. Langerin has been shown to play a role 
in antigen processing 84 
Immature LCs congregate in the epidermis, particularly in the hair follicles 79, and extend 
their dendrites to capture antigen entering the skin. Upon detecting antigen, LCs mature by 
upregulating MHC-II and co-stimulatory molecules such as CD80 and CD86, and 
downregulating E-cadherin to detach from the surrounding keratinocytes. They also 
increase expression of the chemokine receptors CXCR4 and CCR7; CXCR4 allows them 
to migrate out of the epidermis by sensing CXCL12 produced in the dermis. Once in the 
dermis, LCs further upregulate CCR7 and downregulate CXCR4, and migrate towards the 
dermal lymphatic vessels via CCL19/21. From here they migrate to a skin draining lymph 
node, again via CCR7, and enter the T cell follicle to prime naïve T cells. 
Unlike other DC populations, Langerhans cells are initially derived from a precursor 
population that colonises the epidermis during development and is able to stably self-
renew under steady-state conditions 85. During stress, LCs can also be replenished from 
Gr-1+ precursors recruited from the blood 86. LC development is driven by TGF-β1, which 
is also essential for their survival 87,88. It is thought that paracrine TGF-β1 from 
haematopoietic origin initiates LC development, then TGF-β1 secreted by keratinocytes 
and LCs themselves maintains their survival once they reach the epidermis. LC precursors 
are attracted to the epidermis by chemokines produced by hair follicle keratinocytes in 
response to stress. 
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1.4.3 γδT Cells 
The only skin-resident subset of T cells in the mouse are Vγ3/Vδ1 T cells, also known as 
dendritic epidermal T cells (DETCs). These are a form of innate-like leukocytes, meaning 
they possess invariant TCRs. DETCs are activated by self-antigen expressed by damaged 
keratinocytes 89. There is evidence that this self-antigen is recognised via the γδTCRs of 
DETCs 90. Upon activation, DETCs can enhance the immune response by secreting IFN-γ 
91,92, and a subset of DETCs can produce IL-17A 93. DETCs are also able to secrete the 
inflammatory chemokines CCL3, CCL4, CCL5 and XCL1, which could attract other 
immune cells to the epidermis 94. They appear to play a role in wound healing in the skin, 
by secreting keratinocyte growth factor (KGF), as TCRδ-/- mice show impaired wound 
healing, and this could be restored in skin cultures by adding DETCs or KGF 95. 
1.4.4 Dendritic Cell Migration from Skin to Draining Lymph Nodes 
Skin-resident DCs are continually trafficking between skin and the T cell areas of skin-
draining lymph nodes to present antigen to naïve T cells. This occurs both during 
inflammation when activated DCs induce an immune response, and during steady-state 
conditions when immature DCs help maintain peripheral tolerance. CCR7 signalling is 
crucial for the exit of DCs from the skin in both of these circumstances: while LCs are still 
able to migrate from the epidermis to dermis in CCR7-/- mice, neither LCs or dermal DCs 
can enter lymphatic vessels or reach skin-draining lymph nodes. This is true both for 
inflamed and resting skin 96. CCR7 does not appear to be necessary, however, for the 
initial migration of LCs to the dermis; instead, the receptor CXCR4, which recognises 
CXCL12, is crucial during this process 97. 
Of the two CCR7 ligands, CCL21 appears to be essential for DC egress from the skin, 
while CCL19 plays a redundant role 12,98. It has been shown that CCL21 is able to form 
stable concentration gradients in the skin, as it has a positively-charged C-terminal that 
strongly interacts with extracellular proteoglycans 99. As CCL19 and CCL21 are expressed 
by dermal lymphatic endothelial cells, CCR7 expression allows DCs to migrate towards 
these vessels and enter the lymph flow. 
Once in the lymph node, CCR7 signalling is also required for DCs to reach the cortex and 
associate with naïve T cells. Upon reaching the lymph node in the afferent lymph, DCs 
migrate across the SCS floor and into T cell zones in a CCR7-dependent manner 100. 
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Again, functional gradients of CCL21 in this tissue appear to be required for DCs to cross 
the SCS 101.   
  45 
1.5 Chemokines 
Chemokines are small cytokines that are vital in controlling cell migration. This makes 
them key components of immunity, which requires the correct spatial targeting of cells 
from distant sites in the body. They are also important in processes related to immunity 
such as development of lymphoid organs, wound healing and angiogenesis. Aberrant 
chemokine expression and regulation is implicated in many diseases, including a variety of 
cancers and autoimmune disorders. 
Chemokines are divided into four families: CXC, CC, XC and CX3C, depending on a 
sequence of conserved cysteine residues near the N-terminal 102. The N-terminal region is 
the main receptor-binding site 103, and appears to specify functions including receptor 
agonism/antagonism, desensitisation and signalling via mobilisation of Ca2+ 104. Although 
the amino acid sequences of chemokines are highly variable, they show similar tertiary 
structures with conserved disulphide bonds between cysteine residues 102. 
1.5.1 Post-translational Regulation of Chemokine Function 
Chemokines can be subject to several possible post-translational modifications to their N-
terminal domains that affect their activity, including proteolysis by matrix metalloproteases 
105 or CD26 106. These can alter their affinity for their receptors, and the response generated 
within the cell upon ligand binding, for example inactivating chemokines 105, or causing 
them to become receptor antagonists 107,108. These modifications can also affect the ability 
of chemokines to bind to other proteins 102. 
Chemokines often associate as dimers, tetramers or oligomers 102 and although they are 
generally believed to function as monomers when inducing cell migration 102, receptor 
agonism has been reported for dimerised chemokines including CXCL1 109, and CXCL8 
110. Some chemokines are also capable of heterodimerising 111-113, although there is no 
conclusive evidence that hetero-oligomers are capable of directly inducing any signalling 
via their respective receptors and may instead be involved in modulating chemokine 
availability 102.  
Cell responses to chemokines are also modified depending on the form the chemokine is 
encountered in; glycosaminoglycans (GAGs) are glycoproteins that can often be found 
bound to a protein backbone to form membrane-bound peptidoglycans on the surface of 
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cells. These proteins are negatively charged and can form stable electrostatic bonds with 
the positively-charged C-terminal domains of certain chemokines. This interaction leads to 
chemokine immobilisation on the surface of cells and is vital to the function of many 
chemokines 114.  
When a responding cell recognises a chemokine bound in this way it initiates integrin-
mediated cell-cell adhesion, and leads to either directed migration along a gradient 
(haptotaxis) or random movement (haptokinesis) 115. This is most common on endothelial 
surfaces, including lymphatic endothelium as described (See section 1.2.2.3). 
Alternatively, cells can respond to soluble chemokines, either directed along a soluble 
gradient (chemotaxis) or randomly (chemokinesis) 116,117. Different chemokines have 
varying affinities for GAGs 118, making them more or less likely to be found in soluble or 
immobilised forms. The importance of the C-terminal domain for chemokines is illustrated 
by the observation that DCs are capable of cleaving the highly positively-charged C-
terminal domain of CCL21, generating a soluble form of CCL21 that behaves similarly to 
CCL19 119. Endothelial cells also express different GAGs on their surfaces, which will 
bind to different chemokines, potentially allowing the tissue-specific trapping of different 
chemokines 120. 
Chemokines can also be modified by the addition of various chemical groups, including 
nitration (the addition of peroxynitrite, a reactive oxygen species), which can affect the 
affinity and signal transduction capacity of chemokines for their receptors, or the ability of 
chemokines to bind GAGs 118. 
1.5.2 Inflammatory vs Homeostatic Chemokines 
Chemokines are separated into two families: homeostatic and inflammatory. Homeostatic 
chemokines are expressed constitutively during steady-state conditions to mediate 
leukocyte migration to and from tissues, and often also have roles in cell positioning 
during development. Inflammatory chemokines are generally only upregulated in response 
to a challenge such as infection or wounding. These chemokines are released to attract 
specific subsets of cells to a site of inflammation to carry out their intended function. In 
reality, there are overlaps between the functions of these chemokines, but this definition is 
useful to segregate between events during immune homeostasis and challenge. 
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Two examples of homeostatic chemokines are CCL19 and CCL21, which mediate APC 
migration to the T-cell zones of the lymph node at rest 96. These chemokines also play a 
role in T cell development in the thymus. plt-/- mice, which do not express CCL19 or 
CCL21, show a lack of T cells and reduced lymph node size 121, showing the importance of 
these chemokines in T cell and lymph node development.  
CXCL12 is another example of a homeostatic chemokine. It is constitutively expressed, 
and plays an important role in bone marrow homeostasis, maintaining the pool of 
haematopoietic stem cells within this tissue 122. It is also vital during development, as mice 
lacking CXCL12 or its receptors die during embryogenesis 122. In zebrafish, CXCL12 
signalling has shown to be important in development of the posterior lateral line as the 
initial primordial cells, which seed precursors along the flank of the embryo that develop 
into sense organs, follow a trail of CXCL12 123. 
One example of an inflammatory chemokine is CCL2, which binds to CCR2 on monocytes 
and memory T cells, recruiting them to the site of inflammation. Inflammatory chemokines 
generally attract multiple cell types spanning both innate and adaptive arms of the immune 
system, and these cells will often release chemokines themselves as part of their immune 
response, leading to multiple waves of different cell types that can arrive at the site of 
inflammation as the immune response progresses.  
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1.6 Chemokine Receptors 
As discussed previously, chemokines play a pivotal role in cell migration. In order to 
induce this effect, chemokines must bind to a receptor on the surface of the responding 
cell. Every cell is limited in which chemokines it can respond to, based on the complement 
of chemokine receptors it possesses. There is a large degree of redundancy in these 
relationships, as many chemokines bind multiple receptors and vice versa, allowing each 
cell to respond to a range of overlapping stimuli with varying affinities 124. 
Chemokine receptors are a class of G-protein coupled receptors (GPCRs) which have 
seven membrane-spanning domains. A conserved DRYLAIV motif on the second 
intracellular loop is thought to be important for chemokine receptor function 125. 
Like other GPCRs, chemokine receptors initiate downstream signalling via heterotrimeric 
G-proteins. Each G-protein is formed from Gα, Gβ and Gγ subunits. Gα binds to guanosine 
diphosphate (GDP) and is the subunit that interacts directly with the C-terminal of the 
receptor. Upon ligand binding, the conformation of the receptor C terminal changes, 
activating Gα and allowing it to replace GDP with guanosine triphosphate (GTP). Gα then 
leaves the receptor, while Gβ and γ remain dimerised, and both Gα-GTP and Gβγ initiate 
their own downstream signalling cascades 102. Chemokine-mediated cell migration is 
thought to be strictly via the Gi sub-family of G-proteins as it is sensitive to pertussis toxin, 
which ablates Gi activity 126. 
Once Gα and Gβγ proteins have carried out their downstream functions, they will be 
available for receptor binding once again. The C-terminal domain of the receptor, however, 
is phosphorylated by a G-protein coupled receptor kinase (GRK) upon ligand binding, 
making the previously activated receptor unavailable for G-protein binding 127. Instead, the 
phosphorylated GPCR binds to a β-arrestin which mediates receptor silencing. This is 
either transient, leading to receptor dephosphorylation and recycling to the cell surface, or 
can lead to long-term receptor silencing or permanent degradation 127. This means that 
cells will eventually become unresponsive to high levels of chemokines. 
Below, the main roles for the key receptors relevant to this work have been summarised. 
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1.6.1 CCR7 
CCR7 is the receptor for the chemokines CCL19 and CCL21, both of which are 
homeostatic chemokines with a role in leukocyte migration to SLOs. It is vital for the 
trafficking of APCs and T cells throughout the SLOs and tissues both during inflammation 
and homeostasis 96, which has been described in more detail above (See section 1.4.4), and 
it is also crucial for correct positioning of TFH and FO B cells within the lymph node (See 
section 1.2.2). Here, I will detail the role of CCR7 and CCR9 in thymocyte development. 
1.6.1.1 αβT Cell Development in the Thymus 
T cell precursors, or thymocytes, migrate to the thymus from the bone marrow to undergo 
maturation into naïve T cells. T cell maturation involves a number of crucial interactions 
between thymocytes and the thymus stroma. For these interactions to occur, the spatial 
positioning of thymocytes at various stages of development is key. Chemokines and their 
receptors are a vital part of this process. 
Thymocytes initially lack expression of CD4, CD8 and TCR proteins, and are known as 
double negative (DN) cells. As they mature, DN thymocytes pass through several 
developmental stages characterised by different surface receptors: DN1 cells are CD44+, 
CD25-; these cells upregulate CD25 to become DN2 CD44+ CD25+ cells. CD44 is then 
downregulated in DN3 cells, and DN4 cells then downregulate CD25 to become CD44- 
CD25- 128. While they progress through these developmental stages, thymocytes begin to 
express recombinase-activating genes (RAG-1 and RAG-2), and begin to undergo V(D)J 
recombination in their TCR loci 129. In this manner, a vast range of different TCR subunits 
can be produced from a single gene. This allows the body to produce T cells capable of 
recognising almost any conceivable protein, without the huge genetic burden it would 
require expressing each TCR variant as an individual gene. 
Thymocytes enter the thymus at the cortico-medullary junction, and progression through 
these developmental stages occurs in the cortex of the thymus while the cells migrate 
through this tissue. Chemokine receptor expression has shown to be important for cells to 
progress through these checkpoints, while both CCR7 ligands appear to be constitutively 
expressed in the thymus 130. About half of DN1 and DN2 cells are CCR7+ 130 but mainly 
CCR9- 131, while DN3 and DN4 cells are largely CCR7- and CCR9+ 131. These receptors 
have both been shown to be essential for cells to progress correctly through development 
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and become T cells; deleting CCR7 or CCR9 leads to developmental delay at the DN2 or 
DN3 stages, respectively 130,131.  
DN4 cells migrate back towards the cortico-medullary junction, where they begin to 
progress into the double positive (DP) stage. These cells are characterised by expression of 
both CD4 and CD8 and a lack of CD69 expression. DP cells interact with cortical thymic 
endothelial cells that present MHC molecules 17, and the strength of the interaction 
between the TCR of each DP cell and MHC determines the cell’s fate. Death by neglect 
occurs when cells react too weakly with self-antigen, and do not receive signals for 
survival and proliferation. Positive selection is the promoted survival of cells that weakly 
interact with self-peptides, and negative selection is the active destruction cells that 
strongly react 129. This process is an important part of central tolerance, where strongly 
self-reactive cells are selected against to prevent autoimmunity. 
DP cells that survive this selection continue to migrate from the cortico-medullary junction 
towards the medulla where they undergo further selection based on their reaction to self-
peptides presented by DCs and medullary thymic endothelial cells, and mature into either 
CD4+ or CD8+ single positive (SP) T cells which are highly CCR7+ 130. CCR7 may play a 
role in the migration of SP cells to the medulla, and their retention there while completing 
maturation; this appears to rely on CCL21 as thymus architecture appears normal in Ccl19-
/- mice 12. CCR9 expression on DP cells has also been noted to aid in migration of these 
cells to the medulla, potentially allowing them to outcompete CCR9- cells 131. Once in the 
medulla, most SP cells downregulate CCR9 131, and CCR9 expression on mature T cells is 
variable; in mice, the receptor is restricted to a gut-homing population of CD4+ memory T 
cells, while in humans it is expressed on a subset of CD8+ T cells 131,132. 
1.6.2 CXCR4 
CXCR4 is the receptor for the chemokine CXCL12. It has been implicated in many 
processes in immunity, development and disease, including HIV entry to T cells, cancer 
metastasis, haematopoiesis and cardiac development. As this work focused mainly on the 
skin, I will focus on the involvement by CXCR4 in cutaneous wound healing. 
CXCL12/CXCR4 have been shown to play a role in skin wound healing and chronic 
inflammation. In one study, mice showed increased levels of CXCL12 mRNA and protein 
at the site of a wound which peaked at days 1 and 5 after wounding but returned to normal 
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in between, while anti-CXCL12 antibodies applied to the wound site decreased the rate of 
wound healing; CXCR4-dependent trafficking of bone marrow stem cells to the wound site 
was also observed 133. Direct application of CXCL12 to wounds has also been shown to 
increase the rate of wound healing, and increase recruitment of infiltrating cells to the 
wound site 134. Conversely, topical application of the CXCR4 antagonist AMD3100 
improved wound healing in diabetic mice, leading to enhanced CXCL12 mRNA 
expression 135 and applying the CXCR4 antagonist 4F-benzoyl-TN14003 led to increase 
epithelialization in burn wounds 136. 
There is also some conflicting evidence for CXCL12/CXCR4 involvement in psoriasis. In 
the K14-VEGF-A mouse model of psoriasis - where over proliferation of basal 
keratinocytes is induced by expressing VEGF-A from the keratin 14 promoter 137 - there 
was significant upregulation of CXCR4 and CXCL12 in inflamed skin. Inflammation and 
angiogenesis was reduced by treatment with AMD3100, including reducing the number of 
infiltrating macrophages and CD8+ T cells in the tissue. CXCL12 neutralizing antibodies 
reduced inflammation and number of infiltrating macrophages and T cells in these mice 
138. 
Despite this potential role for CXCL12/CXCR4 signaling in driving inflammation, another 
model of psoriasis has been generated by deleting CXCR4 from basal keratinocytes using a 
K14-Cre conditional knockout and injecting IL-23, a key cytokine involved in psoriasis, to 
locally induce inflammation. This suggested that CXCR4 expression on basal 
keratinocytes has a protective role against IL-23-mediated inflammation 139. IL-23 induces 
proliferation of keratinocytes via STAT3 signaling. SOCS3, an inhibitor of STAT3 
phosphorylation 140, was found to be upregulated in response to CXCL12, suggesting that 
the CXCL12/CXCR4 axis negatively regulates IL-23 mediated cellular proliferation via 
SOCS3 139.  
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1.7 Atypical Chemokine Receptors 
In this introduction, several key processes in immunity have been described which require 
precise and directed cell migration. Chemokine-mediated cell migration is required for 
many of these processes. In particular, the chemokines CCL19, CCL21, CCL25 and 
CXCL12 have been discussed for their roles in immune homeostasis and development. 
Leukocyte trafficking to, and migration within, the lymph nodes is critical for the initiation 
of an adaptive immune response. The fine balance between tolerance and immune response 
that must be maintained in epithelial surfaces contacting the external environment is 
typified by the microenvironment of the skin. 
A further level of regulation is present in the chemokine system was added with the 
discovery of atypical chemokine receptors. Atypical chemokine receptors (ACKRs) are a 
class of chemokine receptors that do not induce cell migration upon ligand binding and are 
not reported to initiate G-protein mediated signalling. Instead, they induce alternative 
cellular functions which may include the internalisation and destruction of chemokines 
coupled with rapid receptor recycling (scavenging) or transporting chemokines across 
endothelial barriers 141. In at least one case, an atypical chemokine receptor can 
heterodimerise with a typical chemokine receptor to directly modify its function 142. The 
four members of the ACKR family are ACKR1 (Duffy Antigen/Chemokine Receptor, 
DARC), ACKR2 (D6), ACKR3 (CXCR7) and ACKR4 (CCX-CKR, CCR11, CCRL1) 125. 
The general function of ACKRs in the immune system appears to be to modulate cell 
migration by maintaining the formation of stable gradients of chemokine, however, this is 
an oversimplification of the true complexity and diversity of ACKR function. 
The structural reasons for atypical chemokine receptors’ unique behaviour are unknown. 
Atypical chemokine receptors have been characterised by the modification of a conserved 
DRYLAIV motif typically found in the second intracellular loop of chemokine receptors. 
In ACKR1, this motif is absent, and in ACKR2, 3 and 4 there are substantial modifications 
to this amino acid sequence; however, the atypical chemokine receptors have many other 
differences to the typical receptors, and there is no clear evidence that altering the 
DRYLAIV motif affects chemokine receptor signalling 125. 
ACKR1 and ACKR2 are highly promiscuous ACKRs that each bind to a host of 
chemokines. ACKR1 is expressed on erythrocytes and vascular endothelial cells 143, 
particularly HEVs 144. Ligand binding in ACKR1 does not activate any detectable 
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downstream signalling, but instead the receptor associates with caveolae, vesicles which 
are involved in transcytosis (transport of molecules across cells), suggesting that ACKR1 
on endothelial cells is able to transport chemokines across vessels 143. ACKR1 on 
erythrocytes appears to modulate levels of chemokines in plasma by scavenging them, thus 
maintaining homeostatic chemokine levels 143.  
ACKR2 binds to most inflammatory CC chemokines, and is most abundantly expressed on 
LECs, although it can also be found on innate-like B cells 143,145. D6 appears to function as 
a scavenging receptor, as the receptor is internalised via β-arrestin signalling then rapidly 
recycled to the cell surface while the ligand is degraded 146,147. D6 often appears to play a 
protective role in inflammation, commensurate with its function as a scavenger for pro-
inflammatory chemokines. For example, Ackr2-/- mice show increased susceptibility to 
skin inflammation upon immune challenge 148 and ACKR2 is raised in non-involved skin 
of psoriasis patients suggesting an anti-inflammatory role 149.  
In this work, I have focused on the two remaining members of the ACKR family: ACKR3 
and ACKR4, which between them bind the homeostatic chemokines discussed in this work 
so far: CXCL12, and CCL19/21/25, respectively.  
1.7.1 ACKR3 
ACKR3 is expressed mainly on endothelial and epithelial cells in a wide range of tissues 
including heart, kidney, liver, spleen and lung 150. ACKR3 expression has also been 
reported by some on MZ B cells, although this is controversial 150-153. ACKR3 binds two 
ligands: CXCL11, which also binds to CXR3, and CXCL12, which binds CXCR4. 
ACKR3 has been shown to scavenge both of these chemokines 154, and in fact binds 
CXCL12 with a greater affinity than CXCR4 does 155. In this work, the CXCL12/CXCR4 
axis has been the focus; partly due to the important roles for this chemokine/receptor 
pairing in diverse processes including skin inflammation, and due to the lack of functional 
CXCL11 in C57BL/6 mice 153, which is the genetic background all transgenic mice used in 
these experiments were bred in.  
ACKR3 has been shown to heterodimerise with CXCR4 where both receptors are 
coexpressed 156, and modulate cell responses to CXCL12 142,157. It has been shown that 
ACKR3 biases CXCL12 signalling towards β-arrestin-mediated responses rather than the 
Gi-mediated responses that predominate when CXCR4 is expressed alone 157. β-arrestin 
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signalling through CXCR4/CXCR7 activates cell proliferation and survival-related 
pathways including p38 MAPK, SAPK and ERK1/2 157. The disruption of Gi-mediated 
signalling does not ablate cell migration completely, but does potentially reduce 
chemotaxis towards low concentrations of CXCL12 in vivo 142. 
ACKR3 has important roles in development: most Ackr3-/- mice die as neonates due to 
cardiac defects 153 similar, but not identical, to those seen in Cxcr4-/- and Cxcl12-/- mice 
122,158, suggesting roles for ACKR3 in this process beyond modulating CXCR4/CXCL12 
activity. ACKR3 scavenging of CXCL12 by endothelial cells is also required for the 
correct development of the posterior lateral line in zebrafish 159. Additionally, ACKR3 on 
the vasculature appears to scavenge CXCL12 from the blood and allow the directed 
migration of CXCR4+ leukocytes to tissues 150.  
In addition to its ability to act as a chemokine scavenging receptor, ACKR3 also appears to 
be capable of downstream signalling events in response to chemokine binding, including 
β-arrestin binding, cell growth, survival, and even cell migration 155,160-163. In the liver, 
ACKR3 expressed on sinusoidal endothelial cells appears to promote regeneration and 
decrease fibrosis after liver injury 164. The ability of ACKR3 to promote cell growth and 
survival is likely the reason why it has been implicated in progression of many types of 
cancer, including breast cancer 165, melanoma 166, liver cancer 167 and kidney cancer 168. 
Here, I have studied ACKR3 mainly in the context of skin inflammation. Conflicting roles 
for CXCR4/CXCL12 involvement in this process have been reported, as described (See 
section 1.6.2), and the functional significance of ACKR3 expression in the skin has not yet 
been explored in depth. 
1.7.2 ACKR4  
ACKR4 is a scavenging receptor for the chemokines CCL19 and CCL21, which are the 
ligands for CCR7 101,169-172. It also binds the CCR9 ligand, CCL25 173. Both CCR7 and 
CCR9 play important roles in thymocyte development, as discussed previously (See 
section 1.6.1.1), and CCR7 is involved in homeostasis of APCs and T cells. CCR9 is also 
involved in homing of plasmacytoid DCs (pDCs) 174 and specific subsets of T cells to the 
gut 175, where subsets of fibroblasts have been reported to be ACKR4+ (C. Thomson, 
personal communication).  
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ACKR4 appears to play a role in the homing of DCs to the lymph node under both steady-
state and inflammatory conditions 176,177, most likely by scavenging CCL19 and/or CCL21: 
both chemokines are elevated in the lymph node, and CCL21 is elevated in the serum, of 
Ackr4-/- mice 178. LECs in the LN SCS express ACKR4, and in Ackr4-/- mice DCs appear to 
congregate in the SCS, unable to enter the lymph node proper, while CCL21 accumulates 
near the SCS wall 101. ACKR4 also appears to be important for DC migration to the skin-
draining lymph nodes during cutaneous inflammation. ACKR4 protein expression and 
function has been reported in keratinocytes in the epidermis, and lymphatic vessels in the 
dermis, using GFP reporter mice 177, immunofluorescence 179 and uptake of fluorescently-
labelled chemokines 179. In Ackr4 knockout mice, Langerhans cell migration from the skin 
to the skin-draining lymph nodes during TPA-mediated inflammation is impaired, and this 
is likely due to the dysregulation of CCL19 in the skin leading to ineffective migration of 
these cells from the dermis to lymphatic vessels 179. ACKR4 on LECs could also play a 
role in the transport of chemokines across endothelial cells, as ligand binding can lead to 
internalisation via caveolae 143, which mediate transcytosis 180.  
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1.8 Aims 
Chemokine-mediated cell migration is vital to both development and to immunity. 
Evidence is emerging to suggest that atypical chemokine receptors can act as an important 
component of immune regulation by carrying out functions including the modulation of 
chemokine availability. The often protective role of ACKR2 scavenging inflammatory 
chemokines in disease models including psoriasis149,181, cancer182, inflammation-induced 
miscarriage183 and lung inflammation184, have been explored to date, but the scavenging 
activity of ACKRs 3 and 4 are less well defined. Despite binding to homeostatic 
chemokines, rather than inflammatory, there is increasing evidence that ACKR3 and 
ACKR4 can also be involved in the innate immune response. In contrast to the 
inflammatory ACKRs, these receptors are fairly restricted in the ligands they can bind, 
making it more feasible to form a more comprehensive model of their interactions with 
chemokines and the cells expressing their receptors.  
The skin is the largest epithelial surface in the body. Cells of the skin are in constant 
contact with foreign antigen and must present both a physical and immunological barrier to 
external pathogens as well as physical injury. In this work, the relationships between 
ACKRs 3 and 4, their ligands and related receptors were further characterised in a model 
system. Other epithelia, particularly in the lungs and the gut, play important roles in 
immune surveillance and tolerance, but the skin was chosen as the main tissue of use for 
this study due to its relative ease of manipulation and dissection, availability of cells 
derived from donor human tissue, the past work carried out by other group members on 
this tissue, and the expression of both ACKR3 and ACKR4 by several subsets of stromal 
cells, along with the widespread presence of both CXCL12 and CCL19/21 in this tissue.  
The dynamics of CCL19/21-mediated leukocyte trafficking to and from skin-draining 
lymph nodes during steady state and inflammation have been well characterised, and 
previous investigations in this group have shown that ACKR4 deficiency can upset this 
balance, leading to impaired DC migration from the skin during inflammation. These 
investigations were continued by exploring the function of ACKR4 on skin cells in vitro, 
to obtain a more detailed picture of the mechanisms by which ACKR4 activity may be 
modified. These findings were followed up and expanded using a model of inflammation 
in vivo informed by these in vitro results. 
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ACKR3 has been less extensively studied in this group, and its main role in the literature is 
as a survival factor, particularly important as a negative prognostic factor in several types 
of cancer, and as a co-receptor with CXCR4 for HIV entry to CD4+ T cells; however, its 
role as a chemokine scavenging receptor has received somewhat less attention. Given the 
close similarity in its expression pattern to that of ACKR4, both of these being receptors 
largely restricted to endothelial and epithelial cells, a parallel study into ACKR3 responses 
to inflammation both in vitro and in vivo appeared to be a logical step.   
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1.9 Hypotheses 
The aims of the study were formulated in order to test the following hypotheses: 
1. ACKR3 and ACKR4 are expressed by keratinocytes and LECs in the skin and 
modify their activity in response to inflammatory stimuli in vitro. 
2. ACKR3 and CXCR4 are coexpressed by keratinocytes and LECs in the skin, and 
expression levels of these receptors are modified in response to inflammatory 
stimuli in vitro. 
3. ACKR4 deficiency leads to an enhanced inflammatory phenotype in a model of 
chronic skin inflammation. 
4. ACKR3 and ACKR4 on endothelial cells scavenge homeostatic chemokines to 
modify dendritic cell positioning in the spleen. 
Throughout the course of this project, these hypotheses were modified and refined. Some 
parts of the work had to be prioritised over others, or altered in scope, due to technical 
challenges. The results are presented as a whole in the Discussion section (Chapter 6). 
  
 
 
 
 
 
Chapter 2: Materials and Methods  
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2 Materials and Methods 
2.1 Cell Culture 
Normal human epidermal keratinocytes (nHEK) and human dermal lymphatic endothelial 
cells (HD-LEC) were obtained from single juvenile donors of foreskin tissue, purchased 
from PromoCell. Cells were sub-cultured per the manufacturer's directions, using the 
recommended media and passaging reagents and splitting cells when 70-80% confluent. 
All cells were used between passages 7-9. For long-term storage, cells were immersed in 
liquid nitrogen in cryoSFM media (PromoCell). When thawing cells, tubes were quickly 
warmed to 37° C in a water bath and cells were transferred directly to a T25 (Corning) 
containing fresh pre-warmed media. Media was replaced the following day. nHEKs were 
routinely cultured using media with a low calcium concentration (0.06 mM Ca2+; LoCa) as 
directed by the manufacturer; if producing differentiated keratinocytes for experimental 
reasons, cells were switched to high calcium (0.18 mM Ca2+; HiCa) media five days before 
use. 
2.1.1 Treatment of Human Cells with Immune Stimuli 
Cells were seeded on 6-well plates and cultured until near-confluent. The following 
treatments (Table 2-1) were applied for durations specified in the individual experimental 
descriptions and cells were either used for further experiments or RNA was harvested. 
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Table 2-1: Immune stimuli used for cultured human cells 
TREATMENT CONCENTRATION SUPPLIER 
CpG 100 nM unknown 
IFN-α 100 ng/ml R&D Systems 
IFN-β 100 ng/ml R&D Systems 
IFN-γ 100 ng/ml R&D Systems 
KGF 20 ng/ml R&D Systems 
LPS 500 ng/ml unknown 
TPA 100 nM Invitrogen 
 
2.1.2 RNA Extraction from Cultured Cells 
Cells were grown in 6-well plates using standard growth media until 70% confluent, and 
treatments (e.g. TLR ligands or cytokines) were added as appropriate. After the allotted 
time determined by the individual experiment, media was aspirated, cells were washed 
three times with ice-cold PBS and cells were lysed and RNA extracted using a PureLink 
RNEasy Mini Kit (Ambion) per the manufacturer's instructions. RNA concentration was 
measured using a NanoDrop spectrophotometer, and samples were stored at -80º C until 
required. 
2.1.3 Chemokine Scavenging Assay 
Cells were cultured for 3 days in 12-well plates; at the same time, media-only control wells 
were also set up. Media was aspirated from all wells, and 500 µl phosphate buffered saline 
(PBS)/10% bovine serum albumin (BSA) (w/v) in culture media was added and allowed to 
coat the cells or empty wells for 5 minutes. Recombinant CXCL12 or CCL19 (Almac, 
Peprotech) were added to media and 500 µl was added to each well still containing 
PBS/BSA to give a final chemokine concentration of either 1.56 ng/ml or 7.8 ng/ml. Plates 
were mixed gently, and 25 µl of supernatant was taken from each well and stored at -20º C. 
Cells were cultured with chemokine for 24 hours total, with further aliquots of media taken 
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at fixed timepoints. Chemokine levels in each sample were determined using an ELISA kit 
(R&D Systems) per the manufacturer's directions. 
2.1.4 Immunofluorescent staining of cultured cells 
Cells were grown in 12-well plates on pre-sterilised glass coverslips until confluent. Media 
was aspirated and cells were fixed in warm 4% paraformaldehyde in PBS for 15 minutes. 
Cells were then washed three times for five minutes with ice-cold PBS. Cells were 
incubated for 1 hour at room temperature with blocking buffer [PBS, 10% v/v donkey 
serum]. The buffer was aspirated, and primary antibodies were diluted in blocking buffer 
per the manufacturer's directions and added to wells under a layer of Parafilm. Plates were 
incubated at 4° C overnight, then washed three times in PBS. Secondary antibodies were 
added at the manufacturer's recommended concentration in blocking buffer, and plates 
were incubated for 2 hours at room temperature in the dark. If a second primary antibody 
was used, the procedure was repeated as described using antibodies from different species. 
Cells were washed three times in PBS and coverslips were removed from wells and 
mounted on untreated glass slides using Vectashield mountant with 4',6-diamidino-2-
phenylindole (DAPI; VectorLabs), and sealed with clear nail varnish. Slides were stored in 
the dark at 4° C until viewing with a Zeiss AxioImager M2 fluorescence microscope at 
20X or 35X magnification. 
2.2 Animals 
All animals were bred and maintained under specific pathogen-free conditions (SPF) at the 
Central Research Facility (CRF) at the University of Glasgow unless otherwise indicated. 
All procedures were conducted in accordance with the UK Home Office regulations, were 
designed to comply with the necessary project and personal licenses and received ethical 
approval from the University of Glasgow ethics committee.  
Male animals aged between 6-12 weeks were used for all experiments and age-matched as 
closely as possible within each individual experiment, unless otherwise stated. For crosses 
between wild-type and transgenic mice, wild-type females and transgenic males were 
normally used; for the Ackr3gfp/+ colony this was not always possible due to low numbers 
of transgenic mice retrieved from initial matings. 
• Wild-type (WT) C57BL/6JOlaHSD mice were purchased from Envigo. 
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• Ackr4-/- mice on a C57Bl-6 background were generated as described previously 178. 
These mice have been reported to show reduced numbers of Langerhans cells in 
skin-draining lymph nodes at rest 179 but no overall defects in lymphoid tissue 
development.Ackr4+/gfp knock-in mice on a C57BL/6 background were a kind gift 
from Thomas Bohm and were generated as described 177. Briefly, the N-terminus of 
the coding exon of Ackr4 in these mice was replaced with an in-frame eGFP 
cassette, so that eGFP expression reflects Ackr4 mRNA expression. No differential 
phenotype between Ackr4+/gfp heterozygotes and wild-type mice has been reported. 
Ackr4gfp/gfp homozygotes are functionally Ackr4-null.C57BL/6-Ackr3tm1Litt/J 
(Ackr3+/gfp) knock-in mice were generated by Dan Littman on a C57BL/6 
background 185. These mice were purchased from The Jackson Laboratory and 
imported by Charles River. As with the Ackr4+/gfp knock-in mice, eGFP expression 
reflects Ackr3 expression in this strain. The heterozygotes of this strain have no 
reported phenotype, but homozygotes die as neonates due to cardiac defects. 
• Ackr4-/- Ccl19-/- Double Knockout (DKO) mice were generated by crossing Ackr4-/- 
mice with Ccl19-/- mice, which were obtained from Sanjiv Luther and generated as 
described 12. The phenotype of these mice has not been characterised in detail but is 
presumed to be similar to the single knockouts. Ccl19-/- mice were not reported to 
display any defects in lymphoid tissue development or leukocyte homing at rest 12. 
• OT1 x Ly5.1 mice on a C57BL/6J background were bred and maintained at the 
Beatson Institute under SPF. These mice express the CD45 isoform, CD45.1 on all 
leukocytes. They also express transgenic TCRs leading to MHC-I restricted T cells 
that react specifically to the protein ovalbumin. These mice are slightly immune 
compromised due to their limited T cell repertoire but possess no gross 
abnormalities.  
 
2.2.1 Sample Handling and Preparation 
All tissue was obtained from mice previously culled by asphyxiation in a rising 
concentration of CO2. 
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2.2.1.1 in vitro Generation of Murine Langerhans Cells 
Bone marrow was obtained from wild-type and Ackr4+/gfp knock-in mice by extracting 
bones from hind legs, cutting either end and flushing the bone marrow out using complete 
RPMI (Gibco) in a syringe. Tissue was passed through a 45 µm cell strainer and rinsed 
with complete RPMI. Cells were centrifuged at 300 x g for 5 minutes, resuspended in 10 
ml of RPMI with 40 ng/ml GM-CSF, 2.5 ng/ml TGF-β1 and 5 ng/ml TNF-α. Cells were 
counted and added to 10 cm ultra-low adhesion plates at between 1 x 106- 1 x 108 cells per 
plate. Cytokine-supplemented media as described was added to give a total volume of 10 
ml on each plate. 5ml fresh media was added every second day; cells were re-plated after 4 
days by aspirating media to a centrifuge tube, rinsing plates with 5 ml PBS and 
centrifuging cells at 300 x g for 5 minutes. Cells were resuspended in 10 ml of fresh 
cytokine-supplemented media and seeded on to new 10 cm plates. After 8 days, cells were 
plated on tissue culture-treated plates overnight, and non-adherent cells removed and used 
for further analysis. 
2.2.1.2 Collection and Processing of Mouse Blood 
Prior to blood collection, 100 µl 0.5 M Ethylenediaminetetraacetic acid (EDTA) was added 
to one 1.5 ml Eppendorf per mouse and each aliquot was passed a through a syringe to coat 
the interior. Blood was extracted using pre-coated syringes either via the aorta or the 
posterior vena cava between the kidneys. Blood was transferred to the Eppendorf 
containing EDTA, removing the needle from the syringe to avoid shearing cells. Samples 
were optionally centrifuged at 800 x g for 5 minutes and plasma aspirated if required for 
analysis. Samples were mixed thoroughly with 9 ml dH2O and incubated for one minute to 
lyse red blood cells before 1 ml 10X PBS was added and samples were passed through a 
100 µm cell strainer. Samples were centrifuged at 400 x g for 5 minutes; cell pellets were 
then resuspended in FACS buffer [PBS, 2 nM EDTA, 2% FCS, 0.1% NaNH3] and used for 
flow cytometry analysis. 
2.2.1.3 Preparation of Cell Suspensions from Mouse Ears 
Ears were excised and kept on ice before being split with forceps into dorsal and ventral 
halves and floated dermis-side down on 0.25% Trypsin-EDTA (Sigma). Dorsal halves 
were incubated at 37° C for 22 minutes; the thicker ventral halves (including collagen and 
subcutaneous fat) were incubated at 37° C for 45 minutes. Trypsin was washed from ears 
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by briefly floating dermis side down in PBS. Epidermis was peeled off using forceps from 
the outer tip of the ear in one motion. Epidermis was transferred a 2 ml Eppendorf tube 
containing 1 ml RPMI and stored on ice until incubation of both dorsal and ventral halves 
was complete. Dermis, if required in the experiment, was transferred to a 2 ml Eppendorf 
tube containing 1 ml RPMI. Tissue was minced with scissors and 1 ml 2X stromal digest 
cocktail [RPMI-1640, 1.6 mg/ml Dispase (Roche), 0.4 mg/ml Collagenase P (Roche), 0.2 
mg/ml DNase I (Roche)] was added to each tube. Samples were incubated at 37° C for 10-
12 minutes and passed through 100 µm cell strainers on ice, then flushed with media until 
the tube contained a total volume of 20 ml. Samples were centrifuged at 400 x g at 4° C for 
5 minutes, supernatants discarded, and cells were resuspended in FACS buffer to use for 
flow cytometry analysis. 
2.2.1.4 Preparation of Cell Suspensions from Mouse Heart 
Hearts were excised and stored in RPMI on ice until needed. Each heart was transferred to 
a petri dish containing 5 ml Hank’s Balanced Salt Solution (HBSS; Gibco), cut open to 
expose the inner surfaces of the ventricles and rinsed to remove any traces of blood. The 
heart was transferred to the lid of the dish and minced finely with scissors. The tissue from 
each heart was transferred to a 15 ml Falcon tube on ice containing 5 ml Collagenase I 
solution [HBSS, 1 mg/ml Collagenase I (Roche)]. The tubes were gently mixed and 
incubated at 37° C with shaking for 30 minutes. The tubes were manually agitated every 5-
10 minutes to minimise formation of tissue aggregates. After digestion, tissue was 
disrupted with a 10 ml serological pipette. Samples were centrifuged at 400 x g for 5 
minutes and supernatants were discarded and tissue resuspended in 5 ml ice cold Dispase 
solution [HBSS, 0.25 mg/ml Dispase]. Tubes were incubated for a further 20 minutes at 
37° C with shaking, and the digestion was terminated by adding 5 ml ice-cold HBSS and 
placing on ice. Samples were agitated with a 10 ml serological pipette and passed through 
a 50 µm cell strainer. Cells were centrifuged at 400 x g for 5 minutes and resuspended in 
FACS buffer, then used for flow cytometry analysis. 
2.2.1.5 Preparation of Cell Suspensions from Mouse Lymph Nodes 
Lymph nodes were excised (unless otherwise stated, inguinal lymph nodes were used), 
pierced with fine forceps and stored on ice in RPMI (Gibco) until needed. Media was 
replaced with 3 ml of 1X stromal digest cocktail [RPMI-1640, 0.8 mg/ml Dispase, 0.2 
mg/ml Collagenase P, 0.1 mg/ml DNase I (Roche)] and tissue was incubated at 37° C for 
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20 minutes with shaking. Lymph nodes were gently agitated with a P1000 pipette to 
release leukocytes, tissue was allowed to settle to the bottom of the vial, and the 
supernatant was transferred to a 15 ml Falcon tube on ice containing 5 ml FACS buffer 
with care not to transfer any particulate matter. 2 ml of fresh stromal digest cocktail was 
added to each vial and incubated at 37° C for a further 5 minutes with shaking. Meanwhile, 
the collected supernatant was centrifuged at 400 x g for 5 minutes, and the cells were 
resuspended in 5 ml fresh FACS buffer and stored on ice. The procedure of agitating 
tissue, removing and washing the supernatant and digesting any remaining particulate 
matter was repeated until either the nodes were completely digested or 1 hour elapsed from 
the first addition of stromal digest cocktail. The collected cells and any remaining tissue 
were passed through an 80 µm cell strainer, then used for flow cytometry analysis. 
2.2.1.6 Preparation of Cell Suspensions from Mouse Spleen 
Spleens were excised and kept on ice in RPMI until needed. In a Petri dish, as much fat 
and connective tissue was removed as possible and the spleens were minced using scissors. 
1 ml of HBSS with 1 mg/ml Collagenase D (Roche) was used to flush the tissue into a 1.5 
ml Eppendorf tube. A further 500 µl was used to rinse the Petri dish and ensure all tissue 
was recovered. Tissue was incubated at 37º C for 40 minutes, triturated using a 5 ml 
serological pipette and passed through a 70 µm cell strainer, rinsing with FACS buffer. 
Cells were centrifuged at 400 x g for 5 minutes at 4º C and the pellet was gently 
resuspended in residual buffer to prevent forming of aggregates. Cells were resuspended in 
1 ml RBC lysis buffer (Sigma). After one minute, the samples were flooded with 25 ml of 
FACS buffer. Samples were centrifuged as before and resuspended in 10 ml of FACS 
buffer, then used for flow cytometry analysis. 
2.2.2 Genotyping of Genetically-modified Mice 
Tail tips or ear punches were obtained by animal facility staff and stored in 1.5 ml 
Eppendorfs at -20° C. Samples were incubated at 55° C in 100 µl tail-tip lysis buffer [5 
mM EDTA, 0.1 mg/ml Proteinase K, 0.2% w/v SDS, 100 mM Tris.HCl, 200 mM NaCl] 
for 5 hours or overnight. Samples were heated to 95° C for 5 minutes and 500 µl dH2O was 
added. Samples were then centrifuged for 5 minutes at 13000 rpm in a microcentrifuge to 
remove cellular debris.  
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The supernatant was used in a PCR reaction to determine the genotype of each mouse: A 
stock working primer mix was made by combining equal volumes of all primers required 
for the reaction and diluting this 1:10 in PBS. Each reaction contained 12.5 µl GOTaq G2 
Hot Start Green Master Mix (Promega), 10 µl nuclease-free water, 1.5 µl primer mix and 1 
µl supernatant from lysed tissue. Tubes were mixed gently with a pipette, pulsed in a micro 
centrifuge and the following PCR program was used: 
94°C 5 min 
94°C 15 sec 
60°C 30 sec 
72°C 45 sec 
72°C 10 min  
4°C ¥ 
Samples were electrophoresed for 45 minutes at 100 V on a 2% agarose gel containing 0.5 
µg/ml Ethidium Bromide (EtBR). DNA was visualised using a UV transilluminator. 
PCR Primers used and expected band sizes were as follows: 
Ackr4-gfp 
Forward 1: TGAACTTGTGGCCGTTTACGT 
Reverse 1: CACACACAGCAACAGATGATCC 
Reverse 2: TAGGATTTAGTGACTAAGAGC 
WT band: 300bp 
GFP band: 600bp 
Ackr3-gfp 
Forward 1: GATGTAGCAGTGCGTGTCGT 
Reverse 1: GAACTTCAGGGTCAGCTTGC 
Reverse 2: GTCACTTGGTCGCTCTCCTC 
WT band: 275bp 
GFP band: 175bp 
x35 
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Ccl19-/- 
Forward 1: GCCTCAGATTATCTGCCAT 
Reverse 1: CATTAAGAAGGTAGCGGAAGG 
Reverse 2: ACCTTGTATTCCTTTGTCGAGAGG 
WT band: 1270 bp 
KO band: 1169 bp 
Ackr4-/- 
Forward 1: TGA ACT TGT GGC CGT TTA CGT C 
Reverse 1: CAC ACA CAG CAA CAG ATG ATC C 
Reverse 2: TAG GAT TTA GTG ACT AAG AGC 
WT band: 700 bp 
KO band: 320 bp 
 
Note: Ackr4-/- Ccl19-/- mice were genotyped by Carolyn Thomson. Positive and negative 
controls were not used for genotyping. 
 
Figure 2-1: Example genotyping result for Ackr4-gfp reporter mice. 
2.2.3 In vivo Methods 
2.2.3.1 Chemokine Receptor Blockade 
To block CXCR4 function, AMD3100 (Sigma) reconstituted in PBS was injected 
subcutaneously 24 hours before application of topical irritants at a concentration of 5 
mg/kg (estimated from standard growth curve for C57BL/6J mice provided by Harlan) and 
repeated every 12 hours thereafter over the course of the experiment. 
Ladder 
WT 
GFP 
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2.2.3.2 Induction of Cutaneous Inflammation 
Mice were treated on both surfaces of each ear with topical irritants; alternatively, the 
lower back was shaved and Nair depilatory cream added for 30 seconds before thoroughly 
washing with PBS one day prior to treating the back with topical irritants. 
Table 2-2: Details of Cutaneous Treatments 
IRRITANT PROCEDURE (EAR) PROCEDURE (BACK) 
TPA (12-O-
tetradecanoylphorbol-13-
acetate – Invitrogen) 
50 µl TPA [50 µM, acetone] 
per ear. 
Control: 50 µl acetone per ear 
Single application or three 
daily applications. 
100 µl TPA [50 µM, 
acetone] 
Control: 100 µl acetone 
Single application or 
three daily applications. 
IMQ (Aldara cream, 5% 
imiquimod -3M) 
42 mg 5% IMQ (1/6 sachet) 
per ear 
Control: Vaseline 
Five daily applications 
62.5 mg 5% IMQ (1/4 
sachet) per mouse 
Control: Vaseline 
Single application or 
three daily applications. 
 
2.2.3.3 Adoptive Transfer of Murine Splenocytes 
All steps were carried out in a sterile hood and all reagents were filter sterilised before use. 
Spleens were harvested from male OT1 x Ly5.1 mice aged between 6-8 weeks. Typically, 
1 or 2 pooled spleens were used. Tissue was passed through a 70 µm cell strainer in 
separation buffer [PBS, 2% Foetal Calf Serum, 1 mM EDTA]. Cells were counted and 
either resuspended at 1 x 107 cells/ml in PBS to adoptively transfer all splenocytes, or to 
transfer B cells only splenocytes were resuspended in separation buffer to use with a B 
Cell separation kit (Stem Cell Technologies) per the manufacturer’s directions. Cells were 
then resuspended at a volume of 1 x 107 cells/ml in PBS. Whether splenocytes or B cells 
were used, 100 µl of single cell suspension was injected into each host mouse via the tail 
vein. After 16 hours recipient mice were culled using a Schedule 1 method and lymph 
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nodes, blood and/or spleens were harvested and used for flow cytometry analysis. 
Adoptively transferred splenocytes were identified using anti-CD45.1 antibody. 
2.3 General Techniques 
2.3.1 Protein Extraction from Tissue 
Tissues were excised and kept on ice in RPMI until needed. 2 ml Eppendorf tubes were 
placed on dry ice, and a 5 mm stainless steel bead (Qiagen) was placed into each tube. A 
maximum of 30 mg of tissue was added to each tube. Samples were transferred to ice, and 
200 µl of T-PER (Thermo Fisher) was added to each. Tissue was disrupted using a Qiagen 
TissueLyser at 40 Hz for 5 minutes. Homogenized samples were aspirated and centrifuged 
at 13000 rpm in a bench-top centrifuge for 5 minutes. Supernatants were removed and 
stored at -20º C until required. 
2.3.2 Immunofluorescent Staining of Frozen Tissue Sections 
Excised tissues were immersed in OCT (Tissue Tek) in plastic disposable cryomolds as 
quickly as possible after dissection; however, for GFP knock-in mice, tissues were fixed 
overnight in 4% formaldehyde prior to embedding and protected from light to preserve 
GFP signal. Tissues in OCT were frozen on dry ice then stored at -80° C before preparing 
sections using a cryotome (Thermo Scientific). Sections were cut between 7-15 µm 
depending on the tissue (7 µm: spleen, 15 µm: skin) and transferred to Polysine slides 
(Thermo Scientific). Slides were air dried for 30 minutes or overnight then stored at -80° C 
until required. When using, slides were air-dried for 30 minutes, fixed for 15 minutes in 
cold acetone (this step was not carried out for formaldehyde-fixed sections) then removed 
and the perimeter of each tissue section was marked with a wax pen, forming a 
hydrophobic barrier to keep reagents on the slide and prevent mixing. Slides were blocked 
with blocking buffer [10% donkey serum in PBS] for 30 minutes at room temperature. 
Blocking buffer was removed gently, and primary antibodies were added in PBS at the 
manufacturer’s recommended dilution for 2 hours at room temperature or overnight at 4° 
C. Slides were washed three times for 5 minutes with shaking in PBS. Secondary 
antibodies were added in PBS at the manufacturer’s recommended dilution for 30 minutes 
at room temperature. Slides were washed as before and mounted using Vectashield 
mountant (with or without DAPI as appropriate; Vector Labs) and sealed under a coverslip 
with clear nail varnish.  
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Table 2-3: List of Antibodies Used for Immunofluorescent Staining 
Note: all antibodies are anti-mouse and used at 1:200 unless otherwise stated. 
ANTIGEN CLONE SUPPLIER CONCENTRATION 
ACKR3 
CXCR7 
(α-human) 
11G8 (mouse) R&D Systems 1:100 
ACKR3 
(α-human) 
Polyclonal (rabbit) Abcam 1:100 
ACKR4 
CCRL1 
Polyclonal (goat) Santa Cruz Biotech 1:50 
ACKR4  
CCRL1 
(α-human) 
13E11 BioLegend 1:50 
B220 RA3-6B2 eBioscience  
CCL21 Polyclonal (goat) R&D Systems  
CD169 3D6.112 eBioscience  
CD205 DEC-205 BioLegend 1:100 
CD31 390 BioLegend  
CXCR4 
(α-human) 
12G5 R&D Systems 1:100 
CXCR4 
(α-human/ mouse) 
Polyclonal (rabbit) Abcam 1:100 
DCIR2 33D1 BioLegend 1:100 
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LYVE-1 223322 R&D Systems  
MHC-II M5/114.15.2 BioLegend  
 
2.3.3 Flow Cytometry 
Cells were counted using a haemocytometer or Luna FL (Labtech) with Trypan Blue 
exclusion. Up to 5 x 106 cells were used per tube for flow cytometry. Half of one sample 
was removed and heat-killed by incubating at 65º C for 5 minutes, then mixed with the live 
half to serve as a live-dead only control. Cells were centrifuged at 400 x g for 5 minutes 
and resuspended in 0.1% v/v APC-e780 fixable viability dye (eBioscience) in PBS, then 
incubated on ice for 20 minutes. Cells were centrifuged as before and resuspended in 
FACS buffer containing Fc blocker (BD Biosciences or BioLegend) at a concentration of 
1:100. Samples were incubated on ice for 20 minutes then centrifuged as before. Samples 
were resuspended in FACS buffer containing panels of antibodies for extracellular 
staining, normally at a concentration of 1:200; Fluorescence-minus-one (FMO) controls 
were set up to aid gating, by staining cells with all but one antibody from the panel. In 
practice, this was only done for markers that were difficult to discriminate, to conserve 
antibodies and samples when using large panels of antibodies. Samples were incubated on 
ice for 15 minutes then centrifuged as before. For immediate FACS analysis, cells were 
resuspended in FACS buffer. For future analysis or intracellular staining, cells were 
resuspended in CytoFix/CytoPerm (BD Biosciences) on ice for 20 minutes. If staining for 
intracellular markers, cells were resuspended in antibody diluted in 1 X PermWash (BD 
Biosciences) for 20 minutes on ice. Cells were resuspended in FACS buffer and analysed 
within 3 days. 
When blood was analysed via flow cytometry, the original volume of every sample was 
noted before processing and 10µl fluorescent counting beads (BD Biosciences) was added 
to each tube immediately prior to sample acquisition. The total cell count was obtained by 
the following calculation:  
!"#$%&	()	*+,%	-%**.	&%-(&/%/!"#$%&	()	$%0/.	&%-(&/%/ × !"#$%&	()	$%0/.	0//%/,(*"#%	()	$*((/  
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where the number of beads added was the manufacturer’s stated number of beads per µl 
multiplied by the volume added to each tube. Beads were identified by their high 
fluorescence in the FITC/PerCP channels and FSC/SSC properties. 
 
Figure 2-2: Flow Cytometry Gating Strategy for Identifying Counting Beads. 
Single-stained compensation controls were set up for each antibody using UltraComp 
eBeads (eBioscience) according to the manufacturer’s directions. For viability dyes, a 
small sample of heat-killed cells (incubated for 10 minutes at 64º C) mixed equally with 
viable cells was stained with viability dye as described. 
Table 2-4: List of Antibodies Used for Flow Cytometry 
Note: all antibodies are anti-mouse and used at 1:200 unless otherwise stated. 
ANTIGEN CLONE SUPPLIER CONCENTRATION 
ACKR3 
(α-human/ mouse) 
11G8 (mouse) R&D Systems 1:100 
ACKR4 Polyclonal (goat) Santa Cruz 1:50 
B220 RA3-6B2 eBioscience  
CCR2 475301 R&D systems 1:20 
CD101 Moushi101 eBioscience  
CD103 2E7 BioLegend  
CD11b M1/70 BioLegend  
Beads 
0.84% 
PE 
FI
TC
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CD11c N418 eBioscience  
CD205 DEC-205 BioLegend 1:100 
CD207 
Langerin 
EbioL31 eBioscience 1:50 
CD31 390   
CD31 390 BioLegend 1:200 
CD326 
EpCAM 
G8.8 eBioscience  
CD34 MEC14.7 BioLegend  
CD3ε 145-2C11 BioLegend  
CD4 RM4-5 eBioscience  
CD45 30-F11 BioLegend  
CD45.1 A20 BioLegend  
CD49f 
α6 integrin 
(α-human/ mouse) 
GoH3 BioLegend  
CD8α 53-6.7 BioLegend  
CXCR4 
(α-human/ mouse) 
Polyclonal (rabbit) Abcam 1:100 
CXCR4 
(α-mouse) 
2B11 eBioscience 1:50 
DCIR2 33D1 BioLegend 1:100 
gp38 8.1.1 BioLegend  
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Ly6C HK1.4 BioLegend  
LYVE-1 223322 R&D Systems  
MadCAM1 MECA-367 BD Biosciences  
MCAM-1 
CD146 
ME-9F1 BioLegend  
MHC-II M5/114.15.2 eBioscience  
NK1.1 PK136 BioLegend  
Sca-1 
Ly6A/E 
D7 eBioscience  
SiglecH 440c BD Biosciences  
TCRβ H57-597 BioLegend  
VCAM-1 
CD106 
429(MVCAM.A) BD Biosciences  
VE-Cadherin 
CD144 
BV13 eBioscience  
γδTCR GL3 BioLegend  
 
2.3.4 Fluorescent Chemokine Uptake 
Up to 2 x 106 cells per well were added to ultra-low binding round-bottom 96-well plates 
(Sigma). Cells were centrifuged at 400 x g for 5 minutes and resuspended in PBS to wash 
three times. Cells were then resuspended thoroughly in 50 µl of serum-free RPMI with 2.5 
nM chemokine fluorescently labelled with Alexa Fluor 647 (Almac), either with or without 
25 nM unlabelled chemokine (Almac). The wells with unlabelled chemokine were used as 
controls to detect non-specific uptake of the labelled chemokine, as the excess 
concentration of unlabelled chemokine will out-compete labelled chemokines for receptor-
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mediated uptake, whereas non-specific uptake (e.g. pinocytosis) is not saturated by the 
quantity of ligand. Cells were incubated for 1 hour at 37º C, then washed 3 times in PBS as 
previously described. At this stage cells were resuspended in FACS buffer and used for 
flow cytometry analysis. 
Table 2-5: List of recombinant chemokines used 
CHEMOKINE FORMATS SUPPLIER 
CCL19 Biotinylated, AF647-
conjugated, native 
Almac 
CXCL12 AF647-conjugated, 
native 
Almac (both), 
Peprotech (native) 
CXCL11 Native Almac 
 
2.3.5 Bradford Assay 
Protein concentrations were determined using Bio-Rad Bradford reagent. The reagent was 
diluted 1:5 in distilled water and passed through Whatman no. 1 filter paper. Six standards 
were prepared by diluting appropriate volumes of a 1.5 mg/ml stock solution of BSA in 1 
ml of Bradford reagent to obtain concentrations of 9 µg/ml, 7.5 µg/ml, 6 µg/ml, 4.5 µg/ml, 
3 µg/ml and 1.5 µg/ml. 1 µl of each sample was added to 1 ml of Bradford reagent and 200 
µl per well of each standard or sample was added in duplicate to a 96-well plate, and the 
absorbance was measured at 595 nm using a Teacan Sunrise plate reader. 
2.3.6 SDS-PAGE and Western blotting 
Samples were diluted in 4X LDS sample buffer (Invitrogen) with 50 mM DTT and heated 
to 65º C for 5 minutes. Proteins were run on 4-12% Bis-Tris gels (Invitrogen) at 200 V for 
50 minutes in MOPS running buffer (Invitrogen). Gels were transferred to PVDF 
membranes using the Novex iBlot system per the manufacturer's directions. Membranes 
were then rinsed with PBS, blocked with 1% milk-PBS (dried milk powder: Marvel) for 30 
minutes and incubated with primary antibodies in 5% BSA-PBS either for 3 hours at room 
temperature or overnight at 4º C. Membranes were washed 5 times for 5 minutes with 
  77 
PBS/T [PBS, 0.1% v/v Tween-20], blocked for 30 minutes in 5% milk-PBS/T and 
incubated with HRP-conjugated secondary antibody in 1% milk-PBS/T for 2 hours at room 
temperature. Membranes were washed twice in PBS/T, twice in high salt PBS/T [1X 
PBS/T, 400 mM NaCl] and once in PBS/T. 1 ml ECL solution (Pierce) was added to each 
membrane for 1 minute, then images were developed by placing X-ray film (Kodak) over 
the blot in a developing cassette and using a film developer to obtain images. Successive 
films were typically exposed for 10 seconds, 30 seconds, 1 minute and 10 minutes. 
2.3.7 RNA Extraction from Tissue 
Tissue was harvested and placed immediately on ice. To process later, tissue was stored in 
RNAlater (Ambion) at -20° C until required. Up to 10 mg of tissue was placed in a 2 ml 
RNAse free Eppendorf tube on dry ice containing one 5 mm stainless steel bead (Qiagen) 
along with 1 ml TriZol reagent (Ambion). Tubes were added to the pre-cooled insert of a 
Qiagen TissueLyser and processed for 5 minutes at 50 Hz. Samples were then placed on 
ice until chilled again. These steps were repeated until tissue was lysed. Samples were then 
centrifuged at 12000 rpm for 2 minutes in a micro centrifuge to pellet any debris, and 
supernatants transferred to fresh tubes. Samples were passed ten times through a 21 Ga 
syringe to homogenise. RNA was then extracted using a PureLink RNeasy mini kit 
(Ambion) per the manufacturer's directions. 
2.3.8 Quantitative Polymerase Chain Reaction 
Reverse transcription polymerase chain reaction (RT-PCR) was carried out on RNA 
samples using a QuantiTect Reverse Transcription Kit (Qiagen) per the manufacturer's 
directions to obtain cDNA. Samples were stored at -20º C until required. Samples were 
analysed in triplicate on 384-well plates using TaqMan probes (Applied Biosystems) and 
TaqMan 2X Master Mix without UNG (Applied Biosystems) according to the 
manufacturer's directions. All samples were run in triplicate, and each experimental group 
contained at least three biological replicates for mouse studies. For cultured human cells, 
using separate donors was not feasible but at least three separate wells of cells were used 
for each experiment as a technical replicate. In addition, every experiment included a - RT 
sample for each treatment group (no reverse transcriptase enzyme added during reverse 
transcription, to ensure no DNA contamination was present in the RNA samples) and a no-
template control (to ensure no RNA contamination was present in the qPCR reagents). 
Additionally, all probes used spanned exons to prevent amplification of any DNA 
 78 
contamination if present. Plates were analysed on an Applied Biosystems 7500 Fast or 
Applied Biosystems Quantstudio 6 Flex using the standard qPCR program. All samples 
were normalised to TBP or GAPDH expression by subtracting the CT value of the 
reference gene from the CT value of the target gene to obtain the ΔCT and calculating 
relative gene expression using the 2- ΔCT method (Arbitrary Units; AU – used where no 
single ‘control’ sample exists) or the 2-ΔΔCT method (Relative Quantification; RQ – where 
there is a single ‘control’ sample to express all other samples relative to). CV values of 
technical replicates were checked and any outliers excluded; sample groups showing 
multiple outliers were discarded or re-analysed.  
Table 2-6: List of TaqMan probes used 
TARGET SPECIES ASSAY ID 
ACKR3 Human Hs00664172_s1 
ACKR4 Human Hs00664347_s1 
CCL19 Human Hs00171149_m1 
CCL21 Human Hs00171076_m1 
CXCL11 Human Hs00171138_m1 
CXCL12 Human Hs03676656_mH 
CXCR4 Human Hs00607978_s1 
Ackr3 Mouse Mm04931206_s1 
Ackr4 Mouse Mm02620636_s1 
Ccl19 Mouse Mm00839967_g1 
Ccl21 Mouse Mm03646971_gH 
Cxcl12 Mouse Mm00445553_m1 
Cxcr4 Mouse Mm01996749_s1 
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2.4 Analysis 
2.4.1 Flow Cytometric Analysis 
All data obtained from flow cytometry was analysed using FlowJo software (Treestar). 
Samples were always gated initially on forward and side-scatter parameters to exclude 
debris, forward scatter average against height to exclude doublets and cells negative for 
viability dye to exclude dead cells which could be stained non-specifically. Individual 
stains were gated based on FMO, if available. For individual tissues and cell types, 
standard gating strategies were applied as detailed in the results section. 
2.4.2 Statistical Analysis 
For statistical analysis, Prism (GraphPad) was used. Unless otherwise stated, all analyses 
used the following methods: Where there were two groups, t-tests were used: these were 
unpaired two-tailed t-tests and the Holm-Sidak correction was applied where multiple 
comparisons were carried out. For three or more groups, one-way analysis of variance 
(ANOVA) was used with Tukey’s correction for multiple comparisons. To compare two or 
more parameters simultaneously, two-way ANOVA was used with Tukey’s correction for 
multiple comparisons. Statistical significance was denoted as follows: *P≤0.05, **P≤0.01, 
***P≤0.001, ****P≤0.0001, ns = P>0.05. All error bars represented the standard deviation 
of the mean. 
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3 Atypical Chemokine Receptor Expression and Function in 
vitro 
3.1 Introduction 
ACKR3 and ACKR4 both have potential roles to play during skin inflammation but have 
not yet been extensively studied in this context. As outlined in the introduction (See 
section 1.7.2), ACKR4 protein is known to be functional on keratinocytes and lymphatic 
endothelial cells (LECs) in the skin, and likely modulates Langerhans cell (LC) and dermal 
DC trafficking to the skin-draining lymph nodes both during homeostasis and immune 
challenge by scavenging CCR7 ligands 177,179. 
CXCR4/CXCL12 are also expressed in the skin and appear to be implicated in 
inflammation and wound healing, but there is conflicting evidence over their precise roles. 
It is possible that this is at least partly due to the activity of ACKR3 186, which is expressed 
on many of the same cell types that express CXCR4 including keratinocytes and 
fibroblasts in the skin. Notably, several studies use AMD3100 as a CXCR4 antagonist, but 
as this molecule has also been shown to act as an ACKR3 agonist 187, it is conceivable that 
unintended effects occur in cells that express both receptors. Notably, ACKR3 has been 
shown to dimerise with CXCR4 on cells that express both receptors, and to modulate its 
function 142,153, supporting a role for ACKR3 in the CXCR4/CXCL12 axis. 
3.2 Aims 
• To determine expression levels of ACKR4, ACKR3, CXCR4 and their ligands in 
cultured human skin cells (keratinocytes and LECs) at both the mRNA and protein 
level. 
• To evaluate whether ACKR3 and CXCR4 co-localise in these cells. 
• To investigate whether the expression of atypical chemokine receptors and related 
transcripts are affected by inflammatory stimuli. 
• To investigate whether chemokine scavenging by ACKR3 or ACKR4 is detectable 
on these cells, and whether it is affected by inflammatory stimuli or by 
coexpression of CXCR4 (in ACKR3+ cells). 
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3.3 Expression and Modulation of ACKRs on Human Dermal LECs 
As discussed, ACKR4 has potential chemokine scavenging roles on LECs, and ACKR3 
has also been reported on lymphatic vessels 188. LECs are a rare population of cells, 
however, and studying their function in further detail in vivo would be challenging. I was 
also interested in investigating a functional role for ACKR4 in human cells. As a 
consequence, I began by studying cultured human dermal LECs (HD-LECs) to determine 
whether ACKRs 3 and 4 are expressed in these cells, and whether these cells possess 
chemokine scavenging capabilities in vitro. 
3.3.1 Cultured Human Dermal LECs Express ACKR3, ACKR4 and CXCR4 
Antibody staining against chemokine receptors is often challenging, and atypical 
chemokine receptors are no exception. The 13E11 mouse monoclonal antibody (mAb) was 
one of the original antibodies raised against ACKR4 189. This antibody was used in 
immunofluorescent staining to determine whether cultured HD-LECs expressed detectable 
ACKR4 protein. Anti-ACKR4 staining intensity in these cells appears to be variable, 
though a clear majority are ACKR4+ (Figure 3-1A). The protein appears to be largely 
cytoplasmic, and the punctate staining pattern suggests it is localised in vesicles (Figure 3-
1B). This is reminiscent of previous results for ACKR2, which shows a similar staining 
pattern on cultured HD-LECs 190. ACKR2 is recycled between the cell surface and 
endosomal vesicles, allowing it to rapidly internalise chemokines without being 
desensitised. Consequently, the large majority of ACKR2 protein produced by a cell is 
cytoplasmic and associated with intracellular vesicles 146. 
HD-LECs also express CCL21 protein, which can be detected via immunofluorescence 
both extracellularly because its C-terminal interactions with GAGs tether it to the surface 
of cells, and intracellularly, because any protein that has not been secreted by the cell is 
also detectable via antibody staining. Anti-CCL21 staining on HD-LECs showed a variable 
pattern (Figure 3-1C), with some cells more positive than others. It appeared that the 
majority of the CCL21 detected was intracellular, as extracellular protein would tend to 
localise mostly to the edges of the cell; instead anti-CCL21 staining appeared similar in 
character to the punctate anti-ACKR4 staining, and occasionally overlapped with it. 
Next, I examined whether HD-LECs expressed ACKR3 and the other receptor for 
CXCL12, CXCR4. Antibody staining for ACKR3 has also been challenging. Originally, a 
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polyclonal antibody (pAb) was used for immunofluorescence (Figure 3-2A). A mAb, 
11G8, was recommended as the most specific antibody available 191 and showed similar 
staining patterns to the pAb previously used (Figure 3-2B); both antibodies appeared to be 
at least specifically detecting a target as determined by the isotype controls (Figure 3-2C). 
As both the polyclonal and monoclonal antibodies were raised in different species (rabbit 
and mouse, respectively), the specific antibody used from this point onwards was 
determined by the constraints dictated by the species of other antibodies used in each 
experiment.  
Results for anti-ACKR3 staining showed a similar expression pattern to ACKR4, as 
expected for an atypical chemokine receptor: the majority appeared to be intracellular and 
localised in vesicles. Surprisingly, in some cells, there appeared to be nuclear staining for 
ACKR3 (Figure 3-2D). This was quantified by counting ACKR3 positive nuclei in at least 
6 randomly-selected fields of view across three separate experiments. Although the 
average number of cells showing nuclear staining was about 12%, there was high 
variability between each field examined: many showed no nuclear staining in any of the 
LECs present, while the highest proportion of nuclear staining detected in one field of view 
was 75%. 
Although CXCL12 and CXCR4 localisation to the nucleus have been reported 192,193, there 
is no known precedent for ACKR3 protein expression at this site. Bioinformatics tools 
suggested a low possibility that ACKR3 could spend some time in the nucleus: the 
PredictProtein tool 194 suggested the protein would only be localised in the cell membrane 
but with a very low confidence value (14 on a scale of 0-100), and the NucPred tool 195 
gave a score of 0.12, where values over 0.1 suggest a protein spends at least some time in 
the nucleus, but with a very low specificity (45%). These analyses did not rule out the 
possibility that ACKR3 can be localised in the nucleus but did not provide compelling 
evidence in favour of this observation, either. 
To further examine this result, nuclear and cytoplasmic protein fractions were isolated 
from LECs and western blotting was used to attempt to locate ACKR3. Despite multiple 
efforts, and although the antibody used was validated for western blotting by the supplier 
(Abcam), ACKR3 could not be detected using this method. Lower temperatures were used 
for the protein denaturing stage of the protocol as previous experiments have shown the 
atypical chemokine receptor ACKR2 forms aggregates when higher temperatures are used 
196, more sensitive ECL reagents were tested, and human heart lysate (PromoKine) was 
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used as a positive control as this tissue is known to be ACKR3+ 150, but no positive 
ACKR3 signal could be detected. 
Anti-CXCR4 staining appeared to localise largely to the plasma membrane, as indicated by 
the intensity of signal near the edges of the cell (Figure 3-3A). The pattern of anti-CXCR4 
staining appeared to be strand-like, as though associated with the cytoskeleton; however, 
anti-CXCR4 staining with a different antibody did not appear to replicate this pattern (data 
not shown). 
The principal motivation for investigating CXCR4 staining on HD-LECs was to determine 
the degree of ACKR3 and CXCR4 co-staining in these cells, as it has been reported that 
ACKR3 and CXCR4 can heterodimerise in cells expressing both receptors 142,157. These 
results were challenging to obtain, as the antibodies used most successfully for single 
staining of both these proteins were rabbit pAbs. Unfortunately, the mouse mAb 11G8 did 
not give satisfactory results when used in combination with anti-CXCR4 antibodies, 
showing weak and low-level antibody staining.  
3.3.2 ACKR3, ACKR4 and CXCR4 in Cultured HD-LECs Are Mostly Intracellular 
To verify the results obtained from immunofluorescence, and to obtain some quantification 
of the expression levels of ACKR4 on HD-LECs, the same anti-ACKR4 mAb (13E11) was 
used for flow cytometry analysis. Cells were either stained before fixing, or after fixing 
using buffer containing saponin to maintain the permeability of cell membranes. Results 
showed that only a small subset of non-permeabilised HD-LECs express detectable 
ACKR4 (Figure 3-4A, left panel). When permeabilised, the proportion of ACKR4+ cells 
detected rose substantially (Figure 3-4A, right panel). The overall fluorescence intensity 
also rose from non-permeabilised to permeabilised cells; this is likely due to the 
permeabilisation protocol leading to a higher level of background staining, as the isotype 
control also showed a similar increase in fluorescence intensity. As there was a larger 
differential between the anti-ACKR4 stained sample and the isotype control in the 
permeabilised samples, this suggested that there was a genuine increase in ACKR4 
availability for antibody binding in the permeabilised cells. It also appears to agree with 
the immunofluorescence results obtained previously. 
In this analysis, the peak of the isotype control was higher than the lowest-intensity signal 
for ACKR4 antibody staining both in the permeabilised and non-permeabilised samples. 
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This may have been because the specific kappa chain clone used as an isotype may have 
had a higher affinity for unblocked Fc receptors than the kappa chain on the anti-ACKR4 
antibody 197. Alternatively, the number of fluorophore molecules per antibody (F:P ratio) 
may be different for the two reagents 197 (Both reagents were supplied by BioLegend, but it 
was not possible to obtain this information). From the appearance of the histograms, 
ACKR4 does appear to follow a bimodal distribution in cultured HD-LECs making an 
isotype control less necessary 198. 
Anti-ACKR3 staining showed a similar pattern to ACKR4, with just under half of cells 
positive for ACKR3 surface staining (Figure 3-4B, left panel), while the majority appeared 
as ACKR3 positive when permeabilised (Figure 3-4B, right panel). A small population of 
cells showed surface staining for CXCR4 (Figure 3-4C, left panel), and just under half for 
intracellular staining (Figure 3-4C, right panel). This does not appear to reflect the results 
obtained using immunofluorescence, as most cells were CXCR4+ across many repeated 
experiments. The proportion of CXCR4+ cells obtained may have been underestimated as 
the staining appears to show a ‘gradient’ rather than a specific positive and negative 
population, which suggests some weakly-positive CXCR4+ cells may have been classed as 
negative; however, the gate was drawn based on the isotype, and this is the most reliable 
estimate for positive versus negative staining available in the experiment.  
On cells that were analysed by flow cytometry, a substantial minority of the population 
showed surface staining for ACKR3, ACKR4 and CXCR4, while cells analysed by 
immunofluorescence showed very little extracellular staining. This may have been caused 
by using fixed cells for the immunostaining experiments, rather than the live cells used to 
detect surface staining in flow cytometry experiments. It is possible that paraformaldehyde 
fixation, which permeabilises cells, could lead to a lack of surface receptor detection. This 
could be tested by live-staining cells grown on coverslips prior to fixation. 
Overall, however, the flow cytometry results obtained for ACKRs appear to concur with 
those obtained from immunofluorescence: ACKR3 and ACKR4 expression in cultured 
HD-LECs is heterogeneous, with a minority of cells expressing no detectable protein. A 
clear majority of these cells express ACKR3 and/or ACKR4 internally, although a 
significant fraction of these cells clearly carries detectable surface ACKR3 and/or ACKR4. 
Furthermore, the percentage of cells that expressed detectable intracellular ACKR3 was 
similar to the percentage of cells expressing detectable intracellular ACKR4.  
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3.3.3 ACKRs Expressed by HD-LECs Rarely Co-Localise 
The results obtained from flow cytometry analysis suggested that ACKR3 and ACKR4 
expression by HD-LECs is heterogeneous as both receptors only appeared to be present in 
a subset of cells. I was interested in determining to what degree expression of these 
receptors overlapped in HD-LECs, and whether cells expressing both receptors would 
indicate co-localisation. As heterodimerisation between chemokine receptors is well 
known 199, including ACKR3 with CXCR4 142,156,157, it is feasible that ACKRs expressed 
by the same cell could also perform a similar function. As cultured HD-LECs also express 
ACKR2 190, this protein was also included in the analysis. As all primary antibodies were 
raised in either rabbit or mouse, it was only possible to stain cells with two anti-ACKR 
antibodies simultaneously. 
Staining cells with both anti-ACKR3 and anti-ACKR4 antibodies indicated that most HD-
LECs expressed both ACKRs (Figure 3-5A). Close examination showed that some vesicles 
appeared to be positive for both ACKR3 and ACKR4 (Figure 3-5B), although the vast 
majority were positive for one receptor or the other. When both anti-ACKR2 and anti-
ACKR4 antibodies were used, a similar pattern was seen (Figure 3-6A); however, anti-
ACKR4 reactivity appeared to be weaker than often seen during single staining (e.g. figure 
3-1A). Examining individual cells did not reveal any vesicles that appeared to be positive 
for both ACKRs (Figure 3-6B). Finally, when anti-ACKR2 and anti-ACKR3 co-staining 
was attempted, the vast majority of cells appeared to be positive for both receptors (Figure 
3-7A), and occasionally vesicles appeared to be positive for both ACKR2 and ACKR3 
immunoreactivity (Figure 3-7B), but this was rare. 
Taken together, these results suggest that the majority of HD-LECs express ACKR2, 
ACKR3 and ACKR4 proteins, but there is little evidence that these receptors regularly co-
localise, at least under steady-state conditions.  
3.3.4 ACKR3 and ACKR4 Proteins Are Not Localised in Lysosomes 
Because expression of ACKR2, ACKR3 and ACKR4 proteins do not appear to 
significantly overlap, I was interested in determining whether these proteins were localised 
in different subcellular compartments (ACKR2 has previously shown to be continually 
recycled between the cell surface and endosomal vesicles, and is associated with RAB5+ 
early endosomes 146). First, I investigated the lysosomes. This can be done using a pH-
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responsive dye that is phagocytosed by cells. When exposed to the low-pH environment of 
the lysosomes, it becomes fluorescent and can be detected via fluorescence microscopy. 
This experiment showed that neither ACKR3 (Figure 3-8) nor ACKR4 (Figure 3-9) are 
localised in lysosomes. 
3.3.5 ACKR4 Protein is Localised in RAB5A+ Vesicles 
As ACKR3 and ACKR4 are not localised in the lysosomes, I hypothesised they would be 
constrained to the early recycling endosomes if they behave in a similar fashion to 
ACKR2. A transient transfection method was used to cause HD-LECs to express a Rab5a-
GFP fusion protein from a virally-delivered plasmid. In these cells, anti-ACKR4 staining 
indicated that the protein was clearly co-localised with RAB5A+ vesicles (Figure 3-10), 
suggesting that it is functioning similarly to ACKR2. This result was interesting because 
ACKR2 and ACKR4 do not appear to co-localise, yet both are confined mainly to the early 
endosomes. Unfortunately, there was not time to finish these investigations by carrying out 
anti-ACKR3 staining in these cells. 
3.3.6 mRNA Expression of ACKRs and Related Genes by HD-LECs May Be 
Regulated in Response to Inflammation 
mRNA expression of ACKR3 and ACKR4 were also examined in HD-LECs, including 
their regulation in response to various inflammatory signals. It was not possible to include 
true biological replicates in these experiments, as the expense of obtaining cells from a 
sufficient number of donors would be prohibitive, but experiments were carried out on 
multiple technical replicates as a means to begin investigating expression of ACKRs and 
related transcripts in cultured human cells. Consequently, statistical analysis was not 
appropriate, and only large apparent differences in mRNA expression can be commented 
on. 
I hypothesised that ACKRs would be upregulated in response to inflammation, increasing 
scavenging activity to balance out the available signal from chemokines which may be 
upregulated by other cell types (or LECs themselves) in response to inflammatory stimuli. 
CXCL12 and CCL21 were also included in this analysis as all of these chemokines are 
known to be expressed by LECs 200,201 and I hoped to determine whether expression of 
these genes is regulated in tandem with their scavenging receptors. CCL19 expression was 
not detected by HD-LECs. Although CXCR4 was detected in HD-LECs, results were 
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extremely variable and there was no amplification in some samples, making the level of 
CXCR4 expression uncertain. As detection of CXCR4 protein in HD-LECs also appeared 
to be unreliable, given that flow cytometry and immunofluorescence results did not appear 
to agree, I decided to focus on investigating the receptors ACKR3 and ACKR4 only. 
IFN-α, IFN-β and IFN-γ have previously been shown to induce ACKR2 expression in 
cultured HD-LECs 190, and I hoped to determine whether other ACKRs would show 
similar expression patterns in these cells. Lipopolysaccharide (LPS) and unmethylated 
CpG DNA were also investigated as they are ligands for TLRs 4 and 9 respectively, both 
of which are expressed by LECs 202, and any modulation of ACKRs in response to these 
PAMPs would most likely represent a direct response to an inflammatory stimulus 
detected by LECs rather than to cytokines secreted by other cells. This may suggest 
specific response pathways ACKRs are involved in. 
Results showed some interesting patterns of ACKR4 mRNA expression. Both IFN-α 
(Figure 3-11A) and IFN-β (Figure 3-11B) appeared to cause a modest increase in ACKR4 
mRNA expression that had fallen by 48 hours post-treatment. IFN-γ led to greater than 
100-fold increase in ACKR4 mRNA (Figure 3-11C), but this response appeared to peak at 
24 hours post-treatment and had returned to baseline levels by 48 hours post-treatment. 
CpG treatment also appeared to lead to an induction of ACKR4 mRNA at 48 hours post 
treatment (Figure 3-11D). LPS did not appear to have any striking effect on ACKR4 
expression levels (Figure 3-11E). 
CCL21 expression also appeared to be modulated in response to some of these stimuli, 
often appearing to peak later than ACKR4: an induction was seen at the 48-hour timepoint, 
but not before, in response to IFN-α (Figure 3-11A) and IFN-β (Figure 3-11B). No strong 
differences in CCL21 expression were detected in response to IFN-γ (Figure 3-11C), CpG 
(Figure 3-11D) or LPS (Figure 3-11E). 
ACKR3 and CXCL12 expression showed some minor potential changes in response to 
inflammatory stimuli. Interestingly, ACKR3 and CXCL12 appeared to show either very 
similar, or opposing, changes in response to each treatment. All changes in expression, 
however, were too small to comment on further in the absence of any statistical analysis.  
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3.3.7 ACKR4-Mediated Chemokine Uptake Occurs at Low Levels on Cultured 
Cells 
The results obtained so far suggested that expression of ACKR3 and ACKR4 by HD-LECs 
may be affected by immunomodulatory signals, particularly IFN-γ in the case of ACKR4. 
Given other studies showing ACKR4-dependent in vivo CCL19 scavenging capabilities of 
dermal LECs 179 and in vitro scavenging of CCL2 by cultured HD-LECs via ACKR2 190, I 
hoped to ascertain whether ACKR3 and ACKR4 expressed by HD-LECs may play a 
similar role in vitro. I further reasoned that treating HD-LECs with IFN-γ for 24 hours may 
lead to an increase in the reported chemokine scavenging function of ACKR4. To test this 
hypothesis, I used a chemokine uptake assay. This protocol was developed to overcome the 
issue of poor reagents for detecting chemokine receptors 203, and is advantageous 
compared to antibody staining as it can measure receptor activity. The assay has been used 
in this manner previously, both in vivo and in vitro 179,190,204,205. 
To perform an uptake assay, cells are incubated at a pre-determined optimal concentration 
of fluorescently-labelled recombinant chemokine. Some samples simultaneously receive an 
excess, normally ten times greater, of native chemokine. Cells possessing the correct 
chemokine receptor will bind and internalise the chemokine at a rate limited by the number 
and activity of receptor molecules present on their surface. In samples where cells also 
receive unlabelled chemokine, this will bind equally to the chemokine receptors and so 
outcompete the labelled chemokine for binding sites due to their vastly increased 
availability. Any non-specific uptake of labelled chemokine, for example through 
pinocytosis, is not limited by the availability of receptors so is not saturated by the quantity 
of chemokine present. Therefore, non-specific uptake of labelled chemokine will not be 
disrupted by adding unlabelled competition, but receptor-mediated uptake will. Similar 
results can be achieved by using biotinylated chemokine incubated with streptavidin-
conjugated fluorophores, which form tetramers due to the four available biotin binding 
sites on each streptavidin molecule. Streptavidin-fluorophore alone is used as a control in 
this assay to detect non-specific uptake. 
In these experiments, CCL19 was used as an ACKR4 ligand. CCL21 is less soluble due to 
its C terminal binding to GAGs on the surface of LECs, making it less suitable for in-vitro 
applications. The results showed no detectable CCL19 or CXCL12 uptake on HD-LECs. 
Although IFN-γ treatment induced ACKR4 mRNA expression, there was no detectable 
effect on the receptor’s scavenging activity in vitro. Murine splenocytes were used as a 
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positive control as there are large numbers of CCR7+ DCs and T cells and CXCR4+ cells 
including monocytes in the spleen. This validated the assay for CCL19 by showing a 
strong AF647 signal in CCL19-only samples that was abrogated by inclusion of unlabelled 
competitor (Figure 3-13A, left panel), while there was no difference in signal between HD-
LECs cultured with CCL19-AF647 only or with competitor as well (Figure 3-13A, right 
panel). Interestingly, the peak of fluorescence for HD-LECs was far higher than that seen 
for splenocytes despite these cells being analysed sequentially using the same cytometer 
settings. If the positive gate was set based on the splenocyte control, nearly all HD-LECs 
were CCL19+ in the presence or absence of unlabelled CCL19. As there was no unstained 
HD-LEC control, however, higher levels of autofluorescence by these cells could not be 
ruled out. 
As both CXCR4 and ACKR3 are capable of binding CXCL12, using the competitive 
binding assay with CXCL12 alone would not determine which receptor was responsible 
for the fluorescent signal. To investigate ACKR3-mediated scavenging, therefore, an 
uptake assay was carried out using three different conditions: labelled CXL12 alone, 
labelled CXCL12 with excess unlabelled CXCL12 competitor and labelled CXCL12 with 
excess unlabelled CXCL11. As CXL11 binds to ACKR3 and not CXCR4, I reasoned that 
both ACKR3 and CXCR4-mediated uptake would be inhibited by competition from 
CXCL12, while only ACKR3-mediated uptake would be inhibited by competition from 
CXCL11. As CXCL11 has a lower affinity for ACKR3 than CXCL12 does 155, unlabelled 
CXCL11 was added at five times the concentration of labelled CXCL12. 
In this experiment, it was not possible to detect a very strong CXCL12 uptake signal from 
splenocytes (Figure 3-13C, left panel), although the vast majority of this did appear to be 
abrogated by competition from unlabelled CXCL12 and not CXCL11, suggesting the 
uptake detected was mainly due to CXCR4 activity. In HD-LECs, however, no CXCL12 
uptake was detected (Figure 3-13C, right panel). This suggested issues with the assay 
itself, as there was a lack of uptake detected in the positive control, but it was not clear 
what differences in experimental technique could have led to this failure and repeated 
attempts to replicate the result obtained with CCL19 were unsuccessful. 
Although chemokine scavenging activity has previously been reported on cultured HD-
LECs via ACKR2 190, and on transfected cells via ACKR3 and ACKR4, these results could 
not be reliably reproduced. One potential explanation is that previous in vitro studies have 
often used transfected cells overexpressing ACKR3 or ACKR4 154,170, while in the study 
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showing CCL2 uptake on LECs there was only significant signal detected when LECs 
were virally stimulated 190; it may be that neither of these scenarios represent a natural 
level of ACKR activity for HD-LECs.  
Uptake assays were also attempted instead using microscopy, to determine whether the 
manual disruption caused by moving HD-LECs from their culture surface to a single-cell 
suspension had any effect on ACKR4 activity. Cells were cultured on coverslips then 
incubated with either biotinylated chemokines bound to streptavidin-conjugated 
fluorophores, or the streptavidin-fluorophore conjugate alone. The results of this assay 
showed that most of the fluorescent CCL19 signal was found outside cells (Figure 3-14A). 
Surprisingly, when streptavidin-fluorophore alone was used, more of the fluorescent signal 
was associated with LECs than when CCL19 tetramers were used (Figure 3-14B). Thus, 
there is no evidence for the specific uptake of CCL19 tetramers by cultured HD-LECs. 
3.3.8 Chemokine Scavenging Assays on Human Dermal-LECs 
In the uptake assays described here, cells may have degraded chemokines rapidly once 
they were internalised, leading to a lack of fluorescent signal. To address this potential 
issue, a chemokine scavenging assay was performed. In this assay, cells are incubated with 
media containing a known concentration of chemokine, and aliquots of the culture media 
are taken at fixed timepoints and analysed using ELISA to detect the chemokine 
concentration of the media. If cells are internalising and degrading the chemokine, the 
concentration would be expected to decrease. A well is also included containing no cells, 
as a control to detect chemokine removal from the media via protease activity, chemokine 
binding to GAGs on the surface of cells, or chemokine binding to the culture surface. 
In this assay, both CCL19 (Figure 3-15A) and CXCL12 (Figure 3-15B) were rapidly 
removed from the media, whether cells were present or not; IFN-γ treatment was used on 
HD-LECs receiving CCL19, as I reasoned from the qPCR results shown previously that 
this may increase ACKR4 activity, but this did not lead to an increased rate of CCL19 
removal (Figure 3-15A). Taken together, these findings suggested that chemokines were 
adhering to the surface of the culture vessel rather than being internalised by cells, or that 
they were being degraded by endogenous proteases in the endothelial cell growth medium. 
A variety of blocking strategies used prior to the addition of chemokines were tested, along 
with the addition of protease inhibitors to the media and altering the initial chemokine 
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concentrations, but it was not possible to prevent the rapid drop-off in chemokine 
concentration in the control wells. 
It is possible that chemokines were also removed from the media by binding to GAGs or 
other proteins on the culture surface; although this occurred at the same rate in both wells 
containing cells and those that contained media only, so is unlikely to represent binding to 
factors specific to HD-LECs. An incubation with heparinase before removing aliquots for 
ELISA would release chemokines bound to GAGs. This would confirm whether 
chemokines were depleted from the media or sequestered on the cell surface. 
Nevertheless, the observations made in the scavenging assays, along with the chemokine 
uptake experiments, provide no evidence that ACKR3 or ACKR4 expressed by cultured 
HD-LECs engage in chemokine scavenging in vitro. 
3.3.9 Expression and Modulation of ACKRs on Cultured Human Keratinocytes 
Due to the lack of detectable chemokine scavenging activity in cultured HD-LECs, another 
cell type was also studied. Cultured normal human keratinocytes (nHEKs) were chosen 
due to the expression and function of ACKRs reported on these cells. Results in the skin of 
Ackr4gfp/+ reporter mice have shown that keratinocytes are GFP+ and capable of 
internalising CCL19 in situ in an Ackr4-dependent manner 179. ACKR4 has also been 
shown to be expressed by keratinocytes by immunofluorescent microscopy 179 and ACKR4 
mRNA by qPCR (K. Shams, personal communication). Previous work in our group has 
suggested that GFP protein levels are highest in the basal layer of the interfollicular 
epidermis, decreasing in intensity in cells located closer towards the hair follicle bulge. As 
discussed in the introduction (See section 1.4.1), the cells in the bulge region of the hair 
follicle and the basal layer of the epidermis are the least differentiated and most 
proliferative cells, while those of the outer epidermis are the most differentiated and least 
proliferative cells. This suggests that murine Ackr4 expression could be modulated during 
keratinocyte differentiation. ACKR3 expression by keratinocytes has not yet been studied 
in depth in these cells; therefore, the regulation and function of both these ACKRs in 
keratinocytes has not yet been determined. 
To investigate this further, I examined whether there was any detectable ACKR4 
expression or function in nHEKs, and if so, if this was modified during keratinocyte 
differentiation. To maintain a basal, proliferative status, primary keratinocytes are typically 
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cultured in low calcium (LoCa) medium, with a calcium concentration of 0.06 mM. 
Increasing the calcium concentration in the growth medium induces terminal 
differentiation followed by senescence 74,75. When cultured at 0.18 mM Ca2+ (HiCa), 
nHEKs appear to alter their morphology and become less regular in shape and size, 
suggesting they may be at different stages of differentiation (Figure 3-16). Culturing cells 
in HiCa media for 5 days was sufficient to induce the described morphology, and these 
cells were used as a comparison with LoCa cells to determine whether any difference in 
ACKR4 expression or function could be detected. 
3.3.10 Cultured Human Keratinocytes Express ACKR4 Protein 
The protein expression of ACKR4 appeared similar in most LoCa nHEKs to that of HD-
LECs (Figure 3-17A). Expression appeared variable, with many cells showing low-level or 
absent anti-ACKR4 staining. Those that were ACKR4+ appeared to express the protein 
mainly within the cytoplasm, with a punctate staining pattern reminiscent of endosomal or 
lysosomal vesicles. Some cells showed a more limited, localised pattern of ACKR4 
staining where the vesicles appeared to be restricted to one area of the cytoplasm. In HiCa 
nHEKs, almost all the cells that were ACKR4+ appeared to express the protein in this 
pattern, with only one or two concentrated foci of ACKR4 expression within the cell 
(Figure 3-17B). This suggests a potential for ACKR4 protein to be polarised to specific 
areas of the cytoplasm. When these cells were examined for ACKR4 mRNA expression, 
however, there appeared to be no difference between LoCa and HiCa cells (Figure 3-17C). 
This suggests that any difference in ACKR4 expression between LoCa and HiCa nHEKs is 
at the protein level. 
This result failed to support any evidence for the modulation of ACKR4 mRNA levels in 
keratinocytes from different subsets, but this could indicate that HiCa keratinocytes 
represent a heterogeneous population at different stages of differentiation. Furthermore, 
anti-ACKR4 immunostaining suggested differential regulation of protein localisation in 
these cells, which could feasibly lead to notable differences in ACKR4 functionality in 
these cells. Therefore, although ACKR4 mRNA levels do not appear to change in 
differentiated vs basal keratinocytes, this does not rule out any differences in ACKR4 
protein expression or function. 
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3.3.11 mRNA of ACKRs and Ligands are Regulated in Response to Inflammation 
To further assess the expression and regulation of ACKRs and their pathways in nHEKs, 
the mRNA expression of ACKR4, ACKR3 and CXCR4 in LoCa cells was tested after 48 
hours’ incubation with various immunostimulatory treatments. As with the results obtained 
in HD-LECs, only one true biological replicate was possible, so statistical analysis was not 
carried out. The chosen treatments were IFN-α, IFN-β, IFN-γ, Keratinocyte Growth Factor 
(KGF) and LPS. Interferons were chosen due to their ability to elicit ACKR3, ACKR4, 
CCL21 and CXCL12 responses in cultured HD-LECs. KGF has previously been reported 
to induce ACKR4 expression in keratinocytes (R. Nibbs, personal communication), and 
LPS was chosen as keratinocytes express TLR4 206 and may modulate gene expression in 
response to its ligand. 
Results showed that ACKR4, ACKR3 and CXCR4 mRNA were all expressed by 
keratinocytes, while CXCL12, CCL19 and CCL21 were all tested but could not be 
detected. ACKR4 expression appeared to be induced by IFN-β and IFN-γ, but not IFN-α, 
KGF or LPS (Figure 3-18A). This data partially agrees with that obtained from HD-LECs, 
as IFN-β significantly raised ACKR4 expression by 48 hours post-treatment in both cell 
types; however, ACKR4 expression had returned to normal by 48 hours after IFN-γ 
treatment in HD-LECs, and was still raised by about 20-fold at this timepoint in nHEKs. 
ACKR3 expression in nHEKs did not appear to show many similarities to that in HD-LECs 
(Figure 3-18B): in nHEKs, ACKR3 appeared to be strongly induced by KGF and LPS, 
while it was downregulated by treatment with all three IFNs. In HD-LECs, ACKR3 did not 
appear to be induced by LPS, and was not strongly affected by any of the IFNs used, while 
KGF was not tested on HD-LECs. 
ACKR3 and CXCR4 expression in nHEKs showed an interesting relationship: ACKR3 was 
induced by KGF and LPS, but appeared to be downregulated in response to IFNs. 
Conversely, CXCR4 appeared to be induced in response to IFNs and downregulated in 
response to KGF and LPS (Figure 3-18C). Taken together, these results suggested that 
ACKR3, ACKR4 and CXCR4 are expressed by nHEKs, and may modulated in response to 
immunostimulatory treatments, but that the specific manner in which these genes were 
regulated often differed between nHEKs and HD-LECs. 
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3.3.12 ACKR4-Mediated Chemokine Scavenging is Not Detected on nHEKs 
To determine whether ACKR4 scavenging function could be detected on nHEKs, and 
whether the modifications in mRNA expression of ACKR4 had any effect on this, CCL19 
uptake assays were performed on these cells. Inflammatory stimuli were used to treat the 
cells before performing the assay, and the mean fluorescence intensity compared between 
cells incubated with either CCL19-AF647 alone, or with an excess of unlabelled CCL19, 
as described for HD-LECs (Figure 3-19A). The results of this experiment showed no clear 
differences in CCL19-AF647 signal when competitor was present, although only two 
replicates were performed so it was not possible to perform statistical analysis. 
Nevertheless, the results of this experiment did not show any clear differences in 
chemokine uptake with or without unlabelled CCL19 or after stimulation with treatments 
shown to induce a large increase in ACKR4 mRNA in these cells. 
Uptake assays were repeated using a greater number of replicates but only IFN- γ 
treatment, as this cytokine had caused the strongest induction in ACKR4 mRNA expression 
(Figure 3-19B). Again, no clear difference in uptake of fluorescently-labelled CCL19 was 
detected between samples with and without unlabelled competition, and IFN-γ treatment 
did not appear to affect this. 
The assay was also attempted using biotinylated CCL19 incubated to form tetramers with 
sva-AF647, or sva-AF647 alone (Figure 3-19C). This variation of the assay showed a 
slight difference between samples with and without CCL19, but this only represented a 
small number of potentially CCL19+ cells when immunostaining results have suggested 
the majority of nHEKs express ACKR4 at the protein level. Although this experiment did 
not have a positive control, and therefore experimental error could not be ruled out, similar 
issues were encountered during experiments with HD-LECs and could not be accounted 
for. Due to the difficulty in performing chemokine uptake assays on both nHEKs and HD-
LECs, these investigations were not pursued further. 
3.4 Key Findings 
• Cultured human dermal LECs express ACKR4, ACKR3 and CXCR4 at the protein 
level. ACKR3 and ACKR4 show staining patterns consistent with those observed 
for ACKR2, with the majority of the protein appearing to be associated with 
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intracellular vesicles that rarely overlapped in distribution between ACKRs 2, 3 
and 4. For ACKR4, these were confirmed as RAB5A+ early endosomes. 
• ACKR3 appeared to localise to the nucleus in a significant minority of cells by 
immunostaining, but this result could not be confirmed. 
• CXCR4 expression by HD-LECs is uncertain, with cells showing positive staining 
by immunofluorescence, but unreliable mRNA expression. ACKR3/CXCR4 co-
staining could not be determined. 
• HD-LECs express CCL21 at the protein and mRNA level. CXCR4 was detected 
unreliably at the protein and mRNA level, and CXCL12 was detected at the mRNA 
level. 
• ACKR4, CCL21, ACKR3 and CXCL12 mRNA are potentially modulated by HD-
LECs in response to immune stimuli. In particular, ACKR4 appeared to be 
upregulated in response to both IFNs and CpG. This suggests that expression of 
ACKR4 on HD-LECs is modified both in response to pathogens detected directly 
by keratinocytes via TLR ligands, and to cytokines secreted by other cells. 
• Cultured HD-LECs do not exhibit any detectable chemokine scavenging activity 
via ACKR3 or ACKR4. 
• Cultured human epidermal keratinocytes express ACKR4 at the protein level, with 
basal proliferative cells showing staining patterns consistent with HD-LECs, while 
more differentiated cells appeared to localise most of their ACKR4 in discrete foci. 
This did not appear to represent any difference in ACKR4 mRNA expression. 
• nHEKs express ACKR4, ACKR3 and CXCR4 at the mRNA level. ACKR4 appears 
to be induced in response to IFN- α, IFN-β and IFN-γ but not KGF or LPS. ACKR3 
and CXCR4 expression profiles suggest reciprocal regulation, where ACKR3 is 
induced in response to KGF and LPS but downregulated by IFNs, and CXCR4 
shows the opposite pattern. Overall, there appears to be little overlap between the 
regulation of ACKR3 and ACKR4 between nHEKs and HD-LECs in response to 
these inflammatory stimuli.
 97 
 
Figure 3-1: ACKR4 and CCL21 proteins are expressed by cultured HD-LECs. 
Human dermal LECs were cultured on sterile coverslips until confluent, fixed in 
paraformaldehyde and incubated with anti-ACKR4 antibody. All images shown are 
representative of three replicates. A) Anti-ACKR4 staining (left panel) compared with 
mouse IgG2b, κ isotype (right panel); scale bar = 50 µm. B) Left panel: anti-ACKR4 
staining on HD-LECs; right panel: magnified view of cell highlighted in left panel showing 
the punctate staining pattern of ACKR4 protein; scale bar = 20 µm C) Left panel: ACKR4 
and CCL21 protein expression on cultured HD-LECs; right panel: magnified view of cell 
highlighted in left panel. Three potential areas of co-localisation are highlighted (arrows); 
scale bar = 50 µm.  
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Figure 3-2: ACKR3 protein is expressed by cultured HD-LECs 
Human dermal LECs were cultured on sterile coverslips until confluent, fixed in 
paraformaldehyde and incubated with anti-ACKR3 antibody. All images shown are 
representative of three replicates. Scale bars: 20 µm. A) Left panel: anti-ACKR3 staining 
(rabbit pAb) on cultured HD-LECs; right panel: magnified view of cell highlighted in left 
panel. B) Anti-ACKR3 staining (mouse mAb 11G8) on cultured HD-LECs. C) Isotype 
controls: rabbit polyclonal (top panel) isotype for A, mouse IgG2a, κ isotype for B. D) 
Demonstration of nuclear anti-ACKR3 staining on cultured HD-LECs. Top left panel: a 
field of view showing several cells counterstained with DAPI, some of which appear to 
show nuclear ACKR3 staining. Lower panels: magnified single-channel views of 
highlighted cell. Right panel: percentage of ACKR3+ nuclei. Each point represents a 
single image recorded at 20X magnification; each cluster represents a separate 
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experiment. The dotted line indicates the pooled mean value of 11%. Error bars represent 
SD of the mean.  
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Figure 3-3: ACKR3 and CXCR4 proteins are expressed by cultured HD-LECs. 
Human dermal LECs were cultured on sterile coverslips until confluent, fixed in 
paraformaldehyde and incubated with anti-CXCR4 antibody. All images shown are 
representative of three replicates. Scale bars: 20 µm. A) Left panel: anti-CXCR4 staining 
on cultured HD-LECs; right panel: magnified view of cell highlighted in left panel. B) 
Cultured HD-LECs stained with polyclonal rabbit IgG isotype control.   
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Figure 3-4: ACKR3, ACKR4 and CXCR4 are mainly expressed intracellularly by 
cultured HD-LECs. 
Human dermal LECs were cultured until 70% confluent, removed from the culture vessel 
using trypsin and stained for flow cytometry. Cells were either fixed and permeabilised 
before antibody staining, or fixed after staining. Histograms are representative of three 
replicates for receptor staining (◼); one sample was stained with each isotype (◻). Gates 
and numbers represent the proportion of positive cells in the antibody-stained sample. A) 
Anti-ACKR4 surface staining (left panel) and intracellular staining (right panel) B) Anti-
ACKR3 surface staining (left panel) and intracellular staining (right panel) C) Anti-CXCR4 
surface staining (left panel) and intracellular staining (right panel)  
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Figure 3-5: ACKR3 and ACKR4 rarely co-localise in HD-LECs 
Human dermal LECs were cultured on coverslips until confluent, fixed and stained with 
anti-ACKR3 and anti-ACKR4 antibodies and DAPI counterstain. A) Overview of anti-
ACKR3 and anti-ACKR4 staining. Image is representative of three replicates (scale bar = 
50 µm). B) View of an individual cell stained with anti-ACKR3 and anti-ACKR4 antibodies. 
Left panels: individual stain images and merged views of anti-ACKR3 and anti-ACKR4 
staining and DAPI counterstaining. Right panel: magnified view. Arrows show possible 
overlap between anti-ACKR3 and anti-ACKR4 staining. Scale bar = 20 µm.   
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Figure 3-6: ACKR2 and ACKR4 do not co-localise in HD-LECs 
Human dermal LECs were cultured on coverslips until confluent, fixed and stained with 
anti-ACKR2 and anti-ACKR4 antibodies and DAPI counterstain. A) Overview of anti-
ACKR2 and anti-ACKR4 staining. Image is representative of three replicates (scale bar = 
50 µm). B) View of an individual cell stained with anti-ACKR2 and anti-ACKR4 antibodies. 
Left panels: individual stain images and merged views of anti-ACKR2 and anti-ACKR4 
staining and DAPI counterstaining. Right panel: magnified view. There was no detectable 
overlap between ACKR2+ and ACKR4+ vesicles.   
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Figure 3-7: ACKR2 and ACKR3 rarely co-localise in HD-LECs 
Human dermal LECs were cultured on coverslips until confluent, fixed and stained with 
anti-ACKR2 and anti-ACKR3 antibodies and DAPI counterstain. A) Overview of anti-
ACKR2 and anti-ACKR3 staining. Image is representative of three replicates (scale bar = 
50 µm). B) View of an individual cell stained with anti-ACKR2 and anti-ACKR3 antibodies. 
Left panels: individual stain images and merged views of anti-ACKR2 and anti-ACKR3 
staining and DAPI counterstaining. Right panel: magnified view. Arrow shows possible 
overlap between anti-ACKR3 and anti-ACKR4 staining.  
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Figure 3-8: ACKR3 protein localisation relative to lysosomes in cultured LECs. 
Human dermal LECs were grown until confluent on coverslips and incubated with 
LysoTracker (Molecular Probes) according to the manufacturer’s directions before being 
fixed and stained with anti-ACKR3 antibody and counterstained with DAPI. Images are 
representative of three replicates. (scale bars = 20 µm) A) Representative image of anti-
ACKR3 staining overlaid with LysoTracker and DAPI counterstains. B) Magnified 
individual channel views of the cell highlighted in A.  
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Figure 3-9: ACKR4 protein localisation relative to lysosomes in cultured LECs. 
Human dermal LECs were grown until confluent on coverslips and incubated with 
LysoTracker (Molecular Probes) according to the manufacturer’s directions before being 
fixed and stained with anti-ACKR4 antibody and counterstained with DAPI. Images are 
representative of three replicates. (scale bars = 20 µm) A) Representative image of anti-
ACKR4 staining overlaid with LysoTracker and DAPI counterstains. B) Individual channel 
views of the cell shown in A.
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Figure 3-10: ACKR4 co-localises with RAB5+ early endosomes in cultured HD-
LECs. 
Human dermal LECs were grown until confluent on coverslips and incubated with 
CellLights Early Endosomes (Molecular Probes) according to the manufacturer’s 
directions before being fixed and stained with anti-ACKR4 antibody and counterstained 
with DAPI. Images are representative of three replicates. (scale bars = 20 µm). Left 
panels: individual stain images and merged views of LysoTracker, anti-ACKR4 staining 
and DAPI counterstaining. Right panel: magnified view.  
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Figure 3-11: Cultured human LECs may alter mRNA expression of ACKR4 and 
CCL21 in response to inflammatory stimuli.  
HD-LECs were cultured until 70-80% confluent and treated with cytokines and TLR 
ligands at the concentrations described in the materials and methods section. After either 
24 or 48h, cells were harvested, and RNA was extracted to generate cDNA for qPCR 
analysis (n=1, 3 technical replicates per treatment group). Graphs show expression of 
ACKR4 (◼) and CCL21 (◼) as relative quantification (RQ) values calculated using the 2-
ΔΔCT method. 0h timepoint was used as the calibrator and represents pooled 
measurements of PBS-treated cells taken at 24 and 48 hours. Error bars represent SD of 
the mean. mRNA expression is shown in cells treated with A) IFN-α, B) IFN-β, C) IFN-γ, 
D) Unmethylated CpG DNA or E) LPS.  
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Figure 3-12: Cultured human LECs may alter mRNA expression of ACKR3 and 
CXCL12 in response to inflammatory stimuli. 
HD-LECs were cultured until 70-80% confluent and treated with cytokines and TLR 
ligands at the concentrations described in the materials and methods section. After either 
24 or 48h, cells were harvested, and RNA was extracted to generate cDNA for qPCR 
analysis (n=1, 3 technical replicates per treatment group). Graphs show expression of 
ACKR3 (◼) and CXCL12 (◼) as relative quantification (RQ) values calculated using the 2-
ΔΔCT method. 0h timepoint was used as the calibrator and represents pooled 
measurements of PBS-treated cells taken at 24 and 48 hours. Error bars represent SD of 
the mean. mRNA expression is shown in cells treated with A) IFN-α, B) IFN-β, C) IFN-γ, 
D) Unmethylated CpG DNA or E) LPS.  
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Figure 3-13: ACKR4-mediated uptake of CCL19 and CXCL12 by human dermal LECs 
cannot be detected via flow cytometry. 
Cells were grown on 6-well plates until 70% confluent, and IFN-γ, if using, was added to 
media to a concentration of 100 ng/ml 24 hours prior to the uptake assay. Freshly 
harvested spleens were processed to obtain single-cell suspensions. Cells were then 
transferred to ultra-low binding plates and incubated with chemokines for 1 hour at 37º C, 
before using for flow cytometry analysis. Histograms are representative of 3 replicates. A 
Histograms showing fluorescent CCL19 uptake (◼) and fluorescent CCL19 uptake with 
excess unlabelled CCL19 (◻) in splenocytes (left panel) and cultured HD-LECs treated 
with IFN-γ (right panel). The gate on the left panel represents the percentage of CCL19+ 
cells in the CCL19-AF647 group. B) Histograms showing fluorescent CXCL12 uptake (◼) 
and fluorescent CXCL12 uptake with excess unlabelled competition from CXCL11 (◻) or 
CXCL12 (◻) in splenocytes (left panel) and cultured HD-LECs (right panel). The gate on 
the left panel represents the percentage of CXCL12+ cells in the CXCL12-AF647 group.  
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Figure 3-14: Cultured human LECs show no evidence of ACKR4-mediated CCL19 
uptake via microscopy. 
Human dermal LECs were grown on coverslips until 70-80% confluent and incubated with 
25 ng/ml biotinylated CCL19 conjugated with 2.5 ng/ml sva-AF555, or 2.5 ng/ml sva-
AF555 alone for one hour. Cells were stained with anti-ACKR4 antibody and 
counterstained with DAPI. Images are representative of three replicates. Scale bars = 50 
µm A) HD-LECs incubated with biotinylated CCL19 conjugated with sva-AF555. B) HD-
LECs incubated with sva-AF555 only.  
ACKR4 
CCL19-AF555 
DAPI 
merge A 
B 
 112 
 
Figure 3-15: Cultured human dermal LECs show no evidence of ACKR4-mediated 
CCL19 uptake by in vitro scavenging assay. 
Human dermal LECs were cultured in 12-well plates until confluent, and native 
recombinant CCL19 or CXCL12 were added to a final concentration of 75 ng/ml. No-cell 
control wells were included to detect non-specific binding of chemokines to culture 
surfaces. Aliquots of the media were taken 0h, 2h, 4h, 8h, 24h, 38h and 48h after addition 
of chemokine and ELISAs were used to determine chemokine concentration. (n=3 + 1 no-
cell control well). Error bars represent SD of the mean. A) Concentration of CCL19 
detected in the media over the time-course for wells containing HD-LECs pre-incubated 
with 100 ng/ml IFN-γ for 24 hours before addition of chemokine (◼), HD-LECs with 100 
ng/ml IFN-γ added concurrently with chemokine (◼) and untreated HD-LECs (◼) 
compared to the no-cell control well (◼). B) Concentration of CXCL12 detected in the 
media over the time-course for wells containing untreated HD-LECs (◼) compared to the 
no-cell control well (◼).  
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Figure 3-16: Incubation with HiCa media induces morphology changes by cultured 
human keratinocytes. 
Cells were cultured for 5 days in either LoCa media to retain their basal proliferative state, 
or HiCa media to induce differentiation. Cells were viewed using phase contrast light 
microscopy at 20X magnification. Scale bars: 50µm. Upper panel: Basal keratinocytes, 
showing a typical ‘cobblestone’-like morphology. Lower panel: differentiated keratinocytes, 
showing a more variable morphology.  
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Figure 3-17 Basal and differentiated cultured human keratinocytes show differential 
expression of ACKR4 at the protein, but not the mRNA, level. 
Normal human epidermal keratinocytes were cultured on coverslips in LoCa or HiCa 
media for 5 days, and either processed for immunofluorescence with anti-ACKR4 
antibody and counterstained with DAPI, or RNA was extracted, and cDNA generated for 
qPCR analysis. Images are representative of three replicates. Scale bars = 20 µm. A) 
Anti-ACKR4 staining on LoCa nHEKs. Left panel: overview of staining; right panel: 
magnified view of cell highlighted in left panel. B) Anti-ACKR4 staining on HiCa nHEKs. 
Left panel: overview of staining; right panel: magnified view of cell highlighted in left panel. 
C) mRNA expression of ACKR4 in LoCa (◼) and HiCa (◼) keratinocytes. Statistical 
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significance was determined using an unpaired t-test. Error bars represent SD of the 
mean.  
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Figure 3-18: Cultured human keratinocytes may alter mRNA expression of ACKR4, 
ACKR3 and CXCR4 in response to inflammatory stimuli. 
Normal human epidermal keratinocytes were cultured in LoCa media until 70-80% 
confluent and treated with cytokines or TLR ligands at the concentrations described in the 
materials and methods section. After 48h, cells were harvested, and RNA was extracted 
to generate cDNA for qPCR analysis. Three technical replicates were performed by 
carrying out each treatment on three separate wells, and each sample was run in 
triplicate. Graphs show expression of A) ACKR4, B) ACKR3 and C) CXCR4 as relative 
quantification (RQ) values calculated by the 2-ΔΔCT method using cells treated with PBS as 
the reference sample; CXCL12, CCL19, CCL21 and CCL25 were also tested but were not 
detected. Error bars represent SD of the mean.  
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Figure 3-19: Cultured human keratinocytes show no evidence of ACKR4-mediated 
CCL19 uptake by flow cytometry. 
Normal human epidermal keratinocytes were cultured in LoCa conditions until 70% 
confluent and immunostimulatory treatments, if using, were added for 24 hours (IFNs: 100 
ng/ml, CpG: 100 nM, KGF: 20 ng/ml) before cells were transferred to 96-well ultra-low 
binding plates for chemokine uptake assays and analysed using flow cytometry. A) 
nHEKs were treated with IFN-α, IFN-β, IFN-γ, CpG, KGF or left untreated, and incubated 
either with CCL19-AF647 alone, or with CCL19-AF647 and a ten-fold higher concentration 
of unlabelled CCL19 as competition. Mean fluorescence intensity values were taken for 
each sample (n=2). Error bars represent SD of the mean. B) nHEKs were either left 
untreated or incubated with IFN-γ for 24 hours before performing uptake assays using 
CCL19-AF647 or CCL19-AF647 plus a ten-fold higher concentration of unlabelled CCL19. 
Representative histograms of each group are shown (n=3). C) nHEKs were incubated 
with either biotinylated CCL19 pre-incubated with sva-AF647, or sva-AF647 alone. 
Histogram is representative of two technical replicates. 
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Chapter 4: Exploring ACKR3 and 
ACKR4 Expression in vivo 
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4 Exploring ACKR3 and ACKR4 Expression in vivo 
4.1 Introduction 
Understanding the location where a gene or protein is expressed, and how it is regulated, 
are the first steps to understanding its function. The tissue and cell types that express the 
gene/protein have their own unique functions and capabilities and understanding these can 
give valuable insights into the potential role of the transcript. The types of conditions that 
modulate expression of the gene/protein can also provide clues as to the functions it is 
involved in. Additionally, determining the specific cells that express a transcript can allow 
more targeted functional analyses to be carried out; for example, isolating that particular 
niche for further study, as I did in the previous chapter by examining expression and 
modulation of ACKR3, ACKR4 and related genes by cultured human cells.  
In this chapter, I have investigated ACKR3 and ACKR4 gene and protein expression in 
vivo using GFP reporter mice and antibody staining, both at rest and under immune 
challenge, to further characterise the specific cell types that express these receptors and 
what their involvement in the immune response may be. 
4.2 Aims 
• To further characterise eGFP+ cells in Ackr3+/gfp and Ackr4+/gfp reporter mice. 
• To determine whether enhanced CXCR4 signal in the skin following TPA 
treatment reflects only an influx of CXCR4+ cells or includes modulation of 
CXCR4 expression by keratinocytes. 
• To identify whether any keratinocyte subsets show differential ACKR3/CXCR4 
expression during inflammation. 
• To explore a potential role for ACKRs in modulating the positioning of specific 
chemokine-receptor-expressing subsets of DCs in the spleen. 
4.3 Characterisation of Ackr3+/gfp Reporter Mice 
ACKR3 protein expression has been previously reported on endothelial cells in a wide 
range of tissues by immunostaining 150, and I reasoned that it would be valuable to confirm 
these findings, potentially explore them in more detail, and relate this to expression data 
already obtained for ACKR3 expression in cultured human cells.  
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To this end, I carried out experiments to characterise eGFP expression in several key 
tissues of Ackr3+/gfp reporter mice. To maximise the data obtained from a limited number 
of mice, I received support from Carolyn Thomson, who kindly carried out flow cytometry 
analysis on small intestine, colon and mesenteric lymph node (MLN) samples. 
4.3.1 Ackr3 Expression in the Skin 
I was particularly interested to discover which cells in the skin expressed ACKR3 protein 
given the results from cultured human cells in the previous chapter showing ACKR3 to be 
found on keratinocytes and dermal LECs. ACKR3 has previously been reported on basal 
keratinocytes 207,208 but I could find no detailed analysis of its precise localisation or 
function in healthy skin in the literature. I therefore chose to use flow cytometry to 
determine the specific subsets of cells that expressed eGFP in the skin of Ackr3+/gfp 
reporter mice at rest.  
These experiments were carried out by separating epidermis and dermis and investigating 
the tissues individually. Generating single cell suspensions from the dermis for flow 
cytometry proved to be challenging, due to the complex extracellular matrix comprising 
this tissue, which led to poor cell yields and made it difficult to definitively identify sub-
populations of cells. For this reason, no analysis beyond total CD45+ or CD45- cells was 
carried out on the dermis. It was possible, however, to reliably isolate keratinocytes and 
leukocytes from the epidermis, although levels of extracellular debris were generally too 
high to allow for reliable absolute cell counts and yields often appeared low making it 
difficult to justify running FMO controls.  
Initial examination of the epidermis showed that there was negligible eGFP signal on 
leukocytes (CD45+ cells), while the vast majority of stromal cells (CD45- cells) were 
positive for eGFP (Figure 4-1). Cells were further analysed with surface markers to 
separate leukocytes and stromal cells into the major subsets present in the skin. 
Keratinocytes were separated into four subsets relating to their position in the hair follicle 
(Figure 4-2A), ordered from superficial to basal using Sca-1 and EpCAM 79: EpCAM- 
Sca-1+ cells (interfollicular epidermis), EpCAM+ Sca-1+ cells (Infundibulum), EpCAM+ 
Sca-1- cells (Isthmus) and EpCAM- Sca-1- cells (hair follicle bulge) (Figure 4-2B,C). Due 
to the low yield of epidermal cells and the need to investigate leukocytes as well as stromal 
cells, the full panel of antibodies could not be used to definitively identify hair follicle 
bulge cells, which should express CD34 and can be further delineated into basal and supra-
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basal bulge cells as α6 integrin (CD49f) positive and negative cells, respectively. There 
was no clear information available on markers identifying hair follicle bulb cells, but it was 
assumed that all stromal cells in the epidermis were keratinocytes, and that EpCAM- Sca-
1- cells therefore represented a combination of the hair follicle bulge and bulb subsets. 
Some degree of contamination of the epidermis with cells from the dermis, including 
fibroblasts, cannot be ruled out, making the EpCAM- Sca-1- population likely to be highly 
heterogeneous; nevertheless, this group of cells were referred to as ‘bulge’ for simplicity. 
eGFP expression was clearly detected in some cell subsets identified in the epidermis of 
Ackr3+/gfp mice. Epidermal leukocytes were generally eGFP- (Figure 4-3A), but there were 
low levels of potential eGFP signal in dermal γδT cells and Langerhans cells (LCs); the 
signal from LCs appeared to be autofluorescence, as the eGFP signal in WT control mice 
was also raised. Ackr3 expression has not previously been reported by any of these cells, 
and leukocytes are generally considered to be ACKR3 negative 151; given that the eGFP 
signal was very weak, this was not considered to be a positive result. 
Results from the epidermal stroma (Figure 4-3B) showed that eGFP expression is present 
on all keratinocyte subsets, but largely restricted to the cells nearest the outer surface of the 
skin; the cells of the interfollicular epidermis and infundibulum were both over 90% 
eGFP+, while isthmus and bulge cells were only 20-30% eGFP+ (Figure 4-3C).  
4.3.1.1 CXCR4 and Ackr3 Expression in the Skin 
Given this intriguing result suggesting differential expression of ACKR3 within the hair 
follicle, epidermal cell subsets were studied in more depth. CXCR4 expression has 
previously been reported on keratinocytes 186, and given the potential for ACKR3 to 
heterodimerise with CXCR4 and modulate its responsiveness to CXCL12 142,156,157, I 
hoped to determine whether CXCR4, too, was expressed differentially by keratinocyte 
subsets in the epidermis. 
Anti-CXCR4 staining was used to explore CXCR4 expression in leukocytes and stromal 
cells at rest and determine whether this overlapped with eGFP expression. Due to low cell 
yields from the epidermis, and lack of available Ackr3+/gfp reporter mice to provide 
additional tissue for controls, a CXCR4 isotype or FMO control was not available for these 
studies. Instead, an internal control was used to set the gates for CXCR4 expression: 
Dendritic epidermal T cells (DETCs), the epidermis-resident subtype of γδT cells (See 
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section 1.4.3) are the only known subset of γδT cell that do not express CXCR4 according 
to the ImmGen database 209, and no reference to CXCR4 expression on these cells could be 
found in the literature. As expected, epidermal γδT cells in the epidermis appeared to be 
CXCR4 negative, and when overlaid as a histogram, their fluorescence peak coincided 
with the negative population in the bimodal CXCR4 expression of MHC-II- γδTCR- 
leukocytes in the skin (Figure 4-4A, left panel). Many of these CXCR4 positive cells are 
likely to be tissue-resident memory T cells and monocytes/macrophages. Interestingly, 
Langerhans cells in the epidermis appeared to be mainly CXCR4+ (Figure 4-4A, right 
panel), which would be expected of these cells upon activation, when they use 
CXCL12/CXCR4 signalling to migrate into the dermis 97. 
Results in the stroma showed that CXCR4 protein was present on keratinocytes, as 
expected, and that its expression varied between the subsets. The strongest CXCR4 
expression was detected in the infundibulum (Figure 4-4B), while the cells in the bulge 
subset did not express CXCR4. CXCR4 expression in the four stromal cell subsets is 
summarised in Figure 4-4C. 
Once the expression of both CXCR4 and ACKR3 had been detected on some subsets of 
keratinocytes, I investigated whether the expression of these receptors overlapped (Figure 
4-5A). It did not appear that coexpression of these two receptors was common in 
keratinocytes, with the exception of the infundibulum subset, where the majority of 
CXCR4+ cells were eGFP+, and around half of eGFP+ cells were CXCR4+ (Figure 4-5B). 
Although the anti-CXCR4 antibody has been used successfully here, chemokine receptor 
staining is often difficult to interpret as cells can lie on a continuum from weakly to 
strongly positive. To corroborate these findings, the mean fluorescence intensity (MFI) of 
the CXCR4 channel was measured in eGFP+ and eGFP- cells from each keratinocyte 
subset. In IE and IF, eGFP+ cells showed a significantly higher MFI value than eGFP- 
cells, suggesting that eGFP+ cells are more likely to express CXCR4 than eGFP- cells in 
these subsets (Figure 4-5C). This can be confirmed visually by comparing populations 2 
and 3 in the scatterplots shown in FIG 4-5A.  
These experiments have shown that both eGFP and CXCR4 are differentially expressed in 
the four keratinocyte subsets examined in Ackr3+/gfp mice, and that the degree of 
eGFP/CXCR4 coexpression also varies between subsets, with the infundibulum showing 
the highest proportion of CXCR4+ cells, the second-highest proportion of eGFP+ cells, 
and the highest proportion of eGFP+ CXCR4+ cells.  
  123 
4.3.1.2 CXCR4 and Ackr3 in the TPA model 
Previous results obtained in our group showed that after topical application of the phorbol 
ester 12-O-Tetradecanoylphorbol-13-acetate (TPA) to mouse ears, mRNA levels of both 
Ackr3 and Cxcr4 are raised in the epidermis (S. Bryce, personal communication). Ackr3 
expression peaks at 4 hours post treatment and Cxcr4 expression peaks at 24 hours post 
treatment. As this experiment studied mRNA expression in the tissue as a whole, I aimed 
to determine whether TPA treatment had any direct effect on ACKR3 or CXCR4 expression 
by keratinocytes using cultured nHEKs. 
Results showed that cultured human keratinocytes downregulated ACKR3 and upregulated 
CXCR4 four hours after treatment with TPA (Figure 4-6); this suggested that the 
upregulation of Ackr3 seen in the mouse epidermis was not due to keratinocytes, but as 
cultured nHEKs in LoCa conditions are likely to represent only the most basal cells of the 
epidermis, I decided to investigate eGFP and CXCR4 expression in Ackr3+/gfp reporter 
mice after TPA treatment to determine whether these transcripts were differentially 
regulated between keratinocyte subsets during inflammation. 
4.3.1.3 CXCR4+ Leukocytes Enter the Skin 16h Post TPA 
Initial experiments were carried out on WT mice only as Ackr3+/gfp mice were not yet 
available. These experiments were used to examine CXCR4 expression and to determine 
whether a single TPA treatment or multiple treatments would be more suitable for future 
experiments. When the epidermis was examined 16 hours after a single treatment with 
TPA, flow cytometry analysis indicated leukocyte recruitment to the skin, as the 
proportion of live cells that were CD45+ significantly increased in both epidermis and 
dermis after TPA treatment (Figure 4-7A). There was very little change in the proportions 
of the leukocyte subsets examined after TPA treatment (Figure 4-7B). The ‘other 
leukocytes’ subset were stratified based on Ly6C expression in this experiment, which 
showed that Ly6Chi cells, most likely monocytes or macrophages, made up a greater 
proportion of leukocytes in TPA-treated epidermis, while Ly6C- cells were proportionally 
underrepresented. Amongst stromal cells, the infundibulum cells made up a higher 
proportion in TPA-treated epidermis, while none of the other subsets were significantly 
affected (Figure 4-7C).  
  124 
Examining CXCR4 expression in these cells showed that the percentage of positive cells 
was unaffected in all of the leukocyte subsets identified (Figure 4-8A). There was also no 
detectable modulation of CXCR4 expression in any of the keratinocyte subsets, although 
there was a slight trend towards increased CXCR4 expression in all subsets except the 
bulge (Figure 4-8B). This appeared to combine to create a weakly significant increase in 
CXCR4 expression amongst stromal cells as a whole, in both epidermis and dermis (Figure 
4-8C). CXCR4 expression in the dermal stroma is most likely on vascular endothelial cells 
138.  
These results suggest that, while a single TPA treatment can induce detectable leukocyte 
infiltration to the skin, no detectable modulation of CXCR4 protein is detectable after 16 
hours. It also indicated that the induction of Cxcr4 mRNA detected in mouse skin is most 
likely partially due to the infiltration of CXCR4+ leukocytes and partially due to the 
modest upregulation of CXCR4 by most keratinocyte subsets. Both treated and untreated 
skin showed a similar proportion of viable cells (data not shown), suggesting that these 
results were not due to excess cell death in the treated group. 
4.3.1.4 Multiple TPA Treatments Enhance CXCR4 Expression in Keratinocytes 
To determine whether CXCR4 might be modulated in response to a more severe 
inflammatory stimulus, flow cytometry analysis was carried out on skin that had been 
treated three times daily with TPA. When the cellularity of the epidermis was analysed, it 
showed significant infiltration of leukocytes. This was more pronounced than after a single 
TPA treatment (Figure 4-9A). As a proportion of leukocytes, γδT cells were significantly 
underrepresented after multiple TPA treatments but no other subset was affected (Figure 4-
9B). Among the stroma, cells of the interfollicular epidermis were decreased as a 
proportion, while the infundibulum made up a larger proportion of keratinocytes after 
multiple TPA treatments; isthmus and bulge were unaffected. 
Analysis of CXCR4 expression showed that leukocytes in the epidermis did not upregulate 
this receptor in response to multiple TPA treatments (Figure 4-10A). Among CD45- cells 
in the epidermis, IE, IF and IM keratinocytes all significantly upregulated CXCR4 (Figure 
4-10B). Among CD45- cells as a whole, CXCR4 was significantly induced in both 
epidermis and dermis (Figure 4-10C). This suggested that multiple TPA treatments were 
required to induce upregulation of CXCR4 expression among keratinocytes in the skin. 
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4.3.1.5 eGFP Expression Is Reduced in the Infundibulum After Multiple TPA 
Treatments 
Next, I hoped to determine whether the regulation of CXCR4 in response to multiple TPA 
treatments would reflect any modulation in Ackr3 expression, particularly in the IF subset: 
previous analysis has shown that many of these cells coexpress eGFP and CXCR4 at rest 
in Ackr3+/gfp reporter mice. Differential Ackr3 expression in keratinocyte subsets may 
correspond to differential regulation of ACKR3 in response to inflammatory stimuli. 
Multiple TPA treatments on Ackr3+/gfp mice led to little modulation in the proportion of 
eGFP+ cells in most subsets, however, in the infundibulum there was a striking decrease in 
eGFP expression after TPA (Figure 4-11A, top right panel). Analysis showed that a 
significant reduction in the proportion of eGFP+ cells was apparent in the IF and bulge 
subsets (Figure 4-11B). 
Although there were insufficient Ackr3+/gfp reporter mice available to complete these 
investigations, these initial results are intriguing and suggest differential regulation of 
Ackr3 and CXCR4 in stromal cell subsets of the epidermis. This was most striking the 
infundibulum subset of keratinocytes, which appeared to significantly downregulate Ackr3 
and upregulate CXCR4 in response to multiple TPA treatments. 
4.3.2 Ackr3 Expression in the Gut 
Promising results were attained by exploring eGFP expression in the epidermis of 
Ackr3+/gfp reporter mice, particularly the EpCAM+ cells of the infundibulum. Because 
Ackr3+/gfp reporter mice have been poorly characterised to date, I further explored Ackr3 
expression on other epithelial surfaces, particularly those thought to be sites of Ackr4 
expression. For this reason, eGFP expression was examined in the small intestine and 
colon, and stromal cells were subdivided into epithelial (EpCAM+) cells, and non-
epithelial LECs (CD31+ gp38+), blood endothelial cells (BECs; CD31+ gp38-), intestinal 
mesenchymal cells (iMCs; CD31- gp38+) and double negative (DN; CD31- gp38-) cells 
(Figure 4-12A).  
In the small intestine, no GFP expression was detected on epithelial cells, while LECs and 
BECs included the highest proportions of eGFP+ cells (Figure 4-12B). This suggested that 
Ackr3 expression is mainly restricted to the vasculature in the small intestine; however, a 
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significant proportion of iMCs were also eGFP+. In the colon, a small subset of epithelial 
cells was eGFP+, and while LECs and BECs were still highly eGFP+, a large proportion of 
iMCs and DN cells also expressed eGFP (Figure 4-12C). This suggests that Ackr3 
expression is more widespread in the colon than the small intestine, but in both tissues, this 
was restricted to stromal cells as eGFP signal was not detected on leukocytes (data not 
shown). 
These results were of particular interest because eGFP expression has also been detected in 
the mesoepithelium and lumen of the gut in Ackr4+/gfp reporter mice 177. Further analysis 
showed that the majority of eGFP+ cells in the intestine are specific subsets of fibroblasts 
in the lamina propria, which are part of the iMC gate (C. Thomson, personal 
communication). This suggests that Ackr3 expression is much more widespread and less 
restricted to specific cell subsets in the intestine than Ackr4. 
4.3.3 Ackr3 Expression in the Mesenteric Lymph Node 
Expression of both ACKR4 and ACKR3 were detected by human dermal LECs in the 
previous chapter, and ACKR4 expression has also been shown by the lymph node stroma 
101. CXCL12 also plays a role in FO B cell positioning in the lymph node 33. ACKR3 has 
been reported to be expressed on sinusoidal vessels in lymph node, but not on lymphatic 
endothelium in several tissues 150; however, due to the results showing Ackr3 expression 
on LECs in the gut, and expression of ACKR3 by human dermal LECs, I examined eGFP 
expression in the MLN of Ackr3+/gfp reporter mice. Stromal cells in this tissue were divided 
into FRCs (CD31-, gp38+), LECs, BECs and DN cells (Figure 4-13A) LECs and BECs 
had the most convincing eGFP signals, while eGFP signals on FRCs and DN cells were 
negligible (Figure 4-13B). No eGFP expression was detected on leukocytes (data not 
shown). 
This expression pattern is reminiscent of Ackr4, which labels a subset of LECs in eGFP 
reporter mice 101, and a small subset of BECs, but not FRCs or DN cells (S. Bryce, 
personal communication). Ackr3 expression appeared to be less widespread in the lymph 
node compared to Ackr4 expression, however, as the subset of LECs labelled by Ackr3 is 
much smaller than the Ackr4+ subset (S. Bryce, personal communication). 
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4.3.4 Ackr3 Expression in the Spleen 
ACKR3 protein expression has been previously reported on sinusoidal endothelial cells in 
the spleen by immunofluorescence 150. To confirm these findings, and to examine Ackr3 
expression in another SLO, I investigated whether these cells would show eGFP 
expression in Ackr3+/gfp mice. Flow cytometry analysis revealed a population of eGFP+ 
CD45- cells (Figure 4-14A) but further investigation of these cells proved challenging, due 
to poor staining by endothelial markers; however, previous studies have shown that 
ACKR3 in the spleen is present on sinusoidal endothelial cells in the red pulp 150. 
Investigating leukocytes in the spleen showed that most subsets were not eGFP+, but there 
was a small population of eGFP+ MZ B cells (Figure 4-14B), which concurs with some 
previous results showing antibody staining for ACKR3 in MZ B cells  152. This result is 
interesting because MZ B cells have also been shown to express ACRK2 145; however, it is 
possible that Ackr3 transcript in MZ B cells represents an upregulation due to the stress of 
experimental handling in these cells 210. 
4.4 Exploring ACKR4 Expression in vivo 
4.4.1 Investigating a Role for ACKR4 in Splenic Dendritic Cell Positioning 
4.4.1.1 Characterisation of ACKR4+ Cells in the Spleen 
I aimed to explore ACKR4 expression in vivo further and determine whether it is found in 
an SLO other than the lymph node. Because the white pulp of the spleen has a broadly 
analogous structure and function to the lymph node, and due to the expression of eGFP in 
splenic sinusoidal endothelial cells by Ackr3+/gfp mice, I investigated whether ACKR4 is 
also found there. 
Immunostaining showed that ACKR4 is present in the spleen, and that it is restricted to 
CD31+ cells (Figure 4-15A). Anti-CD169 antibody was used as an anatomical marker to 
locate MMMs in the marginal zone. This made it possible to determine that the ACKR4+ 
CD31+ cells were located in the red pulp, which are likely to be blood vessels due to their 
morphological appearance. Although all ACKR4+ cells detected were CD31+, not all 
CD31+ cells were ACKR4+. This suggested only a subset of endothelial cells in the spleen 
express ACKR4, so I hoped to further characterise these cells. Spleen cells from 
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Ackr4gfp/gfp mice were analysed using flow cytometry (Figure 4-16A). This revealed that 
the CD45- eGFP+ cells in the spleen are VE-Cadherin+, CD34+, CD31+, MCAM-1-, 
EpCAM+ (Figure 4-16B).  
Unfortunately, it was not possible to determine whether splenic vascular cells coexpress 
ACKR3 and ACKR4. The most reliable antibody clone against ACKR3, 11G8 191, is a 
mouse antibody and obtaining specific staining was too challenging. The antibody that 
gave reliable results for anti-ACKR4 staining in mouse tissues was a specific batch of a 
polyclonal antibody, and when the antibody was replaced to attempt staining on Ackr3+/gfp 
mice, specific anti-ACKR4 immunoreactivity was no longer attainable. 
4.4.1.2 Investigating Chemokine Receptor Expression in Splenic DC Subsets 
Previous work has indicated that different subsets of DCs in the spleen express the 
chemokine receptors CCR2, CXCR4 and CX3CR1 at varying levels (C. Cullen, personal 
communication). I intended to explore whether differential expression of chemokine 
receptors on these cells may allow them to fine-tune their positioning in the spleen to carry 
out specific functions; for example, priming specific T cell subsets or antigen capture. 
Furthermore, ACKRs may be involved in regulating the local concentrations of 
chemokines to aid in DC positioning. ACKR3 scavenges the CXCR4 ligand, CXCL12, and 
ACKR4 was investigated because it scavenges the CCR7 ligands CCL19 and CCL21, and 
mature DCs and T cells in SLOs are known to express CCR7 101. Ackr3 and ACKR4 have 
both been detected in the splenic vasculature in this chapter, and different subsets of DCs 
are known to occupy different locations in the spleen 60. I hypothesised that ACKR3 and 
ACKR4 could be involved in modulating the positions of DCs expressing varying levels of 
CXCR4 and/or CCR7 by modulating the availability of their ligands.  
Splenic DCs are normally divided into CD8α+ CD11b- and CD8α- CD11b+ subsets (these 
will be referred to as CD8+ and CD11b+, respectively) and their functions were discussed 
in the introduction (Section 1.3.2). Flow cytometry analysis has shown that among 
CD11b+ DCs, a further subdivision could be made based on CD4 and CD101 expression 
(C. Cullen, personal communication). Unfortunately, it was rarely possible to replicate 
CD4/CD101 staining on CD11b+ DCs, as the proportions falling into each subset varied 
from experiment to experiment, so only the total CD8+ and CD11b+ subsets were 
examined (Figure 4-18). 
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CXCR4 expression on DCs was measured using antibody staining, while CCR7 expression 
was investigated using uptake of fluorescently-labelled CCL19, with biotinylated 
CCL19/sva-AF488 tetramers and sva-AF488 only as a control. This was due to the lack of 
adequate antibodies available for this receptor. These experiments showed that CD11b+ 
and CD8+ DCs have comparable levels of functional CCR7 (Figure 4-19A) and anti-
CXCR4 staining (Figure 4-19B), and that a significantly higher proportion of cells are 
CCR7+ in the CXCR4+ subset than the CXCR4- subset for both CD8+ and CD11b+ DCs 
(Figure 4-19C). This suggests that, while chemokine receptor expression does not vary 
between the subsets, cells that express one chemokine receptor are more likely to express 
multiple receptors.  
Although an analysis of splenic DC subsets in WT vs KO mice was attempted, there were 
no differences detected in the proportions of the different subsets identified via flow 
cytometry (data not shown). 
4.4.1.3 Locating Splenic DC Subsets in the Spleen 
To attempt to further examine splenic DC subsets, immunofluorescence was employed to 
reveal DC positioning within the spleen. Identifying CD8+ and CD11b+ DC subsets using 
traditional markers by immunostaining is challenging, as a large number of stains would be 
required to definitively identify these cells given that CD8 labels cytotoxic T cells and 
CD11b labels many leukocytes including NK cells and monocytes. It has been reported, 
however, that CD8+ and CD11b+ subsets can be recognised by their expression of the 
markers CD205 (CD8+) or DCIR2 (CD11b+) 60,61. Anti-CD205 and anti-DCIR2 staining 
was attempted to identify these DC subsets in the spleen. 
Attaining anti-DCIR2 immunoreactivity was challenging. Initially, staining was attempted 
with a purified antibody (clone 33D1) followed by a labelled secondary antibody. 
According to the supplier (eBioscience), secondary antibodies raised in goat have a low 
affinity for this clone. The only other secondary antibody available was a mouse anti-rat 
antibody, and in mouse tissue this led to high levels of non-specific staining. The only 
directly-conjugated 33D1 antibody available was a PE conjugate, which is not suitable for 
microscopy because it is only weakly excited by the wavelengths used in most fluorescent 
microscope filter sets and becomes photobleached very quickly. The eventual solution to 
this problem was to use the PE-conjugated antibody followed by staining with biotinylated 
anti-PE antibody and finally sva-AF555. 
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These results showed anti-DCIR2 staining was confined mainly to the red pulp and to the 
bridging channels of the marginal zone, while CD205+ cells were mainly localised in the 
white pulp (Figure 4-20A). This was the pattern that would be expected if these markers 
successfully stained CD11b+ and CD8+ DCs respectively 60,64. Investigating further 
showed that DCIR2+ cells were very clearly localised in the bridging channels (Figure 4-
20B), but CD205+ cells did not appear to be restricted to the T cell zones as expected; they 
appeared to be roughly evenly distributed between B cell follicles and the T cell zones 
(Figure 4-20C). 
Due to this unexpected result, flow cytometry was used to attempt to validate CD205 and 
DCIR2 antibodies and determine whether CD11b+ and CD8+ subsets were correctly 
identified by these antibodies. Although CD205 expression was restricted to the CD8α+ 
subset as expected, both subsets were positive for DCIR2 (Data not shown).  
There was a high level of variability in results from these investigations that made it 
impossible to continue, despite many efforts to fine-tune the concentrations of reagents and 
methods used. The lack of reproducibility encountered was most likely due to unreliability 
in the antibodies used, as immunostaining for chemokine receptors is often challenging; 
however, identifying the CD4 and CD101 subsets of CD11b+ cells also proved difficult on 
many occasions, with little positive staining obtained for either marker. The further 
inability to definitively identify the CD205+ and DCIR2+ subsets in immunostaining the 
spleen made these cells’ spatial positioning uncertain. For these reasons, and despite some 
promising results, this line of investigation was not continued further due to limited time 
and resources. 
4.5   Key Findings 
• Keratinocyte subsets in the epidermis differentially express CXCR4 and Ackr3 in 
Ackr3+/gfp reporter mice. The highest degree of coexpression was seen in the 
infundibulum, while the lowest was in the heterogeneous bulge subset. 
•  Most subsets of keratinocytes significantly upregulate CXCR4 in response to 
multiple TPA treatments, while Ackr3 is downregulated in the infundibulum and 
bulge. 
• Ackr3 is expressed on endothelial cells in gut, spleen, skin and mesenteric lymph 
nodes. The following cell types showed evidence of Ackr3 expression: 
o A subset of LECs and BECs in the MLN 
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o All stromal cells in the colon 
o LECs and BECs in the small intestine 
o MZ B cells and endothelial cells in the spleen 
o Keratinocytes in the skin 
• ACKR4 is expressed on CD31+ VE-Cadherin+ EpCAM+ CD34+ MCAM-1- 
vessels in the splenic red pulp. 
• Subsets of CD8+ and CD11b+ DCs in the spleen express CXCR4 and CCR7 
receptors.
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Figure 4-1: eGFP expression in the epidermis of Ackr3+/gfp mice is mainly restricted 
to CD45- cells. 
Ears from Ackr3gfp/+ reporter mice (◼) or WT control (◻) were excised and epidermal 
sheets were processed to obtain single cell suspensions for flow cytometry analysis (n=5, 
+1 WT control). Representative histograms show eGFP expression in CD45+ cells (left 
panel) and CD45- cells (right panel). Gates represent the proportion of eGFP+ cells in the 
Ackr3+/gfp mouse.  
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Figure 4-2: Flow cytometry gating strategy for identifying epidermal cell types. 
Single cell suspensions were prepared from dermis and epidermal sheets and cells were 
analysed via flow cytometry. Samples were pre-gated to exclude debris, doublets and 
dead cells. A) Schematic diagram representing the locations of the four keratinocyte 
subsets in a telogen hair follicle. B) Representative scatter plots of inflamed epidermis 
(16h TPA) showing the gating strategies to identify epidermal cell types. (These cell types 
are all present in non-inflamed skin, but gating was easier in inflamed skin due to higher 
numbers of leukocytes). CD45- cells were subdivided based on Sca-1 and EpCAM 
expression, while CD45+ cells were divided into γδTCR+ MHC-II-, γδTCR- MHC-II+ and 
γδTCR- MHC-II- subsets. The γδTCR- MHC-II+ subset was then gated for EpCAM+ cells. 
C) Table summarising the identified populations.
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Figure 4-3: eGFP is expressed by subsets of CD45- cells in the skin of Ackr3+/gfp 
mice. 
Ears from Ackr3gfp/+ reporter mice (◼) or WT control (◻) were excised and epidermal 
sheets were processed to obtain single cell suspensions for flow cytometry analysis (n=5, 
+1 WT control). A) eGFP expression in epidermal CD45+ cell types: γδT Cells, 
Langerhans Cells and Other Leukocytes. Representative histograms show eGFP 
expression in WT vs Ackr3+/gfp mice. B) eGFP expression in epidermal keratinocyte 
subsets identified in Figure 4-2. Representative histograms show eGFP expression in WT 
vs Ackr3+/gfp mice. C) Graph summarising data obtained in B, showing comparative eGFP 
expression between keratinocyte subsets. Error bars represent SD of the mean.  
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Figure 4-4: CXCR4 is expressed by keratinocytes, Langerhans Cells and other 
leukocytes in the epidermis. 
Mouse ears were excised and epidermal sheets were processed to obtain single cell 
suspensions for flow cytometry analysis (n=5). γδT cells are used as a negative control for 
CXCR4 expression. A) Representative histograms show CXCR4 expression in CD45+ cell 
populations. B) Representative histograms show CXCR4 expression in the four 
keratinocyte subsets detected. C) Graph showing the percentage of CXCR4 positive cells 
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detected in the epidermal keratinocyte subsets identified in Figure 4-2. Error bars 
represent SD of the mean.  
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Figure 4-5: eGFP and CXCR4 are coexpressed by subsets of keratinocytes in 
Ackr3+/gfp mice. 
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Ears from Ackr3gfp/+ reporter mice were excised and epidermal sheets were processed to 
obtain single cell suspensions for flow cytometry analysis (n=5). A) Representative scatter 
plots showing eGFP and CXCR4 expression in the four stromal subsets identified in 
Figure 4-2: Interfollicular Epidermis (IE), Infundibulum (IF), Isthmus (IM) and Hair follicle 
bulge (Bulge). Cells are separated into four subsets: 1) eGFP+ CXCR4-, 2) eGFP+ 
CXCR4+, 3) eGFP- CXCR4+, 4) eGFP- CXCR4-. Error bars represent SD of the mean. B) 
Expression of the four eGFP/CXCR4 subsets identified in A by the four stromal cell 
populations. Top left: Sca-1+ EpCAM- (interfollicular epidermis, IE), top right: Sca-1+ 
EpCAM+ (infundibulum, IF), bottom left: Sca-1- EpCAM- (hair follicle bulge), bottom right: 
Sca-1- EpCAM+ (isthmus, IM). C) Mean fluorescence intensity (MFI) of anti-CXCR4 
staining on eGFP- (◼) and eGFP+ (◼) cells within the four identified keratinocyte subsets. 
Statistical significance between eGFP- and eGFP+ populations was calculated using t 
tests corrected for multiple comparisons using the Holm-Sidak method (*P≤0.05).
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Figure 4-6: ACKR3 mRNA is downregulated and CXCR4 mRNA is upregulated in 
response to TPA in cultured human keratinocytes. 
Normal human epidermal keratinocytes (nHEKs) were cultured in LoCa media until 70-
80% confluent and treated with PBS (◼) or 100 nM TPA (◼). After 4h, cells were 
harvested and RNA was extracted to generate cDNA for qPCR analysis. Three technical 
replicates were performed by carrying out each treatment on three separate wells, and 
each sample was run in triplicate. Graphs show expression of ACKR3 and CXCR4 as 
arbitrary units (AU) calculated by the ΔΔCT method. Error bars represent SD of the mean.
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Figure 4-7: A single topical TPA treatment leads to an increased proportion of 
leukocytes in both epidermis and dermis. 
WT mice were treated once on the ear skin with TPA (◼) or acetone (◼) and 16 hours 
after treatment, ears were separated into epidermis and dermis and processed to obtain 
single cell suspensions for flow cytometry analysis (n=3). Statistical significance was 
determined using t tests corrected for multiple comparisons using the Holm-Sidak method 
(*P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0.0001). Error bars represent SD of the mean. A) 
The percentage of live cells represented by leukocytes in the epidermis and dermis of 
acetone and TPA-treated mice. B) The percentage of CD45+ cells that fall into each 
leukocyte subset in the epidermis of acetone and TPA-treated mice. C) The percentage of 
CD45- cells represented by each subset of keratinocytes in the epidermis of acetone and 
TPA-treated mice.   
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Figure 4-8: CXCR4 expression in the skin increases 16 hours after a single TPA 
treatment due to increased proportions of CXCR4+ cells. 
WT mice were treated once on the ear skin with TPA (◼) or acetone (◼) and 16 hours 
after treatment, ears were separated into epidermis and dermis and processed to obtain 
single cell suspensions for flow cytometry analysis (n=3). Statistical significance was 
determined using t tests corrected for multiple comparisons using the Holm-Sidak method 
(*P≤0.05, **P≤0.01). Error bars represent SD of the mean. A) CXCR4 expression in 
epidermal leukocytes. B) Percentage of CXCR4+ cells in epidermal CD45- subsets. C) 
Percentage of all CD45- cells that are CXCR4+ in the dermis and epidermis.  
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Figure 4-9: Repeated TPA treatments lead to changes in the proportions of 
epidermal leukocytes and keratinocytes. 
WT mice were treated once daily for three days on the ear skin with TPA (◼) or acetone 
(◼) and 16 hours after the final treatment, ears were separated into epidermis and dermis 
and processed to obtain single cell suspensions for flow cytometry analysis (n=3). 
Statistical significance was determined using t tests corrected for multiple comparisons 
using the Holm-Sidak method (*P≤0.05, **P≤0.01, ***P≤0.001). Error bars represent SD of 
the mean. A) The percentage of live cells represented by leukocytes in the epidermis and 
dermis of acetone and TPA-treated mice. B) The percentage of CD45+ cells that fall into 
each leukocyte subset in the epidermis of acetone and TPA-treated mice. C) The 
percentage of CD45- cells represented by each subset of keratinocytes in the epidermis 
of acetone and TPA-treated mice.  
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Figure 4-10: CXCR4 expression by keratinocytes is increased after repeated TPA 
treatments. 
WT mice were treated once daily for three days on the ear skin with TPA (◼) or acetone 
(◼) and 16 hours after the final treatment, ears were separated into epidermis and dermis 
and processed to obtain single cell suspensions for flow cytometry analysis (n=3). 
Statistical significance was determined using t tests corrected for multiple comparisons 
using the Holm-Sidak method (*P≤0.05, **P≤0.01). Error bars represent SD of the mean. 
A) CXCR4 expression in epidermal leukocytes. B) Percentage of CXCR4+ cells in 
epidermal CD45- subsets. C) Percentage of all CD45- cells that are CXCR4+ in the 
dermis and epidermis.  
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Figure 4-11: Repeated TPA treatments reduce eGFP expression in the infundibulum 
of Ackr3+/gfp mice. 
Ackr3+/gfp mice were treated once daily for three days on the ear skin with TPA or acetone 
and 16 hours after the final treatment, ears were separated into epidermis and dermis and 
processed to obtain single cell suspensions for flow cytometry analysis (n=3 + 1 WT 
control). A) Representative histograms show eGFP expression in each keratinocyte 
subset of WT acetone-treated (◻), Ackr3+/gfp acetone-treated (◻) and Ackr3+/gfp TPA-
treated (◼) mice. Gates represent the proportion of eGFP+ cells in the Ackr3+/gfp TPA-
treated sample. B) Graph showing the proportion of eGFP cells in each keratinocyte 
subset between mice treated with acetone (◼) and TPA (◼). Statistical significance was 
determined using t tests corrected for multiple comparisons using the Holm-Sidak method 
(*P≤0.05). Error bars represent SD of the mean.  
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Figure 4-12: eGFP is widely expressed in the small intestine and colon of Ackr3+/gfp 
mice. 
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Small intestine and colon were harvested from WT (◼) and Ackr3+/gfp (◻) mice and 
processed to obtain single cell suspensions for flow cytometry analysis. (WT: n=1, 
Ackr3+/gfp: n=3). Note that females 14 weeks of age were used for this analysis due to 
limited availability of mice. A) Gating strategy to identify the stromal cell subsets analysed. 
All samples were initially gated to exclude debris, doublets and dead cells. Cells were 
divided into CD45- EpCAM+ (Epithelial), CD45- EpCAM- gp38+ CD31- (iMC), CD45- 
EpCAM- gp38+ CD31+ (LEC), CD45- EpCAM- gp38- CD31+ (BEC), CD45- EpCAM- 
gp38- CD31- (DN). eGFP+ cells are overlaid over total cells in these plots to represent the 
distribution of eGFP expression. B) Expression of eGFP in the five identified stromal 
subsets of the small intestine in WT and Ackr3+/gfp mice. C) Expression of eGFP in the five 
identified stromal subsets of the colon in WT and Ackr3+/gfp mice.  
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Figure 4-13: eGFP is expressed by LECs and BECs in the mesenteric lymph nodes 
of Ackr3+/gfp mice. 
Mesenteric lymph nodes were harvested from WT (◼) and Ackr3+/gfp (◻) mice and 
processed to obtain single cell suspensions for flow cytometry analysis. (WT: n=1, 
Ackr3+/gfp: n=3). Note that females 14 weeks of age were used for this analysis due to 
limited availability of mice. A) Gating strategy to identify the stromal cell subsets analysed. 
All samples were initially gated to exclude debris, doublets and dead cells. Cells were 
divided into CD45- gp38+ CD31- (FRC), CD45- gp38+ CD31+ (LEC), CD45- gp38- 
CD31+ (BEC) and CD45- gp38- CD31- (DN). eGFP+ cells are overlaid over total cells in 
these plots to represent the distribution of eGFP expression. B) Expression of eGFP in the 
four identified stromal subsets of the MLN.   
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Figure 4-14: eGFP is expressed by stromal cells and MZ B cells in the spleen of 
Ackr3+/gfp mice 
Spleens were harvested from WT and Ackr3+/gfp mice and processed to obtain single cell 
suspensions for flow cytometry analysis. (WT: n=1, Ackr3+/gfp: n=3). Note that females 14 
weeks of age were used for this analysis due to limited availability of mice. A) 
Representative scatter plots showing the identification of eGFP+ stromal cells. B) eGFP 
expression in splenic leukocytes: left panel shows the gating strategy to identify B220+ 
leukocytes, the middle panel shows MZ B cells within this gate (CD21+ CD23- cells) and 
the right panels show eGFP expression by MZ B cells in Ackr3+/gfp (top) and WT (bottom) 
mice.  
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Figure 4-15: ACKR4 protein in the spleen is mainly located on CD31+ cells in the 
red pulp. 
Spleens from resting WT and Ackr4-/- (KO) mice were harvested and cryosections were 
prepared. Sections were incubated with anti-ACKR4, CD31 and CD169 antibodies and 
viewed using fluorescent microscopy. Images are representative of three replicates. Scale 
bars = 100 µm. A) In a WT background, individual channel images show ACKR4 staining 
(top left panel) and CD31 staining (top right panel), and all channels are shown 
superimposed (lower panel) with anatomical details highlighted: WP = white pulp, RP = 
red pulp, MZ = marginal zone. All arrows in the three images highlight the same positions, 
showing vessels that appear to co-stain with ACKR4 and CD31 antibodies. B) The KO 
mouse shows no ACKR4 staining, indicating the antibody used has good specificity.  
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Figure 4-16: ACKR4 is expressed on vascular endothelial cells in the spleen. 
Spleens from resting WT and Ackr4gfp/gfp (Hom) mice were excised and processed to 
obtain single cell suspensions for flow cytometry analysis (n=2). A) Representative scatter 
plots showing the identification of eGFP+ stromal cells. B) Representative histograms 
showing expression of endothelial cell surface markers on eGFP+ cells (◻) and eGFP- 
cells (◼).  
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Figure 4-17: Flow cytometry gating strategy to identify DC subsets in the spleen. 
Spleens from resting WT mice were processed to obtain single cell suspensions for flow 
cytometry analysis. Representative histograms show the gating strategy used to identify 
DC subsets in the spleen. First, debris, doublets and dead cells were excluded. DCs were 
defined as CD11b+ MHC-II+ CD3ε- NK1.1- B220- cells (anti-CD3ε, anti-NK1.1 and anti-
B220 antibodies were all combined into a single dump channel). DCs were then 
subdivided into CD8α+ and CD11b+ subsets.  
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Figure 4-18: CD8+ and CD11b+ DCs show similar expression levels of CCR7 and 
CXCR4. 
Spleens from resting WT mice were processed to obtain single cell suspensions for flow 
cytometry analysis and fluorescent chemokine uptake assays were carried out using 
tetramers of biotinylated CCL19 and sva-AF488, with sva-AF488 only as a control. 
Populations were defined as detailed in Figure 4-17. (n=3 + 1 sva-AF488 only control). 
Statistical significance was determined using two-way ANOVA (*=P≤0.05, **=P≤0.01, 
***=P≤0.001). A) Representative histograms showing AF488 signal in cells receiving 
CCL19 tetramers (◼) and sva-AF488 only (◻). Left panel: CD11b+ DCs; Right panel: 
CD8+ DCs. B) Representative histograms showing anti-CXCR4 staining (◼) compared to 
FMO control (◻) on DCs. Left panel: CD11b+ DCs; Right panel: CD8+ DCs. C) Graph 
showing the percentage of AF488+ cells in CXCR4+ (◼) and CXCR4- (◼) CD8+ and 
CD11b+ DCs. Error bars represent SD of the mean.
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Figure 4-19: Anti- DCIR2 and CD205 antibodies identify distinct populations of cells 
in the spleen. 
The spleen from a resting WT mice was harvested and processed to obtain cryosections. 
Sections were stained using anti-DCIR2, anti-CD205, anti-CD169 and anti-CD3ε 
antibodies. Images are representative of at least three technical replicates from one 
individual. WP= White pulp, RP= Red pulp, MZ= Marginal zone, BC= Bridging channel, F= 
Follicle, PALS= Periarteriolar lymphoid sheath. Scale bars = 100 µm. A) Anti-CD205 
(green), anti-CD169 (purple) and anti-DCIR2 (orange) staining. CD169+ cells indicate the 
marginal zone. DCIR2+ cells appear to be mostly located in and near to the bridging 
channels, while CD205+ cells are mainly within the white pulp. B) Anti-CD169 (green) and 
anti-DCIR2 (orange) staining. DCIR2+ cells are clearly located in the bridging channels of 
the marginal zone. C) Individual channel images of anti-CD205 (top left), anti-CD169 (top 
right) and anti-CD3 (bottom left) staining. Merged image (bottom right) shows all stains 
plus key anatomical features. Dotted lines indicate the areas that are positive for anti-
CD205 staining.  
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Chapter 5: ACKR4 Involvement in 
Chronic Skin Inflammation 
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5 ACKR4 Involvement in Chronic Skin Inflammation 
5.1 Introduction 
Having determined that ACKR4 expression is modulated in response to inflammatory 
stimuli in cultured human keratinocytes and dermal LECs, I was interested in examining 
the functional implications of this regulation during inflammation. I therefore chose to use 
an in vivo model of inflammation to further examine the function and regulation of 
ACKR4. In addition, Ackr4-/- (KO) mice were available for this study, making studying the 
specific contribution of ACKR4 more feasible. 
The Aldara model was selected to investigate a potential role for ACKR4 in chronic 
cutaneous inflammation. Aldara is a cream currently used in the treatment of superficial 
basal cell carcinoma, actinic keratosis and genital warts. The main active ingredient in 
Aldara cream is imiquimod (IMQ), an immune modulator that activates the innate immune 
system via TLR7/8 signalling. Aldara is often used to generate a mouse model for psoriasis 
due to the heavy involvement of the IL-23/IL-17 axis, and resultant involvement of TH17 
and γδT T cells, which are hallmarks of human psoriasis 211,212.  
In chapter 3, ACKR4 expression and regulation was studied in human keratinocytes and 
dermal LECs. Although neither of these cell types express TLR7, IMQ activates 
plasmacytoid DCs (pDCs) which are known as the main producers of IFN-α and IFN-β 213. 
ACKR4 was shown to be upregulated in response to type I interferons in cultured human 
cells, suggesting Ackr4 may be upregulated in the context of Aldara-mediated skin 
inflammation in mice. Previous studies involving acute TPA-mediated inflammation in 
mice have suggested that ACKR4 plays an important role in Langerhans cell (LC) 
migration from the skin upon activation, as these cells are present in the skin-draining LNs 
in lower numbers in KO- mice 179. I reasoned that an exaggerated phenotype may be 
observed in chronic compared to acute inflammation, as loss of ACKR4 could lead to 
chemokine dysregulation causing accumulation of CCL19 and/or CCL21. I also reasoned 
that correct ACKR4 function may be particularly crucial to the immune response in a 
setting where it is upregulated, rather than downregulated as it is in response to TPA (S. 
Bryce, personal communication). Furthermore, ACKR2 has previously shown to be 
upregulated in lesional and perilesional skin in psoriasis patients 149, so a role for another 
ACKR in chronic skin inflammation would be interesting. 
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5.2 Aims 
• To determine whether mice lacking Ackr4 show a differential response to Aldara-
mediated inflammation. 
• To investigate the potential contribution of CCL19 dysregulation to the 
inflammatory phenotype in Ackr4-/- mice.  
• To study cell migration in the context of Aldara-mediated inflammation in Ackr4-/- 
mice and investigate whether there is a defect in cell migration in these mice 
similar to that reported in the skin during TPA-mediated inflammation. 
5.3 Optimising Aldara Treatments 
5.3.1 Feasibility of Aldara Model in Male Mice 
The Aldara model was piloted by treating male mice with Aldara cream on the shaved 
lower back once daily for five days. Back skin was initially selected for analysis due to 
issues in obtaining sufficient tissue from the ears for flow cytometry analysis in previous 
experiments using TPA. Analysis of skin-draining lymph nodes showed some evidence of 
enlargement (Figure 5-1A), suggesting that an inflammatory response had occurred. 
Spleen enlargement was also observed in treated mice (data not shown) suggesting some 
systemic effects of Aldara treatment were occurring; however, superficial examination of 
the skin revealed only mild redness and no evidence of psoriasis-like lesions (Figure 5-
1B). The lymph node and spleen enlargement observed were potentially due to ingestion of 
the cream, as the expected chronic skin inflammation phenotype previously reported 211 did 
not appear to be present. 
The dose of cream used was 8.33 mg per mouse, which appears to be sufficient from the 
literature 211. The lack of inflammation could be due to the thickness of skin in male mice 
compared to females (A. McColl, personal communication), which may have prevented 
the IMQ from being absorbed sufficiently. Due to the restricted availability of genetically 
modified mice, it was not possible to use females for this study; the model was instead 
used on ear skin which is thinner. Ears are an advantageous treatment site as they are of 
comparable size between mice, making the affected area uniform between individuals. The 
hair on the ears is also extremely fine and does not require removal, so the risk of infection 
or inflammation caused by shaving the mouse and treating with depilatory skin is avoided. 
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5.3.2 Single Aldara Treatments Do Not Modulate Ackr4 mRNA Expression 
The effect of a single Aldara treatment on mRNA expression in the skin was analysed after 
4, 16 or 24 hours. These time points were chosen to mirror previous experiments carried 
out in this lab using TPA in order to determine whether there was a similar role for 
ACKR4 in the early stages of the inflammatory response to IMQ. Genes tested were 
Ackr4, Ccr7, Ccl19 and Ccl21. These transcripts were chosen in order to study the effects 
of Aldara treatment on all members of the ACKR4 pathway. 
Results showed a weakly significant decrease in Ackr4 expression in both epidermis and 
dermis by the 24 hour timepoint (Figure 5-2A), while Ccr7 expression was modestly 
increased in the dermis, but not the epidermis, 16 and 24 hours after treatment suggesting 
either upregulation of this receptor or increased numbers of CCR7+ cells entering the 
dermis (Figure 5-2B). Ccl19 expression was increased in the dermis 24 hours after 
treatment (Figure 5-2C), while Ccl21 expression was unaffected (Figure 5-2D). In the 
epidermis, only Ackr4 was affected at the 24 hour timepoint. As these results only 
extended 24 hours after a single treatment, it was determined that a more pronounced 
phenotype would be likely after multiple Aldara treatments. 
5.4 Potential Role for ACKR4 in Response to Multiple Aldara Treatments 
5.4.1 Multiple Aldara Treatments Modulate mRNA Expression of ACKRs and 
Ligands in the Skin 
After finding a subtle response to a single Aldara treatment, a 5-day treatment model was 
used to investigate expression of Ackr4, Ccr7 and their ligands once a more severe 
inflammatory response was observable. By the 5-day time point, considerable 
inflammation of the skin was apparent, including redness and scaling of the epidermis and 
increased ear thickness (data not shown). I hypothesised that Ackr4 would be upregulated 
in response to Aldara treatment, due to the influx of pDCs producing type I interferon in 
the skin 213: in chapter 3, ACKR4 was shown to be upregulated by type I interferon in HD-
LECS and nHEKs. As expression of ACKR3, CXCR4 and their shared ligand CXCL12 
have also been detected by HD-LECs and/or nHEKs, and CXCR4/Ackr3 regulation has 
been detected by murine keratinocytes in response to acute inflammation, these transcripts 
were also included in the analysis to determine whether the ACKR3 pathway might also 
play a role in chronic inflammation. 
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Surprisingly, the results showed that Ackr4 was in fact down-regulated between 20 and 30-
fold in treated skin compared to control skin, while Ccl19, Ccl21 and Ccr7 expression 
were not affected in either tissue. Ackr3 expression was also reduced in the epidermis 
following Aldara treatment, Cxcr4 expression was unaffected and Cxcl12 expression 
significantly decreased in the epidermis (Figure 5-3).  
The interpretation of these results is not straightforward; as the ear skin was visibly 
inflamed after Aldara treatment, it likely contained a significant number of infiltrating 
leukocytes, so a greater proportion of RNA will originate from leukocytes in inflamed 
skin. Consequently, if stromal cells were to maintain the exact same gene expression 
profile between resting and inflamed skin, this could potentially appear as a 
downregulation of stroma-associated mRNAs due to the increased prevalence of the 
leukocyte expression signature; likewise, a modest mRNA upregulation in stromal cells 
could be neutralised. In particular, Ackr4, Ackr3 and their ligands are not expected to be 
expressed by leukocytes in the skin 151,173 while Cxcr4 is widely expressed on both 
keratinocytes and infiltrating leukocytes, as demonstrated in Chapter 4 , and expected to be 
expressed by dermal LECs from data generated in human cells in Chapter 3. 
Nevertheless, the downregulation of Ackr4 was the most striking result obtained, and it 
appears unlikely that such a large decrease in mRNA expression could be explained by 
infiltrating Ackr4- cells alone. 
5.4.2 Reporter Mice Show Reduced eGFP Expression in Response to Aldara 
To examine Ackr4 expression further, Aldara-treated ear skin from Ackr4+/gfp reporter mice 
was analysed via flow cytometry. This showed a striking reduction in eGFP expression in 
CD45- cells of Aldara-treated mice (Figure 5-4A, B). CD45- cells could not be analysed 
further to identify specific keratinocyte subsets as too few viable cells were retrieved from 
Aldara-treated skin to allow reliable estimation of eGFP expression, or confirmation that 
cells correctly fell into the gates set using untreated mice. This problem persisted both 
when using whole skin and epidermis only for flow cytometry analysis: the epidermis in 
Aldara-treated mice was observed to be extremely fragile and to slough off easily before 
enzymatic digestion. Nevertheless, these results confirm the finding that Ackr4 expression 
in the skin is extensively downregulated at the mRNA level in response to repeated Aldara 
treatments. 
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Although downregulation of Ackr4 was not the expected result, it is clearly strongly 
modulated during Aldara-mediated inflammation. TPA treatment also leads to 
downregulation of Ackr4, yet KO mice have impaired LC migration to the skin-draining 
lymph nodes, so this result does not necessarily exclude a role for ACKR4 during chronic 
skin inflammation. 
5.4.3 Ackr4 Deficiency Has No Detectable Effect on Keratinocyte Proliferation 
As direct investigation of Aldara-treated skin by flow cytometry proved too challenging 
due to low cell viability, sections of ear skin from Aldara-treated WT and KO mice were 
analysed via immunofluorescent microscopy. Keratinocyte proliferation did not appear to 
be altered in KO mice, as antibody staining for ki67, a proliferation marker 214, showed a 
comparable distribution between WT and KO mice, with positive cells located in the basal 
layer of the epidermis and hair follicle bulge (Figure 5-4B). This analysis also showed that 
both WT and KO ear skin contained the same proportion of ki67+ cells after Aldara 
treatment (Figure 5-4C). In resting interfollicular epidermis, keratinocyte nuclei are 
flattened and only 1-2 layers of cells can normally be detected (Figure 5-4B, right panel), 
showing that the architecture of both WT and KO epidermis was significantly altered after 
Aldara treatment.  
5.4.4 Aldara Treatment Leads to Follicle Formation in the Ear-Draining Lymph 
Nodes 
To further investigate the effects of Aldara treatment, particularly with respect to Ackr4 
expression, the ear draining lymph nodes (DLN) were analysed by immunofluorescent 
microscopy in Ackr4+/gfp mice (Figure 5-5). These mice contain one eGFP knock-in allele 
of Ackr4, and one WT allele. One copy of the Ackr4 gene appears to be sufficient to confer 
a WT phenotype. Analysis of the images revealed that after five daily Aldara treatments, 
ear DLN contain more B cell follicles, but these are the same average size as those from 
untreated mice (data not shown). Ackr4 also appears to be downregulated in the Aldara 
treated mice from visual inspection of these images, which would be commensurate with 
the results obtained for the skin; however, this experiment would need to be repeated using 
more animals and quantified to give confidence in this observation. Flow cytometry would 
be a useful tool for this analysis, as it could allow surface marker expression of multiple 
proteins to identify any cells that modify Ackr4 expression and simplify quantification of 
  160 
these results. Unfortunately, technical issues prevented the analysis of lymph nodes from 
Ackr4gfp/gfp homozygous mice, which are analogous to Ackr4-/- mice. 
5.4.4.1 Ackr4 Regulates the Size and Cellularity of Ear-Draining Lymph Nodes 
Draining Aldara-Inflamed Skin 
As Ackr4 deficiency appeared to have no detectable effect on keratinocyte proliferation in 
the skin, I sought to determine whether ACKR4 scavenging of CCL19 and/or CCL21 may 
play a role in the migration of DCs, particularly LCs, from the skin to the draining lymph 
nodes (DLN) during Aldara-mediated inflammation. As CCR7 ligands are also important 
for T cell and pDC migration to SLOs and the positioning of T cells, resident DCs and B 
cells within the nodes. 
To investigate this, WT and KO mice were treated topically with Aldara on both ears daily 
for five days, and ear draining lymph nodes (DLN) were harvested and analysed using 
flow cytometry to identify the main lymphocyte populations: B cells, T cells, pDCs, 
migratory (MCH-IIhi) DCs, resident (MHC-IIint) DCs and pDCs (Figure 5-6A-C).  
Results showed that the overall cellularity of ear DLN was increased in KO mice 
compared to WT, and that the numbers of B cells, T cells and rDCs were significantly 
higher in these mice (Figure 5-7A). Migratory DCs were subdivided based on CD207 and 
CD103 expression, which showed all four subsets of migratory DCs at the same 
proportions in WT and KO mice; The CD103+ and CD103- subsets also represented the 
same proportions of resident DCs in WT and KO mice (Figure 5-7B). 
As there is no difference in lymphocyte numbers or cellularity between resting WT and 
KO DLN (S. Bryce, personal communication), these data suggested that cells in the lymph 
node of Aldara-treated KO mice are either overproliferating, are showing an increased 
level of recruitment to the lymph node or are being retained in lymph nodes. Dysregulation 
of CCL19 and/or CCL21 due to the absence of ACKR4 could potentially play a role in 
aberrant cell migration; CCR7 is expressed by T cells, DCs and B cells. CCL19 and 
CCL21 can also direct the migration of B cells to the boundary of the T cell zone. The 
finding that migratory DCs are unaffected neither supports nor refutes the hypothesis that 
DC migration is impaired after Aldara treatment in KO mice: it is possible that the arrival 
of migratory DCs to the DLN from the skin is delayed in these mice, and that this defect is 
no longer detectable by five days after the first treatment. If an earlier timepoint was 
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studied, there may be a difference; however, as the aim was to study chronic inflammation, 
the initial wave of DC migration to the DLN is less relevant. 
5.4.4.2 Aldara Raises CCL19 Concentration in Plasma and Skin of Ackr4-/- Mice 
In order to determine whether chemokine dysregulation was a feature of Aldara-treated 
KO mice, CCL19 levels in these animals were assayed. Plasma was used to estimate 
systemic CCL19 levels, while punch biopsies from treated ears were incubated in PBS to 
allow CCL19 to leach out. This method ensures that only bioavailable, post-
transcriptionally modified CCL19 is measured, rather than including partially processed 
CCL19 present inside cells, which would be included in the analysis if whole protein lysate 
was used. 
Resting mice were not tested in these experiments. Previous work has shown that resting 
WT and KO mice have serum CCL19 levels below the detection limit of standard ELISAs 
178. A small subset of KO individuals has CCL19 levels just over the detection limit; this 
does not confer statistical significance but suggests that resting CCL19 levels may be 
elevated but still very low in KO mice (D. Asquith, personal communication). 
After five daily Aldara treatments, plasma CCL19 levels in WT mice were below the 
detection level of the ELISA kit, but KO mice had a plasma CCL19 concentration of ~70 
pg/ml (Figure 5-9). Plasma CCL19 was still raised 3 days post-treatment in KO mice, but 
had fallen from its level immediately following the final treatment. Analysis of 
bioavailable CCL19 also showed raised levels in KO mice compared to WT, and that two 
out of three WT individuals analysed had bioavailable CCL19 levels just above the 
detection limit of the assay suggesting some CCL19 is present in the ears of WT mice after 
Aldara treatment. 
5.4.4.3 Increased Leukocyte Numbers Largely Restricted to Ear-Draining Lymph 
Nodes 
The Aldara phenotype was further investigated by comparing the cellularity of ILN, 
mesenteric lymph node (MLN), spleen and blood between Aldara-treated WT and KO 
mice. In ILN, there were no significant differences in overall cellularity, and the only 
difference in any of the individual cell types was a decrease in the number of migratory 
DCs recovered from KO ILN (Figure 5-9). In MLN, there were no significant differences 
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in cellularity observed (Figure 5-10). In the spleens of KO mice, there were significantly 
more cells overall, with the B cells the only leukocyte population analysed that was 
increased in numbers (Figure 5-11). Analysis of the blood showed that there were 
significantly more circulating B cells in KO mice compared to WT (Figure 5-12). 
Together, these results suggest that the differential phenotype seen in KO mice after 
Aldara treatment is largely restricted to the site-draining lymph nodes, although the 
increased numbers of circulating and splenic B cells suggests some systemic dysregulation 
is occurring during Aldara-mediated inflammation in KO mice. These results may indicate 
increased proliferation, but do not appear to suggest deficient migration of leukocytes to 
SLOs. The finding of fewer migratory DCs in ILN, however, could suggest this. 
5.4.4.4 Adoptive Cell Transfer in Aldara-Treated Mice 
After showing that lymphocyte numbers in the DLN and B cell numbers in the blood 
increase in KO mice more markedly than WT after Aldara treatment, I hoped to establish 
whether this was due to retention or proliferation of cells in the lymph node, or increased 
recruitment of cells to the lymph node. Adoptive cell transfer of splenocytes from resting 
WT mice was used 16 hours before culling mice treated with Aldara to help determine this; 
an increase in the number of donor cells retrieved from the tissues of KO recipient mice 
compared to WT would suggest increased recruitment, while any defect in donor leukocyte 
homing would suggest retention of cells that are unable to correctly migrate out of lymph 
nodes.  
There was some difficulty in optimising the adoptive cell transfer protocol; initially, cells 
were stained with the fluorescent marker CMTPX before transfer, but no cells were 
retrieved from recipient mice (Figure 5-13). After experimenting with different fluorescent 
labels, using Ly5.1 donor mice and anti-CD45.1 antibody appeared to be the most effective 
method for retrieving adoptively-transferred cells. This variant of the CD45 molecule 
distinguishes donor mice from WT recipient mice. Although B cells were initially used for 
these experiments due to the accumulation of B cells in the blood of KO animals, whole 
splenocytes appeared to be more reliable to ensure a high yield of viable cells. This also 
made it possible to analyse the homing capabilities of specific splenocyte subsets; for 
example, the dysregulation of CCR7 ligands may disproportionately affect DCs and T cells 
as they rely more heavily on this receptor to migrate to SLOs, while B cells can use 
CXCR4 and CXCR5 215, and pDCs can use CXCR3, CXCR4 and CCR5 216. 
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Results showed that CD45.1+ cells could be clearly identified in spleen, blood, ILN, MLN 
and ear DLN (Figure 5-14). The spleen contained the largest number of adoptively-
transferred cells. Although MLN appeared to contain more adoptively-transferred cells 
than ILN or ear DLN in terms of absolute numbers, these were pooled samples and there 
are more MLN than ILN or ear DLN. There were no apparent differences in the numbers 
of CD45.1+ cells retrieved from any tissue between WT and KO mice, although there were 
significantly fewer CD45.1+ cells in the blood of KO mice than WT. There were also no 
differences between the numbers of each subset of CD45.1+ cells retrieved from WT and 
KO mice (data not shown). The numbers of donor cells retrieved was low; 2x106 cells 
were transferred to each mouse, and only about a quarter of these were detected in each 
mouse. Although some SLOs were not analysed, given the numbers retrieved from ILN, 
MLN ear DLN and blood it is unlikely that the remaining 1.5 million cells were spread 
between these sites. This suggests a high level of cell death may have occurred. 
Overall, these results did not suggest any defect in migration of cells to SLOs, indicating 
that the differential phenotype seen in KO mice may be due to increased retention and/or 
proliferation of lymphocytes. 
5.4.5 Differential Phenotype in Ackr4-/- Mice is Resolved in Ackr4-/-, Ccl19-/- 
Mice  
To determine whether the increased lymph node cellularity observed following Aldara 
treatment in KO mice was due to CCL19 dysregulation, Ackr4-/-, Ccl19-/- (DKO) mice 
were used. I reasoned that if DKO mice showed a similar phenotype to WT mice after 
Aldara treatment, this would suggest that CCL19 dysregulation contributes to the increased 
number of lymphocytes retrieved from ear DLN. Conversely, if DKO mice showed 
increased lymphocyte numbers compared to WT, this would suggest that CCL19 
dysregulation did not play a role. 
Analysis showed no detectable difference in numbers of any leukocyte subset analysed. 
Along with data showing raised CCL19 levels in the plasma and treated ear skin, this 
suggests that the increased leukocyte numbers in the lymph nodes of KO mice compared to 
WT was due to CCL19 dysregulation in Ackr4-deficient mice. Although there was no 
gross defect in DC homing to the ear DLN at the time point studied, it is possible that this 
occurs earlier in the model, or that DC migration to the node is unaffected but egress is 
impaired. 
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5.5 Key Findings 
• Ackr4, Ccr7 and Ccl19 expression are modulated in the skin, particularly the 
dermis, after a single Aldara treatment; however, after repeated Aldara treatments, 
only Ackr4 is still modulated with a clear downregulation of transcript in both 
epidermis and dermis, while Ackr3 and Cxcl12 are also downregulated in the 
epidermis. The result for Ackr4 was confirmed using eGFP expression on 
Ackr4+/gfp mice. 
• Aldara treatment does not affect keratinocyte proliferation in KO mice compared to 
WT by ki67 staining, but epidermis appears to be increased in cellularity in both 
WT and KO mice compared to WT untreated, as expected for a psoriasis-like 
phenotype. 
• Ear-DLN from KO mice are significantly enlarged compared to WT after five daily 
Aldara treatments. B cells, T cells and resident DCs were more numerous in KO 
nodes compared to WT, but migratory DCs and pDCs were unaffected. The 
proportions of migratory and resident DCs falling into each of the subsets 
examined were also unaffected in KO mice compared to WT. 
• After five daily Aldara treatments, overall cellularity was unchanged in ILN and 
MLN of KO mice compared to WT, although there were fewer migratory DCs in 
the ILN of KO mice. Spleens were significantly enlarged in KO mice, and 
contained more B cells; there were also more B cells circulating in the blood of KO 
mice. 
• CCL19 levels were significantly raised in plasma and ear skin of KO mice 
compared to WT, and plasma CCL19 levels remained raised three days after the 
final Aldara treatment. 
• Adoptive transfer of WT splenocytes showed that there were no gross defects in 
leukocyte homing, as there were no differences in the number of donor cells 
isolated from any of the SLOs examined. There were significantly fewer donor 
cells isolated from the blood. 
• The WT phenotype was restored in Ackr4-/- Ccl19-/- mice, suggesting that CCL19 
dysregulation plays a role in the increased ear DLN size of Ackr4-deficient mice 
after repeated Aldara treatments.  
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Figure 5-1: Pilot of Aldara model on mouse back skin shows a limited inflammatory 
phenotype. 
Mice were treated with Aldara or Vaseline once per day for five days on the shaved lower 
back skin. Mice were culled, skin was photographed and inguinal and axillary lymph 
nodes harvested and weighed. (n=3 Aldara-treated plus one Vaseline-treated) A) graph 
showing weights of inguinal and axillary lymph nodes. Error bars represent SD of the 
mean. B) images of treated area of skin showing lack of visible inflammatory phenotype. 
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Figure 5-2: Expression of Ackr4 and related genes is largely stable up to 24 hours 
after a single Aldara treatment. 
Mice were treated once with Aldara on both ears and culled after 4, 16 or 24 hours; 
control mice received Vaseline and were culled after 24 hours. Ears were excised, 
epidermis (◼) and dermis (◼) were separated and RNA prepared (n=3). Results were 
normalised to TBP expression using the 2-ΔCT method. Statistical significance was 
determined using two-way ANOVA with Dunnett’s correction to compare each timepoint to 
the control (0h) value (*P≤0.05, **P≤0.01). Error bars represent SD of the mean.  
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Figure 5-3: Expression of Ackr4, Ackr3 and related genes show variable responses 
to multiple Aldara treatments. 
Mice were treated once per day for five days with Aldara (◼) or Vaseline (◼) on both ears, 
ears were excised, epidermis and dermis were separated, and RNA prepared for qPCR 
analysis (n=3). mRNA expression of A) Ackr4, B) Ccr7, C) Ccl9, D) Ccl21, E) Ackr3, F) 
Cxcr4 and G) Cxcl12 were measured in each tissue and relative expression was 
represented using arbitrary units (AU) calculated using the 2-ΔCT method. Statistical 
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significance was determined using t-tests with Holm-Sidak correction (*P≤0.05, **P≤0.01, 
***P≤0.001, ****P≤0.0001). Error bars represent SD of the mean.  
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Figure 5-4: Keratinocytes in the ear skin of Aldara-treated mice show no alteration 
in proliferation in the absence of Ackr4. 
Mice were treated once per day for five days with Aldara or Vaseline on both ears as 
previously described, ears were excised and processed for further analysis. A-B) Ears 
from Aldara or Vaseline-treatedAckr4+/gfp mice were used to obtain whole-skin single cell 
suspensions for flow cytometry analysis.  (n=4). Representative histogram in A shows 
eGFP expression in untreated, treated and WT keratinocytes. Graph in B shows overall 
percentage of eGFP+ cells among CD45- cells in Vaseline and Aldara groups. Error bars 
represent SD of the mean. C-D) Ears from Aldara-treated WT and KO mice were 
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processed to obtain cryosections and stained with anti-ki67 antibody along with DAPI 
counterstain. Images in C show representative ki67 and DAPI staining with markers to 
delineate the epidermis from dermis. E = epidermis. An image of DAPI stain in resting ear 
skin is shown for comparison. (scale bar = 50 µm). Graph in D shows the percentage of 
ki67+ cells detected in the epidermis of WT and KO mice. 10 random objectives were 
taken per mouse, and ImageJ software was used to count nuclei and ki67+ nuclei. An 
unpaired t-test was used to determine statistical significance (n=3). Error bars represent 
SD of the mean.  
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Figure 5-5: Number, but not size, of B cell follicles is increased in the ear DLN 
following Aldara treatment. 
Ackr4+/gfp heterozygous mice were treated once per day for five days with Aldara on both 
ears. One hour after the final treatment, ears were excised, snap frozen in OCT on dry ice 
and processed to obtain cryosections. Lymph node sections were stained with anti-B220 
antibodies, and ImageJ software was used to stitch individual objectives into images of 
the whole node.. Images representative of both lymph nodes from two mice in each 
treatment group, and one WT control mouse used as a control for autofluorescence. 
(scale bar = 500 µm).  
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Figure 5-6: Flow cytometry gating strategy to identify lymphocyte subsets in the 
skin-draining lymph nodes. 
DLN from Aldara-treated mice were excised and processed to obtain single cell 
suspensions for flow cytometry as described (materials and methods). A) Representative 
scatter plots showing the gating strategy used to identify cell subsets within the DLN. First, 
debris, doublets and dead cells were excluded, and cells were gated to show CD45+ cells 
only. Within this group, CD11c+ MHC-IIhi and MCH-IIint cells were taken as migratory and 
resident DCs respectively and were further subdivided based on CD103 and Langerin 
expression; B220+ cells were separated into SiglecH- B cells and SiglecH+ pDCs; and 
TCRβ+ cells were defined as T cells. B) Representative histogram showing EpCAM 
expression in CD103- Langerin+ cells (◼) compared to FMO (◻). C) Table summarising 
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the surface marker expression of cell populations outlined in A; the numbers on the plots 
in A correspond with the numbers in the ‘Population’ column.   
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Figure 5-7: Overall cellularity and number of B, T and resident dendritic cells are 
increased in ear DLN of Ackr4-null mice, compared to WT, in response to Aldara 
treatment. 
Wild-type (WT, ◼) and Ackr4-/- (KO, ◼) mice were treated once per day for five days with 
Aldara on both ears as previously described. Ear draining lymph nodes were excised and 
processed to obtain single cell suspensions for flow cytometry. Measurements were 
pooled between multiple experiments; within each experiment n=3-5. Statistical 
significance was determined using unpaired t-tests (*P≤0.05, **P≤0.01, ***P≤0.001). Error 
bars represent SD of the mean. A) Total cellularity, and number of cells in each leukocyte 
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subset analysed between WT (◼) and KO (◼) mice. B) Percentage of cells in each mDC 
(left panel) and rDC (right panel) subset identified in Figure 5-6. (Lang = Langerin; LCs = 
Langerhans Cells).  
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Figure 5-8: Bioavailable CCL19 levels are increased in plasma and ear skin of 
Ackr4-null mice, compared to WT, after Aldara treatment. 
WT (◼) and KO (◼) mice were treated once per day for five days with Aldara on both 
ears. In one group (Aldara +3), mice were culled 3 days after the final treatment; in the 
other group (Aldara), mice were culled 1 hour after the final treatment. Ears and blood 
were harvested for analysis: plasma and total soluble protein from punch biopsies were 
used for ELISAs to determine CCL19 levels. (n=3-5). Statistical significance was 
determined using unpaired t-tests (*P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0.0001). Dotted 
lines on charts indicate the assay manufacturer’s stated detection limit. Error bars 
represent SD of the mean. A) Plasma CCL19 levels in mice culled 1 hour after the final 
treatment (Aldara) and three days post-treatment (Aldara +3) in both WT and KO 
backgrounds. B) Bioavailable CCL19 levels in the ears of Aldara-treated WT and KO 
mice.  
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Figure 5-9: Migratory DCs are reduced in the ILN of Ackr4-null mice, compared to 
WT, after Aldara treatment. 
WT (◼) and KO (◼) mice were treated once per day for five days with Aldara on both ears 
as previously described. Inguinal lymph nodes were excised and processed to obtain 
single cell suspensions for flow cytometry. Both lymph nodes were pooled within each 
animal and cell counts were used to obtain the absolute numbers of each cell population 
outlined in Figure 5-6. (n=4). Statistical significance was determined using unpaired t-tests 
(*P≤0.05). Error bars represent SD of the mean.  
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Figure 5-10: Mesenteric lymph node cellularity is not differentially affected in Ackr4-
null mice, compared to WT, after Aldara treatment. 
WT (◼) and KO (◼) mice were treated once per day for five days with Aldara on both ears 
as previously described. Mesenteric lymph nodes were excised and processed to obtain 
single cell suspensions for flow cytometry. All lymph nodes were pooled within each 
animal and cell counts were used to obtain the absolute numbers of each cell population 
outlined in Figure 5-6. (n=4). Statistical significance was determined using unpaired t-
tests. Error bars represent SD of the mean.  
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Figure 5-11: Overall cellularity and B cell numbers are increased in Ackr4-null mice, 
compared to WT, after Aldara treatment. 
WT (◼) and KO (◼) mice were treated once per day for five days with Aldara on both ears 
as previously described. Spleens were excised and processed to obtain single cell 
suspensions for flow cytometry. Cell counts were used to obtain the absolute numbers of 
each cell population outlined in Figure 5-6. (n=4). Statistical significance was determined 
using unpaired t-tests (*P≤0.05). Error bars represent SD of the mean.  
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Figure 5-12: Blood of Ackr4-null mice contains more circulating B cells than in WT 
mice following Aldara treatment. 
WT (◼) and KO (◼) mice were treated once per day for five days with Aldara on both ears 
as previously described. Blood was taken from the posterior vena cava and processed to 
obtain single cell suspensions for flow cytometry. Fluorescent counting beads, along with 
the original sample volume obtained from each mouse were used to calculate cell 
numbers of each cell population outlined in Figure 5-6, normalised to volume of blood 
(n=6). Statistical significance was determined using unpaired t-tests (*P≤0.05, **P≤0.01). 
Error bars represent SD of the mean.  
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Figure 5-13: Optimisation of Adoptive B Cell Transfer Protocol. 
Spleens were harvested from WT or Ly5.1+ mice and single cell suspensions were 
obtained before enriching for B cells and optionally labelling with CMTPX or CellTrace 
Violet. 2x106 cells were injected into the tail vein of each recipient mouse and tissues 
were harvested 16 hours later for flow cytometry analysis. A) Representative scatter plots 
show CMTPX-labelled B cells from WT donor mice retrieved from the ear DLN of WT or 
KO Aldara-treated mice. (n=3). B) Representative scatter plots show Ly5.1+ splenocytes, 
either labelled with CellTrace Violet or unlabelled, and mixed with unlabelled WT 
splenocytes (no adoptive transfer). Left panel: unlabelled splenocytes were detected 
using CD45.1 antibody; right panel: CellTrace-labelled splenocytes were detected using 
the V450 channel. C) Scatter plots show Ly5.1+ splenic B cells retrieved from spleen, ear 
DLN and blood of a WT recipient mouse (n=1).   
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Figure 5-14: After adoptive transfer of CD45.1+ splenocytes, Ackr4-null mice have 
reduced numbers of donor cells in the blood, compared to WT, following Aldara 
treatment. 
WT (◼) and KO (◼) mice were treated once per day for five days with Aldara on both 
ears. 16 hours before culling, mice were injected with 2x106 splenocytes freshly isolated 
from Ly5.1 mice into the tail vein. ILN, MLN, ear DLN and spleen were excised and 
processed to obtain single cell suspensions for flow cytometry, as were cells isolated from 
blood. All lymph nodes were pooled within each animal and analysed to obtain the 
absolute numbers of each cell population outlined in Figure 5-6. (n=4). Statistical 
significance was determined using unpaired t-tests. (*P≤0.05, **P≤0.01, ***P≤0.001). Error 
bars represent SD of the mean. A) Representative scatter plots show CD45.1+ subsets 
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identified among CD45+ cells in the spleen, blood and MLN. B) Absolute numbers of 
CD45.1+ cells retrieved from ILN, MLN, ear DLN, spleen and blood of WT and KO mice.  
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Figure 5-15: Mice lacking both Ackr4 and Ccl19 transcripts show no difference in 
ear DLN cellularity, compared to WT, in response to Aldara treatment. 
WT (◼) and Ackr4-/-, Ccl19-/- (DKO, ◼) mice were treated once per day for five days with 
Aldara on both ears. Ear-draining lymph nodes were excised, weighed and processed to 
obtain single cell suspensions for flow cytometry. All lymph nodes were pooled within 
each animal and analysed to obtain the absolute numbers of each cell population outlined 
in Figure 5-6. (n=10 across three experiments). Statistical significance was determined 
using one-tailed unpaired t-tests. Error bars represent SD of the mean.
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Chapter 6: Discussion  
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6 Discussion 
6.1 Function of ACKR3 and ACKR4 on Cultured Human Cells 
mRNA and protein expression of ACKRs and their ligands were analysed in cultured 
human dermal LECs and keratinocytes. The broad findings were that HD-LECs express 
ACKR4, CCL19, CCL21, ACKR3 and CXCL12 by qPCR, and ACKR4, CCL21, ACKR3 
and CXCR4 expression were also detected by antibody staining. nHEKs express ACKR4, 
ACKR3 and CXCR4 by qPCR, and ACKR4 expression was also validated by 
immunofluorescence on these cells.  
CXCR4 mRNA expression by LECs appeared highly variable and was not present in all 
samples, making analysis impossible. It is possible that CXCR4 is expressed at extremely 
low levels on resting LECs, which would account for the high variability between samples, 
and perhaps lead to the transcript being undetectable if cells downregulate CXCR4. This 
could also potentially have been due to RNA degradation during sample handling, 
although other transcripts were detected successfully in cDNA samples from the same 
reverse transcription reaction, so this is unlikely, and all -RT controls (no reverse 
transcriptase enzyme in the reverse transcription reaction) failed to amplify suggesting any 
CXCR4 detected was unlikely to be due to DNA contamination. 
One of the striking results from the mRNA expression profiling is that both type I and type 
II interferons appear to be potent inducers of ACKR4 expression, both in keratinocytes and 
LECs. IFN-γ showed the strongest effect in both cell types. Unmethylated CpG DNA also 
induces ACKR4 expression in LECs but not keratinocytes, while LPS appears to induce 
ACKR3 expression strongly in keratinocytes and weakly in LECs, albeit at too low a level 
to accept confidently without the ability to perform statistical analysis.  
Taken together, these results suggest that ACKR4 can be induced in HD-LECs in response 
to viral and microbial pathogens, either directly via unmethylated CpG DNA binding to 
TLR9 or LPS binding to TLR4, and indirectly via type I/II interferons. IFN-α and β are 
both secreted at high levels by pDCs 213, and are normally involved in anti-viral responses, 
while IFN-γ is mainly produced by activated NK and T cells 217, and is involved in both 
anti-viral and anti-microbial responses 217. Most cell types are capable of producing type I 
interferons in response to TLR4/9 signalling 218, so ACKR4 could potentially be induced 
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directly by TLR ligand binding, by resulting type I interferon produced by LECs, or by 
both.  
In keratinocytes, ACKR3 and CXCR4 appear to be differentially regulated in response to 
Keratinocyte Growth Factor (KGF), with ACKR3 showing a trend towards upregulation, 
while CXCR4 appears to be downregulated. Although gene expression data originally 
suggested ACKR4 was upregulated by KGF (R. Nibbs, personal communication), it had no 
effect on ACKR4 expression on cultured human keratinocytes. The result for KGF 
modulation of ACKR3/CXCR4 expression is interesting as KGF is a growth factor 
expressed in the skin that promotes keratinocyte proliferation and differentiation. Given 
that ACKR3 is associated with cell survival and proliferation 155,157,162, it is interesting that 
ACKR3 is potentially upregulated in response to this protein. 
The regulation of chemokines secreted by LECs was interesting; as these cells express both 
CCL21 and CXCL12, yet also express scavenging receptors for these chemokines. In some 
cases, mRNA for both atypical receptor and chemokine are elevated, for example ACKR4 
and CCL21 in response to IFN-α, IFN-β and IFN-γ; and ACKR3 and CXCL12 in response 
to IFN-α. This seems counter-intuitive, as increased chemokine production and increased 
scavenging receptor expression would appear to be redundant. One consideration is that 
LECs may be involved in the transport of chemokines via ACKR4; in this scenario, CCL21 
upregulation and increased ACKR4 expression could suggest increased presentation of 
CCL21 on the tissue-facing surfaces of LECs.  
6.1.1 Cell Culture Issues 
Unfortunately, many of the analyses performed on HD-LECs could not be repeated on 
nHEKs, and several planned experimental enquiries could not be carried out due to 
continual issues with cell culture contamination and poor proliferative capacity of these 
cells. Four batches of cells became contaminated. With each batch, all cell culture reagents 
(media, trypsin and HEPES) were incubated at 37º C to attempt to detect infections. In the 
first instance, there was a low-level bacterial contamination in the culture medium that 
went undetected at 4º C. For future batches of cells, all media were filter-sterilised before 
use to prevent future problems. When a second batch became infected, and the media used 
appeared free of infection after incubation at 37º C for a week, the water bath was 
suspected, and care was taken to thoroughly disinfect vials of cells before thawing. In the 
next batch, the pipette gun used for cell culture was replaced with a communal piece of 
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equipment as no other lab members appeared to be having infection issues. These steps did 
not solve the problem of cell culture contamination. Although operator error is, of course, a 
possibility, every care was taken to practice aseptic technique, and cell culture was carried 
out successfully for several years using these cell lines before any issues arose. Infection 
introduced by the supplier could not be ruled out. 
One batch of cells also had to be discarded due to poor proliferative capacity, as cells 
would not adhere to the culture vessel upon thawing. This was most likely due to the cells 
becoming over-confluent before storing in liquid nitrogen. Due to the significant expense 
incurred in purchasing human primary cells, these investigations had to be cut short. 
Future analyses would have included ACKR3 surface staining on keratinocytes, 
particularly in tandem with CXCR4 if possible, and investigation of lysosomal/endosomal 
localisation of these proteins. A scratch assay could also be performed, where a monolayer 
of serum-starved cells is wounded with a pipette tip, and the clear area is monitored via 
microscopy to compare the healing of the monolayer. As the cells are incubated without 
serum during the assay, this should represent cell migration rather than proliferation. This 
could be carried out in the presence or absence of CCX771, AMD3100 and/or CXCL12 to 
determine the contribution of ACKR3 and CXCR4 signalling to keratinocyte migration. 
6.1.2 Lack of Chemokine Scavenging Activity in vitro 
Despite clear mRNA expression and modulation of ACKR3 and ACKR4 by keratinocytes 
and LECs, and confirmation of ACKR4 protein expression by both cell types, no 
detectable chemokine scavenging occurred in either LECs or keratinocytes. This was 
studied more extensively in LECs, but none of the experimental conditions tested were 
successful. This is surprising, as cultured HD-LECs have been shown to scavenge CCL2 in 
vitro 190 and murine dermal LECs to scavenge CCL19 in vivo 179. This suggests that the 
explanation is neither a lack of scavenging activity on LECs, nor an unsuitability of the 
assay for this cell type. Furthermore, ACKR4 activity was measured by several 
mechanisms: uptake of fluorescently-labelled chemokines detected by flow cytometry or 
fluorescence microscopy, and chemokine depletion from the media. 
All of these assays had flaws: in the scavenging assay, the chemokines were removed from 
the media as quickly in wells containing no cells as in those that did contain cells, 
suggesting either chemokine sequestration on the culture surface or degradation by 
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proteases. This does not necessarily suggest chemokine scavenging does not occur but 
makes it impossible to detect. Uptake of fluorescently-labelled chemokines has been used 
very successfully in the past, but may be less suitable for cultured cells: although HD-
LECs have been successfully used to demonstrate chemokine scavenging via ACKR2, 
there was very little fluorescent signal in untreated cells, and the only convincing 
fluorescent chemokine uptake was seen in virally-stimulated cells 190; however, 
experiments were attempted with IFN-γ-treated cells, which appear to upregulate ACKR4 
by around 100-fold, with no success. 
Positive controls did not always show any uptake signal, which suggests an experimental 
error was at least partly to blame, but it is uncertain what this could be. In the microscopy 
experiment, fluorescent CCL19 appeared to associate more readily with the culture surface 
than with cells, while the streptavidin-fluorophore conjugate used as a control appeared to 
be highly associated with cells. This, perhaps, suggests that chemokines do rapidly adhere 
to culture surfaces and that this was a limitation of any assays using chemokines on tissue-
culture treated plates.  
HD-LECs were used within the 9 passages suggested by the supplier, but evidence has 
shown that LECs cultured ex vivo begin to alter their gene expression profile after 6 
passages in culture 219; this could be a potential explanation for the lack of scavenging 
activity detected in these cells. Interestingly, CCL21 expression in LECs also increases 
after 6 passages in vitro 219, suggesting this could have played a role in CCL21 expression 
by these cells. 
Another explanation for the lack of ACKR4 scavenging activity detected is the possibility 
that ACKR4 on LECs does not mainly act as a chemokine scavenging receptor, but instead 
is involved in transporting chemokines across endothelial surfaces. This is a logical role 
for ACKR4 on LECs: in order to present CCL21 to CCR7+ DCs and/or T cells migrating 
into and out of the vessel, CCL21 needs to be bound to the correct surface of the 
endothelial wall. To support this idea, there is some evidence that ACKR4 is associated 
with caveolae 143, which are vesicles involved in transcytosis. 
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6.2 ACKR3/CXCR4 Expression in vivo 
6.2.1 Modulation in the Infundibulum Subset 
One striking result from the analysis of ACKR3 and CXCR4 in resting and inflamed skin 
was the expression and modulation of CXCR4, and of eGFP in Ackr3+/gfp reporter mice, 
within the IF subset of keratinocytes. At rest, IF appeared to be the keratinocyte subset 
with the highest levels of eGFP and second-highest levels of CXCR4 expression, as well as 
the highest levels of eGFP/CXCR4 coexpression. In inflamed skin, cells in the IF 
compartment downregulated eGFP expression and upregulated CXCR4 expression, 
although coexpression data was not available for these cells. Results from cultured human 
keratinocytes showed similar regulation of these genes in response to TPA, with ACKR3 
downregulated and CXCR4 upregulated in response to a single treatment. Although 
cultured basal keratinocytes in low calcium conditions may not be representative of the IF 
subset, this does suggest reciprocal regulation of the two proteins occurs in response to 
TPA in both human and mouse cells.  
As discussed in the introduction (See section 1.7.1), ACKR3/CXCR4 heterodimers appear 
to generate differential responses to CXCL12 compared to CXCR4 alone, particularly 
showing a bias towards β-arrestin signalling as opposed to G-protein signalling 157. 
Although there is not sufficient data to form any conclusions, the concurrent 
downregulation of Ackr3 and upregulation of CXCR4 in the IF could suggest a cellular 
‘switch’ from CXCL12 inducing β-arrestin-mediated signalling through ACKR3/CXCR4 
heterodimers, towards G-protein-mediated signalling through CXCR4 homodimers. This 
could potentially represent a functional bias away from cell proliferation and survival and 
towards cell migration; however, ACKR3 appears to be capable of inducing cell migration 
itself through Gi-independent mechanisms 163, so this model (Summarised in Figure 6-1) 
would likely be an oversimplification. A ‘switch’ away from ACKR3 signalling and 
towards CXCR4 signalling could alternatively, or concurrently, represent a reduction in 
CXCL12 scavenging and an increase in CXCL12 responsiveness. As ACKR3 has a higher 
affinity for CXCL12 than CXCR4 154, cells expressing ACKR3 are likely to be biased 
towards ACKR3-mediated responses to CXCL12 rather than CXCR4-mediated responses. 
Lower levels of ACKR3 on IF cells could therefore lead to accumulation of CXCL12 near 
the hair follicle opening. 
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Figure 6-1: Proposed model for ACKR3/CXCR4-mediated TPA responses in 
keratinocytes. 
TPA treatment to the skin leads to increased CXCR4 expression and decreased Ackr3 
expression in keratinocytes, particularly those of the infundibulum. The proposed model 
shows PKC inhibition of KGF-mediated responses. Keratinocytes respond to KGF by 
upregulating Ackr3 and downregulating CXCR4; upon TPA treatment, FGFR2 signalling is 
interrupted by PKC inactivation and Ackr3 is instead downregulated while CXCR4 is 
upregulated. Lack of CXCL12 scavenging by ACKR3 may lead to an increased 
concentration of CXCL12, which could aid in recruiting CXCR4+ cells including 
monocytes, macrophages, T cells and Langerhans cells. 
The IF subset is of interest as it lies near the opening to the sebaceous glands as well as 
forming the opening to the hair follicle; this means IF cells come into contact with unique 
microflora and form a crucial part of the body’s barrier against microorganisms 220. IF cells 
have been shown to be a site of chemokine secretion in response to inflammation, 
including CCL2, CCL20, CXCL4, CXCL9, CXCL10 and CXCL11 79. Hair follicles have 
also been shown to be important structures for LC precursor migration into the skin, as this 
is impaired in hairless mice 79, perhaps particularly the infundibulum, as it expresses 
CCL20 which is one of the chemokines required for this process 79,221. Although CXCL12 
is not required for the migration of LCs or their precursors to the skin 79, CXCL12 is 
involved in LC migration from the epidermis to the dermis 97,222. The CXCL12 required for 
egress from the skin is produced by fibroblasts in the dermis, and it is feasible that 
CXCL12 scavenging by keratinocytes maintains functional gradients of this chemokine, 
allowing directional migration of cells towards the dermis and CXCL12+ LECs 97. 
Therefore, chemokine scavenging, as well as production, could be another facet to the role 
hair follicle cells play in modulating cell migration to and from the epidermis. 
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Infundibulum cells have also been shown to contain the highest proportion of eGFP+ cells 
of all the keratinocyte subsets in resting Ackr4+/gfp reporter mice (R. Wilson, personal 
communication). This could suggest that these cells are particularly involved in chemokine 
scavenging activity at rest; cells of the interfollicular epidermis also expressed high levels 
of eGFP in both Ackr3+/gfp and Ackr4+/gfp reporter mice at rest, but did not appear to 
extensively modulate eGFP expression in response to TPA treatment; while Ackr4 
expression is reduced in the skin as a whole after TPA treatment (S. Bryce, personal 
communication), these data are not available for specific keratinocyte subsets. Intriguingly, 
inverse regulation of ACKR3 and CXCR4 also appears to occur in cultured human 
keratinocytes, where ACKR3 mRNA is upregulated in response to KGF and LPS and 
unaffected by IFN-α or IFN-β, while CXCR4 mRNA is upregulated by IFN-α and IFN-β 
but unaffected by KGF or LPS. Although the signalling pathways involved in these 
molecules often overlap (e.g. LPS binding to TLR4 can lead to production of type I 
interferon), this result was striking and once again suggested that keratinocytes could 
potentially switch between states of preferential ACKR3 or CXCR4 responses. 
As outlined in Figure 6.1, this could feasibly occur directly through Protein Kinase C 
activation, which prevents keratinocyte migration, including via KGF/FGFR2 signalling 
223. Given the inverse response to KGF shown by cultured human keratinocytes, PKC-
mediated inhibition of KGF responses could feasibly lead to the observed ‘switch’ in 
phenotype from ACKR3 to CXCR4-mediated signalling. Interestingly, this includes a lack 
of cell migration 223, which is surprising for a pathway that appears to lead to enhanced 
CXCR4 expression. ACKR3-mediated cell migration has been reported in some cases 163, 
and the precise function of CXCR4 on keratinocytes has not yet been determined, so this 
would warrant further study. 
To further investigate these results, it could be valuable to isolate cells from the IF subset 
by fluorescence assisted cell sorting (FACS) and analyse them ex vivo. qPCR could be 
used to quantify mRNA expression, giving a more practical approach for generating 
thorough timecourses to analyse the expression of Ackr3 and Cxcr4 expression after TPA 
treatment. RNA-Seq could also be performed on the different keratinocyte subsets at 
various timepoints after TPA treatment to help identify key pathways involved in these 
cells’ differential responses to this inflammatory signal. 
Isolated infundibulum cells could also be used for functional assays, for example in 
Transwell migration assays to analyse LC migration across the cell layer, or in vitro 
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scratch assays to measure cell migration in response to wounding; receptor 
agonists/antagonists such as AMD3100 (CXCR4 antagonist, ACKR3 agonist) or CCX771 
(ACKR3 antagonist) could also be used during treatment with TPA to attempt to elucidate 
the roles of both these receptors. These approaches could also be carried out in vivo using 
subcutaneously-injected CXCR4 or CCX771 and comparing skin and draining lymph node 
cellularity in treated and untreated mice after TPA treatment. This approach would have 
the limitation that any antagonist applied could potentially affect the migration of 
CXCR4+ infiltrating cells, so the timing of receptor blockade and inflammatory stimulus 
would need to be balanced carefully. Further immune stimuli could be tested, for example, 
LPS, to validate qPCR results obtained from cultured human keratinocytes. 
6.2.2 Challenges with Ackr3+/gfp Mice 
Ackr3+/gfp mice proved challenging to use, because of the need to avoid breeding 
Ackr3gfp/gfp homozygotes, which die as neonates. As only males were used in these studies, 
and age-matching was attempted, this left only a small pool of suitable animals compared 
with the number of mice bred. Finding a reliable method for ACKR3 immunostaining 
would certainly be preferable, but studies on keratinocytes and mouse spleen in the 
previous chapter did not suggest that uptake of fluorescent CXCL12 would be a reliable 
method. Although immunostaining using the 11G8 antibody clone has been reported in 
mouse tissues 150, this was using NOD-SCID mice in order to overcome the problem of 
non-specific staining that would be expected when using a mouse antibody on mouse 
tissue. This would not be appropriate for studies involving the immune response. 
6.3 Increased Lymph Node Cellularity in Aldara-Treated Ackr4-Deficient 
Mice 
Results obtained using the Aldara model of chronic skin inflammation suggested a role for 
ACKR4 in this pathology. Although Ackr4 mRNA was strongly downregulated in the skin 
of Aldara-treated mice, there was apparent enlargement of the lymph nodes draining the 
treatment site in Ackr4-deficient mice compared to wild-types, and increased numbers of B 
cells, T cells and resident DCs. The initial hypothesis was dysregulation of CCL19 and/or 
CCL21 due to lack of ACKR4-mediated chemokine scavenging by endothelial cells and 
keratinocytes. This was largely supported by the evidence obtained: there were elevated 
levels of CCL19 protein in the plasma of Ackr4-deficient mice compared to wild-type 
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mice, and the observed lymph node enlargement in Ackr4-deficient mice was not present 
in mice also lacking functional Ccl19. 
6.3.1 Roles for ACKR4 in Chronic Inflammation 
Figure 6.2 illustrates and summarises the key results obtained in Chapter 5. Unfortunately, 
this work was not concluded to the point of obtaining a satisfactory explanation for the 
differential phenotype seen in Ackr4-/- mice compared to WT after five daily Aldara 
treatments. Some differential observations appear to be widespread (CCL19 
overabundance and increased B cell numbers), while others are limited to the LNs draining 
the treatment site (increased mDC and T cell numbers). 
There are several possibilities for the precise nature of the defect caused by lack of Ackr4 
in these mice: leukocytes are unable to exit lymph nodes, cell proliferation has increased, 
or leukocyte recruitment to the lymph nodes is increased. The third hypothesis appears to 
be unlikely based on evidence in the literature. The dysregulation of CCR7 ligands is 
generally reported to impair rather than enhance leukocyte recruitment to the lymph nodes 
101,177,179. There is some evidence that either supports or fails to refute this hypothesis: 
migration of adoptively-transferred splenocytes to the SLOs of Ackr4-/- Aldara-treated 
mice was unimpaired compared to wild-type, and there were fewer donor B cells isolated 
from the blood of these mice. This could indicate enhanced migration of these cells; 
however, there was no evidence that a greater number of B cells had entered the SLOs. 
This result could, perhaps, represent decreased survival of B cells that did not migrate to an 
SLO, but these findings would require further study. Another intriguing observation was 
the decreased numbers of migratory DCs in the inguinal lymph nodes of Ackr4-deficient 
mice, when these cells were unaffected in the lymph nodes draining the site of Aldara 
treatment. This could suggest a delayed migration of DCs, which is not detectable in the 
site-draining lymph nodes by five days after the first wave of DC migration but may 
become pronounced in more distant skin-draining lymph nodes. This observation could be 
clarified by studying the lymph node phenotype at multiple timepoints during Aldara 
treatment. Skin could also be studied at multiple timepoints to measure DC egress in 
Ackr4-/- and wild-type mice. Due to the difficulties encountered in analysing this tissue 
using flow cytometry, immunohistochemistry could be utilised instead. 
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Figure 6-2: Summary of differential responses to five daily Aldara treatments 
between wild-type and Ackr4-/- mice. 
The main results from chapter 5, section 2 are summarised here, shown with an 
illustrative diagram of the locations of sites analysed. A) In the skin of Ackr4-/- (KO) mice, 
CCL19 is strongly elevated compared to WT, while keratinocyte proliferation is equal 
between the two strains. B) KO spleens have a higher cellularity compared to WT, and 
almost double the number of B cells. C) The ear DLN of KO mice are significantly larger 
than WT, and contain greater numbers of mDCs, T cells and B cells (but not rDCs or 
pDCs). D) in the ILN and MLN, the only difference in cellularity detected between WT and 
KO mice was a decrease in mDCs in the ILN of KO mice. E) An increased number of 
circulating B cells was noticed in KO compared to WT mice, as well as an elevated CCL19 
concentration. 
Interestingly, previous research has suggested that Imiquimod treatment to the skin leads to 
increased Langerhans cell migration to the skin-draining lymph nodes 224; this is in contrast 
with the TPA model of contact hypersensitivity, where LC migration to skin-draining 
lymph nodes is inhibited due to CCL19 dysregulation 179. As LC migration was not 
affected in Ackr4-/- mice compared to WT in this study, this suggests that LCs are able to 
overcome the barrier to their exit from the skin caused by CCL19 dysregulation, and 
perhaps even enhance their migration to the skin-draining lymph nodes, given the 
increased abundance of migratory DCs detected there. 
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6.3.2 Limitations of the Aldara Model 
The Aldara model presents several serious issues that make interpretation of these results 
difficult. One problem is that mice topically treated with Aldara will tend to ingest the 
cream during grooming. It was recently shown that this accounts for not only the systemic 
effects of Aldara treatment, which include splenomegaly, but also increases the severity of 
the skin phenotype 225. The authors of this study used collars to prevent mice licking their 
backs and consequently found a significant reduction in inflammation in response to 
Aldara. I reasoned that this was not crucial to the described experiments: ACKR4 is found 
in the skin, throughout the lymphatic system and on endothelial cells of multiple tissues, 
and therefore the systemic effect is of interest. This does have the limitation that the 
precise role of ACKR4 in the skin cannot yet be determined, but this could be studied in 
more detail in the future by comparing the phenotype in mice with and without collars. 
Ideally, conditional or tissue-specific knock-out mice could be developed to determine the 
role of Ackr4 in different tissues, although the cost involved in this would likely be 
prohibitive.  
Another potential issue is that Aldara cream contains isostearic acid as a carrier, which has 
been shown to have its own inflammatory effects independent of imiquimod 226. 
Unfortunately, the correct cream could not be sourced for use as a control, so this limits the 
conclusions that can be drawn from the study. I believe that these observations are valuable 
as an exploration of the role of ACKR4 in prolonged inflammatory conditions, but it is not 
possible to conclude whether any differences in mRNA or eGFP expression between 
treatment and control groups was in response to imiquimod, isostearic acid, or both. 
More generally, the Aldara model is an imperfect model of psoriasis. Some of the classic 
hallmarks of the disease are present, particularly IL-17A and IL-23  upregulation 212. Some 
features of Aldara-mediated inflammation do not fit with human psoriasis, however, 
particularly the fact that it is not genuinely a chronic phenotype as it can be induced in a 
matter of days. Again, this has limited the conclusions that can be drawn from the study, 
and without investigating clinical samples it is not possible to determine whether these 
findings accurately reflect the regulation of Ackr4 during psoriasis. 
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6.3.3 Future Investigations 
The next steps in this investigation would be to further characterise the cells of the 
inflamed lymph nodes to determine whether and how Ackr4 expression is affected in the 
lymph node stroma. Immunostaining using cell proliferation markers or BrdU labelling 
could potentially reveal any differences in the levels of proliferation in the lymph nodes 
between wild-type and Ackr4-deficient mice. 
One possible next step for investigating the cause of increased lymph node cellularity in 
Ackr4-deficient mice would be to use FTY720, the S1P1 antagonist, to block leukocyte 
egress from the lymph nodes. This could indicate whether or not the phenotype observed 
was related to defects in leukocyte migration from the lymph nodes: if FTY720 treatment 
created the same phenotype in wild-type and Ackr4-deficient mice, this would suggest that 
leukocytes were becoming trapped in the lymph nodes, while if FTY720 treatment led to a 
more severe phenotype in Ackr4-deficient mice, this would suggest that enhanced 
proliferation played a role. 
Determining the precise role, if any, of ACKR4 expressed by keratinocytes on Aldara-
mediated inflammation would be challenging due to the systemic nature of this phenotype 
discussed above. The simplest method would be to prevent mice from licking the treated 
areas by either covering them or using collars to restrain their movement. If a differential 
phenotype between wild-type and Ackr4-deficient mice was still observed, this would 
suggest ACKR4 in the skin played a role in modulating the response to chronic 
inflammation; however, this would not determine which cell types) were crucial for this to 
occur. It is likely that ACKR4 expressed by a variety of endothelial cells throughout the 
body is responsible for scavenging CCL19, leading to the build-up of chemokine observed 
in Ackr4-deficient mice. Any effects of ACKR4 on keratinocytes would most likely be 
detected by closer study of the skin. 
The inability to analyse the Aldara-treated skin by flow cytometry was a serious limitation 
to further exploration of the skin phenotype. Cells were extremely difficult to locate via 
their forward and side-scatter properties, and when comparing treated to untreated cells, it 
appeared that samples contained very few cells. This is unlikely to be the case, particularly 
when visible inflammation suggests a large population of infiltrating leukocytes should be 
present. 
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One possibility is that the properties of the cells in the skin are altered by Aldara treatment, 
or that cells are indeed dying: it has been reported that keratinocytes induce cell death in 
response to Aldara 226. The failure to isolate leukocytes is not explained by this hypothesis; 
although these cells are not very numerous in normal epidermis, they can still be isolated 
reliably, so this should be easier in inflamed skin where the population has increased. 
Epidermis from Aldara-treated mice appeared to be highly disrupted and seemed to slough 
off easily before enzymatic digestion. Ear halves are normally floated on top of trypsin to 
disaggregate the tissue gently, but the permeability barrier of the tissue seemed to be 
impaired, meaning the tissue would sink. This could have contributed to low cell yields, 
and perhaps in the future, a shorter and gentler enzymatic digestion approach could be 
attempted. Immunohistochemistry could also be used to determine the spatial positioning 
of different cell types, which could reveal defects in migration of cells to or from the skin, 
or their positioning. 
If investigations using cultured human cells are continued, it would be valuable to repeat 
these experiments using cells obtained from multiple donors. This would give biological 
replicates which would allow qPCR results to be interpreted with confidence using 
statistical analysis. This was not carried out in this instance due to the prohibitive costs of 
obtaining cells commercially.  
6.4 Conclusions 
The results presented here have shown the expression and modulation of ACKR3 and 
ACKR4 by keratinocytes in the skin, both in vitro in human cells and in vivo in mouse 
tissue, in response to inflammatory stimuli. 
Ackr3 expression was shown to be modulated in response to repeated exposure to the 
phorbol ester TPA, modelling a contact hypersensitivity response. This type of 
inflammatory stimulus would normally initiate an innate, rather than adaptive, immune 
response. As ACKR3 and CXCR4 are proposed to heterodimerise on cells that coexpress 
them, both receptors were investigated. The results showed differential regulation of Ackr3 
and CXCR4 which is intriguing, particularly the finding that the infundibulum subset of 
the hair follicle in particular downregulates Ackr3 while upregulating CXCR4 during the 
inflammatory response. This heterogeneity suggests differential roles for cells of the hair 
follicle, which could conceivably support directed migration of leukocytes to and from 
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specific areas of the skin during inflammation, as well as supporting the growth and/or 
differentiation of particular subsets of keratinocytes. 
AKCR4 also appeared to play a role in mediating the response to Aldara-induced 
inflammation, as the site-draining lymph nodes of Ackr4-/- mice contained significantly 
more cells compared to WT. This phenotype was noted to coincide with accumulation of 
the chemokine CCL19 in both skin and blood. The phenotype of increased lymph node 
size was resolved in Ackr4-/- Ccl19-/- mice, suggesting scavenging of CCL19 by ACKR4 
plays a role in the accumulation of lymphocytes in the site-draining lymph nodes.  
Although it is not known whether the results obtained in this work impact directly on the 
organism’s ability to resolve any specific disease state, or indeed whether the phenotype 
seen in Ackr4-/- mice would be beneficial or detrimental, the finding that epithelial cells 
alter their atypical chemokine receptor expression in response to inflammatory stimuli 
suggests that these receptors do play a role in the inflammatory response, which could have 
potential relevance in a wide range of diseases. The distinction between a normal and 
abnormal immune response will include many different factors and the ability of the body 
to regulate local chemokine concentrations may be one. ACKR-expressing cells could 
have the ability to modify their chemokine-scavenging activities in response to 
inflammatory stimuli in order to support the correct migration of leukocytes to and from 
the site of immune challenge. There is some evidence for the necessity of functioning 
ACKRs in the immune response to maintain cell responsiveness to chemokines 
101,150,179,190. 
ACKR3 and ACKR4 are both found on endothelial cells in a variety of tissues, and while it 
suited the scope of this study to focus mainly on one easily-manipulated experimental site, 
the skin, it is feasible that ACKR3 and/or ACKR4 signalling could play a supporting role 
in resolving a wide range of inflammatory events. Additionally, ACKR3 appears to affect 
cellular processes distinct from chemokine scavenging. This suggests that ACKR3 may 
directly affect how stromal cells contribute to processes including immunity and tissue 
repair, as well as indirectly affecting these processes by modifying availability of 
chemokines to attract and retain infiltrating leukocytes.  
In conclusion, this study has revealed that ACKRs scavenging homeostatic chemokines are 
expressed on epithelial cells in a number of tissues throughout the body, including SLOs, 
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and can be modulated at the mRNA and protein level during inflammation suggesting their 
involvement in a wide range of inflammatory events.
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